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Certain icosahedral plant viruses are capable of undergoing capsid disassembly under 
specific chemical environments. Coat proteins (CP) isolated from the disassembled mix 
could be reassembled in vitro into uniformly sized and precisely structured virus-like 
protein cages (PC). The PC could be an attractive platform for drug delivery as its cavity 
could serve as a carrier of exogenous materials, while the amino acids in the CP could be 
chemically functionalized. To date, however, plant viruses have not been applied to the 
development of targeting anticancer drug delivery systems. The hypothesis for this 
project was that PC derived from the Hibiscus Chlorotic Ringspot virus (HCRSV) could 
be developed into a targeting anticancer drug delivery system. The HCRSV is a member 
of the genus Carmovirus in the Tombusviridae family of plant viruses. It is an icosahedral 
virus of 30 nm diameter, and has a 4 kb genomic RNA enclosed within a capsid of 180 
CP subunits. The in vitro capsid disassembly and CP reassembly of HCRSV have not 
been evaluated. Neither has it been applied as a drug delivery platform.  
HCRSV was successfully cultured in kenaf leaves under controlled environment and 
efficiently purified by serial centrifugation on sucrose gradients to give reproducible 
yields of 4 to 5 mg of purified HCRSV per 100 g of leaves. This method provided a 
stable source of HCRSV for subsequent experimentation. The HCRSV capsids were 
disassembled by incubation with 8 M of urea or by dialysis against a Tris buffer of pH 8 
in the absence of Ca2+. CP isolated from the disassembled mix showed much lower OD260 
nm/OD 280 nm (about 0.6) than the native HCRSV (about 1.5), indicating a successful 
removal of the viral RNA. The purified CP was reassembled into empty PC by dialysis 
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against a sodium acetate buffer of pH 5 in the presence of Ca2+. Circular dichroism 
analysis did not register any changes in the CP conformational structure following capsid 
disassembly and PC reassembly. Particle size measurement, together with transmission 
electron microscopy (TEM), showed the reassembled PC to be comparable in size and 
morphology to the native HCRSV. However, the dialysis method produced PC of more 
uniform size and better defined morphology than the urea incubation method, and was 
used to produce subsequent batches of PC. 
The HCRSV-derived PC had the capacity to accommodate guest molecules in its 
cavity. Analysis by sucrose gradient ultracentrifugation and gel electrophoresis showed 
the loading efficiency to be dependent on electrostatic interactions between the PC and 
the cargo. The positively charged Arg and Lys moieties located at the N-terminal of the 
CP could have made the inner cavity of the PC attractive for the binding of negatively 
charged compounds, as demonstrated by the successful loading of polystyrenesulfonic 
acid (PSA) and polyacrylic acid (PAA). In contrast, neutral FITC-dextran molecules with 
mw ranging from 4 to 150 kDa could not be encapsulated. Even with the polyacids, only 
samples with mw no less than 13 kDa were successfully encapsulated. The failure to load 
PSA below the threshold mw has been attributed to the rapid leaching of these molecules 
through the surface cavities of the PC upon dilution. Cargo loading had to be initiated 
with PC reassembly, as the preformed PC could not be used for the loading of the 
polyacids. PSA (≥13 kDa)- and PAA-loaded PC, despite differences in the mw and acid 
type of their cargoes, were comparable in size, morphology and protein conformation to 
each other and to the native HCRSV with its RNA load.  
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To impart a capability to target cancer tissues that over-express the folic acid receptor, 
the native HCRSV was conjugated with folic acid by a 2-step carbodiimide method. The 
conjugated folic acid did not affect the disassembly of the HCRSV, nor the subsequent 
reassembly of the folic acid-conjugated CP into fPC.  Folic acid conjugation efficiency 
was 1.9%, which translated to about 360 folic acid molecules per fPC. The PSA- and 
PAA-loaded fPC were comparable in size, morphology and conformational structure to 
the corresponding polyacid-loaded PC without folic acid conjugation.  
Doxorubicin, the model anticancer drug used for the project, did not satisfy the twin 
requisites of possessing a negative charge and mw above the specified threshold, for 
loading into the PC. To overcome these barriers, a novel method named “polyacid 
association” was established. This method involved the simultaneous encapsulation of 
doxorubicin with PSA (200 kDa), the PSA aiding in the retention of doxorubicin within 
the PC and fPC through the formation of a semi-stable complex by electrostatic 
interactions. The resultant systems, denoted as PC-Dox and fPC-Dox, were 
homogenously sized and shaped, and were similar in morphology and size to the native 
HCRSV. Drug encapsulation efficiency for both samples was within the acceptable range 
of 49 – 59%, with each PC containing about 900 entrapped doxorubicin molecules. The 
encapsulated drug in PC-Dox and fPC-Dox was readily released upon dilution, with both 
samples exhibiting a sustained drug release profile at simulated physiological condition. 
About 40% of the drug load was released within the initial 4 h, followed by a slower 
release of the remaining drug load from the PC over the next 20 h.  
The efficacy of PC-Dox and fPC-Dox was evaluated in vitro using representative 
cell culture models. The cancer cell models were OVCAR-3 (human ovarian epithelial 
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adenocarcinoma) and CNE-1 (human nasopharyngeal carcinoma), while CCL-186 
(human diploid fibroblast) was used as a normal cell model. Folic acid uptake data 
confirmed the over-expression of folic acid receptors in OVCAR-3 and CNE-1 cells 
cultured in folic acid-deficient RPMI-1640 medium. CCL-186 cells did not over-express 
the folic acid receptor when cultured with the normal RPMI-1640 medium. MTT assay 
data suggested that the HCRSV and PSA at concentrations equivalent to those applied in 
the PC-Dox and fPC-Dox formulations were non-cytotoxic towards the 3 cell lines.  
Data obtained from fluorescence spectroscopy, confocal microscopy and flow 
cytometry were in agreement that the fPC-Dox could effectively enhance doxorubicin 
uptake in the OVCAR-3 and CNE-1 cells. The enhanced drug uptake was correlated with 
higher cytotoxicity as evaluated by the MTT assay. In comparison, the cancer cell uptake 
of PC-Dox was 2- to 3-fold lower. Cellular uptake and cytotoxicity of PC-Dox were 
comparable to doxorubicin in solution, suggesting that doxorubicin encapsulation within 
the PC could not by itself increase drug efficacy in the cancer cell models. This is 
reasonable considering the current lack of evidence to support the cytoinvasive and 
cytotoxicity properties of plant viruses, including the HCRSV, in animal cells. PC-Dox 
could, however, be useful in clinical applications where sustained drug release and/or 
protection against cytotoxic drugs are desired. The enhanced uptake of fPC-Dox in the 
OVCAR-3 and CNE-1 cells was inhibited by excess co-administratered folic acid, 
supporting the role of the folic acid receptor in mediating its uptake. It also accounted for 
the failure of fPC-Dox to show enhanced uptake in the folic acid receptor-deficient CCL-
186 cells. This selectivity of action suggests that the fPC-Dox has the potential to be 
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applied as a targeting platform for anticancer drug delivery, and that it should be further 
evaluated to realize this potential. 
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Cancer, also termed as malignant tumor or neoplasm, includes more than 100 diseases. 
The defining characteristic of cancer is the presence of abnormal cells that multiply very 
rapidly, growing beyond their usual boundaries to invade adjoining tissues and spreading 
to other organs. The latter process, which is referred to as metastasis, is usually the cause 
of death in cancer patients.  
Cancer has surpassed heart disease as the leading cause of death in the world [Jemal 
et al., 2006]. In 2005, 7.6 million people died of cancer, accounting for 13% of the total 
global death. About 22 million people worldwide are cancer patients, and an alarming 10 
million people are added to this number yearly from both developing and developed 
countries. According to the World Health Organization (WHO), worldwide cancer rates 
are set to increase by as much as 50% by the year 2020 unless further preventative 
measures are put into practice [http://www.who.int/cancer/en/, date of access: 
06/11/2006]. WHO estimates cancer will claim 9 million lives in 2015 and 11.4 million 
in 2030 [http://www.who.int/mediacentre/factsheets/fs297/en/index.html, date of access: 
06/11/2006]. 
1.1.2 Treatment 
Common modalities for treating cancer include surgery, radiotherapy and 
chemotherapy. Often, a combination of therapies is required to optimize outcome. For 
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example, radiation therapy or chemotherapy may be performed before, during or after 
surgical excision of the cancer tissue. The main objectives of cancer treatment are to rid 
the body of tumor cells and prevent their spread to other tissues, as well as to prolong and 
improve the quality of life for the patient. Some cancers, such as breast cancer, cervical 
cancer and colorectal cancer, have good prognosis if diagnosed in the early stages.  
Unlike surgery and radiotherapy, which are used only to treat localized cancer, 
chemotherapy can be applied to cancers that have spread to other tissues or organs. 
Cancer chemotherapy employs chemicals that target rapidly dividing cells, and it has the 
advantage of reaching cancer cells that are inaccessible by surgery or radiotherapy. For 
these reasons, chemotherapy is especially suited for the treatment of advanced cancer 
[Bonetti et al., 2006; Vergnenegre et al., 2005].  
Cancer chemotherapeutic agents can be divided into different groups based on their 
mechanisms of action. Alkylating agents, e.g. chlorambucil [Torabian et al., 2006] and 
hexamethylmelamine [Keldsen et al., 2003], prevent cell replication by bonding with the 
electronegative DNA [Walters, 2006; Lawley, 1995]. Antimetabolites, such as the 
antifolates [Bajetta et al., 2003], purine analogs [Fazzi et al., 2003] and pyrimidine 
analogs [Temmink et al., 2006], are structurally related to endogenous compounds, and 
they work by competing for specific enzymes that participate in nucleic acid production. 
A more selective anticancer agent is the monoclonal antibody, designed to bind with a 
membrane protein that is overexpressed in cancer cells. An example is trastuzumab, 
which targets the extracellular domain of the human epidermal growth factor receptor 2 
(HER2), a tyrosine kinase that regulates cell growth and is overexpressed in many cancer 
 Chapter 1. Introduction  
 4
cells, including breast cancer cells [Vogel et al., 2002], gastric cancer cells [Fujimoto-
Ouchi et al., 2006] and uterine papillary serous cancer cells [Villella et al., 2006]. The 
antitumor activity of trastuzumab arises from its ability to diminish cell receptor signaling 
[Baselga et al., 2001], cause the G1 arrest of cell proliferation [Lane et al., 2001], induce 
apoptosis [Chang et al., 2003], and/or provoke an immune response [Cooley et al., 1999]. 
Cytotoxic antibiotics, on the other hand, prevent cell reproduction by blocking the 
synthesis and repair of DNA or RNA [Swift et al., 2006]. They are amongst the most 
widely prescribed anticancer agents, examples of which include doxorubicin, 
mitoxantrone and bleomycin [Muggia and Green, 1991]. Doxorubicin is used as the 
model anticancer agent in this project.  
Doxorubicin (Figure 1-1) is indicated for the treatment of breast cancer [Wong e al., 
2006], soft tissue sarcoma [Di Filippo et al., 2003] and ovarian cancer [Cunningham et al., 
1994]. It interferes with cell reproduction in several ways. Firstly, doxorubicin blocks 
DNA synthesis by direct binding, via intercalation between base pairs on the DNA helix 
[Capranico et al., 1986]. Secondly, it inhibits DNA repair by inactivating topoisomerase 
II [Burden and Osheroff, 1998]. Thirdly, doxorubicin generates .OH radicals that cleave 
the doxorubicin-nucleic acid complex, leading to cell death [Feinstein et al., 1993]. Like 
most cancer chemotherapeutic agents, doxorubicin is highly potent, yet non-selective in 
its action. In targeting rapidly dividing cells, it destroys not only cancer cells but also 
normal cells with high turnover rates, such as those in the bone marrow, skin, hair 
follicles, oral and gastrointestinal mucosae. Consequently, treatment with doxorubicin is 
associated with many serious adverse effects, including a suppressed immune system, 
severe nausea and vomiting, diarrhea or constipation, hair loss, sore mouth, ulcers and 
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poor sense of taste [Burish and Tope, 1992; Wujcik, 1992]. As the adverse effects of 
doxorubicin are believed to be alleviated by delivering the drug specifically to the cancer 
cells, doxorubicin is often employed as a model drug in the development of targeting 
drug delivery platforms [Kalra and Campbell, 2006; Sun et al., 2006; Nasongkla et al., 
2006]. 
 
Figure 1-1 Chemical structure of doxorubicin. 
 
1.2 Targeted drug delivery systems  
1.2.1 Rationale 
Most therapeutic drugs provide little, if any, targeting specificity. Yet, for drugs with 
a narrow therapeutic window, such as the highly cytotoxic anticancer agents, targeted 
delivery has the potential to significantly improve clinical outcome. A drug that is 
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delivered specifically to its therapeutic site would have enhanced uptake and absorption 
by the target tissue and reduced adverse effects from inappropriate disposition at other 
sites [Xu et al., 2006; O'Brien et al., 2004]. Proof of concept has been illustrated in a 
phase III clinical trial of a liposomal formulation of doxorubicin, which passively targets 
the drug to the cancer cells and significantly reduces its cardiotoxic effects [O'Brien et al., 
2004]. Targeted delivery systems have also been designed to resolve problems associated 
with the physicochemical properties of the drug, for example, by improving drug stability 
against degradation [Kleemann et al., 2005] or increasing drug aqueous solubility [Mo 
and Lim, 2005].  
 
1.2.2 Targeting strategies 
Drugs may be delivered to a specified tissue by passive targeting and/or active 
targeting. Passive targeting relies on the natural distribution pattern of the drug or 
delivery system. When applied to cancer chemotherapy, drug uptake and accumulation by 
tumor cells are dependent on factors such as increased permeability of intratumoral 
vessels aided by lack of lymphatic drainage in tumor tissues [Dvorak et al., 1988], 
electrostatic interactions between the drug carrier and plasma membrane [Kohler et al., 
2006], and phagocytosis of the drug carrier by the immune system [Falo et al., 1995]. 
Active targeting, on the other hand, is more selective as it is designed specifically to 
detect molecules unique to cancer cells. 
A wide variety of ligands has been explored for the active targeting of cancer 
chemotherapeutic agents. A novel strategy exploits the advantage of aptamers, which are 
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short, synthetic, single-stranded DNA or RNA molecules that bind with high affinity to 
specific proteins [Chu et al., 2006; Bagalkot et al., 2006]. An example is the conjugation 
of doxorubicin with 2’-fluoropyrimidine RNA aptamer to target prostate cancer cells that 
overexpress the prostate-specific membrane antigen [Bagalkot et al., 2006]. Conjugation 
with a monoclonal antibody may also enhance the targeting efficiency of a delivery 
system. Immunoliposomes of doxorubicin, constructed using the Fab’ fragment from the 
humanized anti-EGFR monoclonal antibodies, have been shown to exhibit significantly 
higher cytotoxicity towards the EGFR-overexpressing colorectal cancer cells compared to 
conventional liposomal doxorubicin [Mamot et al., 2006]. 
Small molecules have also been used as ligands for targeting drug delivery systems 
to cancer cells. A well-known example is folic acid (Figure 1-2). Folic acid is a vitamin 
essential for the synthesis of adenine and thymine, two nucleic acids that make up 
genomic materials. Folic acid is also necessary for the metabolism of the essential amino 
acid, methionine [Stanger, 2002]. Cellular uptake of folic acid is by the transmembrane 
folic acid receptor (FR), which consists of three well-characterized isoforms (α, β and γ), 
with 70–80% similarity in amino acid identity [Shen et al., 1994]. The affinity factors for 
FR α, β and γ are 0.1, 1 and 0.4 nM, respectively [Kamen and Caston, 1986; Costa and 
Rothenberg, 1996; Shen et al., 1995]. 
The principle for using folic acid as a cancer-targeting ligand is based on the 
differential expression of FR on normal and cancer cells. Although certain normal cells, 
such as the renal tubular cells, express a significant level of FR [Weitman et al., 1992], 
most normal epithelia express low levels of FR. In contrast, FR expression is greatly 
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elevated in malignant cancer cells of epithelial origin, such as cancer cells of the ovary, 
uterus, endometrium, brain, kidney, head and neck, and mesothelium [Toffoli et al., 1997; 
Ross et al., 1994]. The upregulated FR expression in malignant cells could approach two 
orders of magnitude compared to normal cells in the same tissue (Figure 1-3) [Ross et al., 
1994; Lu and Low, 2002]. FR expression has been shown to increase with the stage of 
cancers [Toffoli et al., 1997], and is correlated with a stronger resistance to chemotherapy 
[Toffoli et al., 1998]. Thus, folate-targeted therapeutics can be a potential remedy for 
advanced cancers that are resistant to standard chemotherapy. Targeting is also possible 
because of the differential distribution of FR in normal and cancer cells. FR on normal 
epithelial cells is located on the apical (externally-facing) membrane, which limits its 
access from the serosal side. Thus, FR in the renal tubular cells, which aid in the re-
absorption of folates from urine, are located in the luminal membrane [Weitman et al., 
1992], while FR in the blood brain barrier are concentrated on the membrane facing the 
brain tissue and function to retain the vitamin within the cerebrospinal fluid [Patrick et al., 
1997]. By comparison, FR distribution in malignant epithelial cells is not limited to the 
apical membrane because of the lack of polarization of these cells. Consequently, cancer 
cells with overexpressed FR are susceptible to folic acid-conjugated drug delivery 
systems circulating in the blood [Toffoli et al., 1997; Ross et al., 1994] while normal 
tissues with elevated FR expression are not [Weitman et al., 1992; Patrick et al., 1997; Lu 
and Low, 2002]. Proof of concept of the folic acid-mediated targeting systems has been 
obtained with the delivery of drugs and liposomes to a variety of cancer cells [Leamon 
and Low, 1991; Drummond et al., 2000]. 
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Figure 1-2. Chemical structure of folic acid 
 
 
Figure 1-3 Comparison of the FR expression between normal and malignant human 
tissues [Ross et al., 1994]. 
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1.3 Nanoscale drug delivery systems 
1.3.1 Rationale 
Nanoscale systems can be defined as colloidal structures in the size range of 10 to 
1000 nm [Quintanar-Guerrero et al., 1998]. Most nanoscale drug delivery systems are 
prepared from macromolecular materials called carrier molecules, and the drug cargo is 
dissolved, entrapped, adsorbed, dispersed or covalently linked to the carrier molecules 
[Zamboni, 2005; Jain, 2005] 
Nanoscale drug delivery systems have many advantages over conventional 
pharmaceutical dosage forms. Drugs have been incorporated into polymer nanoparticles 
to overcome intractable solubility e.g. the loading of paclitaxel in PLGA nanoparticles 
allowed the poorly water-soluble drug to be administered in an aqueous medium [Mo and 
Lim, 2005]. Peptide drugs encapsulated in nanoscale systems may exhibit stronger 
resistance to chemical and enzymatic degradation [Ma et al., 2005], resulting in 
prolonged action [Luo et al., 2006]. The delivery of 5-aminolevulinic acid (ALA) via 
liposomes smaller than 63.5 nm was statistically (p < 0.05) more efficient than the 
administration of ALA alone [Kosobe et al., 2005]. Nanoscale delivery systems may also 
be designed to provide a specific controlled drug release profile [Allen et al., 2006; Ishida 
et al., 2006], or to direct a drug to specific tissues [Hattori and Maitani, 2005]. Many of 
these benefits are also seen in microscale drug delivery systems; however, the reduction 
of the delivery system to the nanoscale can be helpful in promoting its circulation half-
life, targeting capacity and cellular uptake rate. When injected subcutaneously into mice, 
PEG-distearoylphosphatidylethanolamine liposomes with diameter of 80 to 90 nm were 
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found to translocate with ease from the site of injection into the bloodstream while 
similar but larger vesicles (656 nm) remained at the site of injection [Allen, 1993]. 
Liposomes with diameter of 400 nm were 3 times more efficient than those of 1200 nm 
diameter in targeting the bone marrow in the mongrel dog model [Schettini et al., 2006]. 
Another study showed gold nanoparticles with diameter in the range of 14 to 100 nm to 
be the most efficiently taken up by the HeLa cells, with nanoparticles of 50 nm diameter 
having the highest uptake rate [Chithrani et al., 2006]. 
 
1.3.2 Classification  
Nanoscale drug delivery systems may be classified into several major categories. As 
it is not practical to describe all the categories in this thesis, only 3 major systems, 
namely the micelles, liposomes and polymer nanoparticles are described. Micellar 
systems, which are prepared by self-assembly of amphiphilic block copolymers in 
aqueous media [Liu et al., 2006; Wei et al., 2006], present with a hydrophobic core that 
can accommodate drugs at concentrations exceeding their solubility in water. 
Surrounding the core are the hydrophilic regions of the polymers, which form hydrogen 
bonds with water and serve to protect the encapsulated drug from hydrolysis and 
enzymatic degradation. The hydrophilic palisade also enables the micelles to evade 
recognition by the reticuloendothelial system (RES), thereby prolonging their circulation 
time. Micellar systems are highly versatile, as the chemical composition, molecular 
weight (mw) and block length ratios of the copolymers can readily be changed to control 
the size, morphology and functionality of the micelles. An example of a micellar system 
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is NK105, a formulation produced with polyethylene glycol (PEG) as the hydrophilic 
segment and modified polyaspartate as the hydrophobic segment. The area under the 
plasma concentration-time curve (AUC) of paclitaxel incorporated into NK105 was 90-
fold higher than free paclitaxel when administered by subcutaneous injection into nude 
mice implanted with the human colonic cancer cell line, HT-29 [Hamaguchi et al., 2005]. 
Besides anticancer drugs, inorganic materials, such as superparamagnetic iron oxide for 
MRI imaging, have also been loaded into micelles [Nasongkla et al., 2006] for targeted 
delivery to tumor endothelial cells. 
Liposomes are vesicles consisting of one or more lipid bilayers with aqueous cores. 
Lipids, such as phospholipids [Ickenstein, et al., 2006] or cholesterol [Lee et al., 2005], 
were used to construct the hydrophobic membrane of liposomes. Drugs can be 
encapsulated within the liposomal core [Chen et al., 2004], although amphiphilic or 
lipophilic molecules e.g. gold nanoparticles [Park et al., 2006] and anthrax protective 
antigens [Sloat and Cui, 2006], are incorporated within the phospholipid bilayers. Drugs 
encapsulated in liposomes can be protected from chemical and enzymatic degradation. A 
highly successful formulation is that of doxorubicin encapsulated within PEGylated 
liposomes. Developed by Johnson & Johnson, this formulation has been approved by the 
U.S.A Food Drug Administration (FDA) in 2005 for the treatment of ovarian cancer. 
Doxorubicin is encapsulated within the aqueous core of the liposomes via a salt gradient 
[Lasic et al., 1992] and the conjugated PEG reduces liposomal uptake by the RES 
[Gabizon et al., 1993]. The resultant system improves clinical outcome by increasing the 
tumor uptake of doxorubicin while at the same time reducing its cardiotoxicity 
[Papahadjopoulos et al., 1991].  
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Solid polymeric nanoparticles in the size range of 10 to 400 nm have also been widely 
synthesized for biomedical applications. Nanoparticles produced from biodegradable 
polymers, e. g. chitosan [Huang et al., 2005] and poly(lactide-co-glycolide) [Mo and Lim, 
2005], are particularly popular for drug delivery. Polymer nanoparticles have been 
applied to deliver both large molecules, e.g. peptide [Ma et al., 2002] and gene [Huang et 
al., 2005], and small molecules, e.g. anticancer agents [Bertin et al., 2005; Mo and Lim, 
2005], to a target organ. Polymer nanoparticles can be formulated using one or a 
combination of a wide variety of biocompatible polymers, and further functionalized after 
preparation by chemical manipulation. When conjugated with a targeting ligand, e.g. a 
small molecule such as folic acid [Kim et al., 2005] or a macromolecule, such as wheat 
germ agglutinin (WGA) [Mo and Lim, 2005], polymer nanoparticles could direct the 
drug cargo to specific tumor sites. PEGylation, on the other hand, enables the polymer 
nanoparticles to evade clearance by the RES, thereby prolonging their circulation half-life 
and increasing drug bioavailability [Craparo et al., 2006].  
  
1.4 Virus-based drug delivery systems 
1.4.1 General properties of viruses 
Viruses straddle between living and non-living materials. They are omnipresent and 
can be found residing in all living species, including plants, animals, bacteria and fungi. 
Viruses may be considered to be mere assembles of macromolecules that are as alive as a 
rock, yet they can rapidly multiply and infect increasing number of cells upon contact 
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with the right host. To reproduce, viruses release their genomic materials into the host 
cell, either by fusing their coat protein with the host cell membrane [Henderson and Hope, 
2006], or by direct injection, leaving the empty viral protein shell outside the host cell 
[Jiang et al., 2006]. New viral genomic materials and proteins are subsequently 
synthesized with the aid of the host enzymes, assembled into infective viral particles, 
called virions, and released to infect other cells. Viruses tend to infect only their natural 
host species, although cross-species transfer is not uncommon. In recent years, certain 
animal viruses, such as the hantavirus [Deutz et al., 2003] and SARS-associated 
coronavirus [Peiris et al., 2003], have crossed species to cause new diseases in human 
[Louz et al., 2005]. Plant viruses, however, are generally not equipped to infect animal 
cells although they may be capable of infecting a number of related plants. 
 
1.4.2 Virus Structure 
1.4.2.1 Components  
Viruses are generally composed of genomic materials enclosed within a protein shell 
known as the capsid [Johnson and Speir, 1997]. Viruses may be grouped into DNA 
viruses (e.g. hypovirus, atadenovirus) or RNA viruses (e.g. influenzavirus and carmovirus) 
depending on the type of genomic materials they carry. Most viruses have their genomic 
information encoded in a single stranded RNA. Positive-stranded viruses, e.g. Hibiscus 
latent Singapore virus, Broad bean mottle virus and Cowpea chlorotic mottle virus, use 
the RNA as a messenger RNA for direct synthesis of viral proteins (translation) [Dzianott 
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and Bujarski, 1991], while negative-stranded viruses, such as the simian virus, have 
genomes which are complementary to the mRNA and carry RNA polymerase to 
synthesize the mRNA [Arimilli et al., 2006]. The protein cage (PC) of virus, also named 
capsid, which protects the nucleic acid from enzyme digestion and aids in viral 
penetration of host cell, is made up of repeating copies of structural units known as coat 
proteins [Crick and Watson, 1956]. The capsid, together with the enclosed genomic 
materials, is called the nucleocapsid, which is equivalent to the virion for many plant 
viruses. Most animal viruses, e.g. the human immunodeficiency virus [Zhu et al., 2006], 
also have an envelope structure surrounding the capsid [Szakonyi et al., 2006]. The 
envelope of phospholipids and glycoprotein further protects the virus from chemical and 
enzymatic degradation. Plant viruses, on the other hand, do not often possess an envelope 
structure [Ke et al., 2004]. 
 
1.4.2.2 Architecture 
There are predominantly two kinds of shape found amongst viruses: rods and spheres 
[Klug and Caspar, 1960; Johnson and Speir, 1997]. The Tobacco mosaic virus (TMV) is 
an example of a rod-shaped virus (Figure 1-4). Viewed under a transmission electron 
microscope (TEM), the TMV presents with a straight rod protein shell that has a length of 
about 300nm [Choi and Rao, 2000]. The rod-like capsid comprises of protein subunits 
arranged in a helix model [Klug and Caspar, 1960]. 
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Figure 1-4. The rod shape of Tobacco mosaic virus . (a) Schematic structure showing the 
arrangement of helical protein subunits in the capsid [Klug and Caspar, 1960]. (b) TEM 
micrograph of TMV. Bar = 50 nm [Choi and Rao, 2000]. 
 
Most plant and animal viruses, however, appear as spherical particles under an 
electron microscope. The spherical structure is actually an icosahedron, also known as a 
cubic symmetrical polygon [Crick and Watson, 1956]. Examples of icosahedral viruses 
are the Human immunodeficiency virus (HIV) [Fuller et al., 1997], Cowpea chlorotic 
mottle virus (CCMV) [Speir et al., 1995], Cowpea mosaic virus (CPMV) [Chatterji et al., 
2002] and Hibiscus chlorotic ringspot virus (HCRSV) [Doan et al., 2003]. An 
icosahedron is a highly symmetrical structure with 12 vertices and 20 facets, each facet 
being an equilateral triangle (Figure 1-5, a). As shown in Figure 1-5 b, the edges of the 
triangles have 2-fold axes of symmetry and there are fifteen of such axes in each 
icosahedron. In addition, there are ten 3-fold axes of symmetry extending through each 
facet, and six 5-fold axes of symmetry passing through the vertices of the triangles. The 
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template shown in Figure 1-5 c provides the construction blueprint of an icosahedron. 
Besides hexamers (6 equilateral triangles), the incorporation of pentamers (5 equilateral 
triangles) is necessary, for the convex pentamers introduced curvature into an array of 
hexamers, which would otherwise form a flat or planar sheet. Twelve pentamers are 
required to form the icosahedron structure. Viruses adopt the icosahedral symmetry 
because the quasi-equivalent structure appears to be an economical way to evolve into 
larger volume [Harrison, 2001]. It has been shown that the construction of 20 subunits of 
triangles into an icosahedron is an optimal method for producing a shell of equivalently 
bonded identical structures with minimum free energy [Crick and Watson, 1956]. 
However, it is difficult to maintain the integrity of an icosahedron structure made up 
with only 20 subunits. Even an icosahedral structure with 60 coat proteins is not common 
amongst viruses, a rare example being phi X174 [Leodevico et al., 1994]. Most viruses 
have complex icosahedral structures comprising more than 60 subunits [Olson et al., 
1992]. The number of subunits in an icosahedral viral capsid is calculated in multiples of 
60, the multiple being designated as the triangulation or T number. The T value is 
calculated using the flat template (Figure 1-5 d), and the value is deduced from the 
distance between the hexamers, or pentamers when folded to the icosahedron. T values of 
1, 3, 4, 7, 9, 12 or higher have been obtained. T=1 gives the simplest icosahedral structure 
that is made up of 60 subunits and in which the pentamers are located side by side. Most 
viral structures have T=3 or 180 subunits, the final assembly of which resembles a 
football (Figure 1-5 e) [Speir et al., 1995; Chatterji et al., 2002; Doan et al., 2003]. 








Figure 1-5. Structure of an icosahedron virus. (a) The 20 facets and 12 vertices. (b) The 
2-fold, 3-fold and 5-fold axes of symmetry. (c) Introduction of pentamers induces 
curvature in a planar sheet of hexamers that allow for the formation of an icosahedron. (d) 
Calculation of T value for the icosahedral structures. To form icosahedral structure, the 
green color hexamers shall be replaced by pentamers. (e) Schematic representation of an 
icosahedral structure with T = 3. 
 
The CCMV and CPMV are well-characterized examples of icosahedral viruses with T 
value of 3 and a protein cage of diameter 28 nm comprising of 180 units of coat protein. 
The icosahedral virus is stable enough to maintain its integrity even under harsh 
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conditions, e.g. at pH values ranging from 3.5 to 9 for 1 h [Wang et al., 2002] or when 
subjected to chemical modifications, such as PEG conjugation [Raja et al., 2003]. 
However, a high pH (>7.0) and low ionic strength (I = 0.1) may result in swelling of the 
virus, causing 2 nm-openings along the 3-fold axes of symmetry [Fox et al., 1998]. The 
assembly of the coat proteins of CCMV into the stable icosahedral structure does not 
require a host cell, and has been shown to occur in vitro in the presence of divalent 
cations or low pH [Fox et al., 1998; Douglas and Young, 1998]. These properties render 
the CCMV to be an interesting nanoscale platform to explore for drug delivery [Douglas 
and Young, 2006]. 
 
1.4.3 Pharmaceutical applications 
The majority of viruses are uniform nanoscale assembly of biomacromolecules [Crick 
and Watson, 1956]. This monodispersity in size, coupled with their cytoinvasive 
capability and the potential to manipulate viruses into carrying a cargo other than their 
natural genomic materials, have made viral particles highly attractive vectors for gene 
delivery. For example, the transfection efficiency of pHCMV-β-galactosidase plasmids 
was at least 4-fold higher when delivered by the Herpes simplex virus than by liposomes 
[Rouse et al., 2000].  
Animal viruses have been widely studied as vectors for gene delivery as their inherent 
cytoinvasive property offers a distinct advantage over non-viral nanoscale gene delivery 
platforms [Zhang and Godbey, 2006]. Gene delivery by animal viral vectors, such as the 
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Adeno-associated viruses (AAV), Adenoviruses (Ad) and Retroviruses, has been well 
documented. The AAV has the advantages of being a non-pathogenic human virus 
[Hermonat and Muzyczka 1984] that can infect both dividing and non-dividing cells 
[Kearns et al., 1996]. However, the application of AAV as a gene vector has been limited 
by the costly and labor-intensive purification processes [Zhang et al., 2001] as well as by 
the size limitation of the capsid, which cannot accommodate a therapeutic gene larger 
than 4.7 kb [Dong et al., 1996]. Ad-based systems are able to carry a larger gene cargo as 
the native virus has a double-stranded DNA genome of 36 kb [Mah et al., 2002]. Ad-
based systems are highly efficient in infecting both dividing and non-dividing cells [St 
George, 2003], but they tend to elicit a host immune response [Crystal et al., 1994]. 
Viruses in the Retroviridae family are enveloped, single-stranded RNA-containing 
viruses [Mah et al., 2002]. Retroviral-mediated gene therapy showed efficacy in ex vivo 
gene transfer [Miller et al., 1990; Scharfmann et al., 1991; Mah et al., 2002] but it was 
difficult to engraft the gene-transferred cells back into the hosts [Mah et al., 2002]. The 
Retrovirus family also includes the Lentiviruses, well-known members of which are the 
Human immunodeficiency virus type 1 (HIV-1), Simian immunodeficiency viruses (SIV) 
and Feline immunodeficiency virus (FIV) [Poeschla et al., 1998; Mah et al., 2002]. 
Although lentiviral-based vectors can efficiently transfer and integrate exogenous 
genomic material into non-proliferating cells [Naldini et al., 1996; Kafri et al., 1997; 
Miyoshi et al., 1999], safety is a major concern as they may revert to the extremely 
harmful wild-type viruses, especially the HIV-1 based vectors [Mah et al., 2002]. 
A safer alternative to using intact viral capsid as vectors is to use virosomes, which 
are artificially reconstituted micro- or nano-systems e.g. liposomes conjugated with viral 
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proteins or envelops [Westerfeld et al., 2006]. Virosomes lack infectivity but possess the 
viral functions of interacting and fusing with cell membrane, They have been shown to be 
highly efficient in delivering therapeutic materials as diverse as doxorubicin [Waelti et al., 
2002], malaria-antigens [Westerfeld et al., 2006] and small interfering RNA [de Jonge et 
al., 2006] .  
Compared with animal viruses, plant viruses have rarely been used for biomedical 
applications. An underlying reason may be the significant differences between plant and 
animal viruses in their structure, and the mechanisms of infection and transmission. Thus, 
it is necessary to consider the characteristics of plant viruses to explore whether different 
strategies are required to utilize plant viruses for drug delivery.   
 
1.4.4 Plant viruses for biomedical applications 
1.4.4.1 Mechanisms of Infection and Transmission of Plant viruses 
There are fundamental differences in the infection and transmission mechanisms 
between plant and animal viruses. The coat protein of an animal virus can target specific 
membrane receptor on the host cell that permits entry of its genomic materials into the 
cell [Zhang and Godbey, 2006]. This major mechanism of animal virus transduction is 
exploited in gene delivery. On the other hand, no plant virus to date has been found to 
gain entry into host cells by interacting with a specific cellular receptor. Plants are 
protected by layers of wax and pectin, and the cytoplasmic membranes of plant cells are 
surrounded by a thick overlying cellulose wall [Gamble, 2003]. Successful infection by 
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plant viruses therefore necessitates some form of mechanical damage to the cell wall 
followed by opportunistic penetration by the viruses. For example, the widely used 
vegetative propagation/grafting technique often introduces injury that allows viruses to 
spread to new plants [Crescenzi et al., 2004]. In the laboratory, the infection of plants 
with viruses is carried out by simulating such mechanical injury, usually by rubbing 
virus-containing solutions on plant leaves, the injury to the leaves creating the 
opportunity for viral entry into the plant [Lee et al., 2003]. Plant viruses may also infect 
new host through vectors, such as bacteria, fungi, nematodes, arthropods, mites and 
insects [McPherson, 2006].  
Once they have infected a host plant, plant viruses are observed to spread to all other 
parts and to cause systemic symptoms involving the whole plant [Pacha and Ahlquist, 
1992; Zhou et al., 2006]. However, the transmission of plant viruses between cells occurs 
by a different mechanism from that of animal viruses, which infect new cells via specific 
receptors. It is believed that the spreading of plant viruses in the host is either by direct 
cell-to-cell contact or by the vascular system [Scholthof, 2005]. Some plant viruses 
exploit the plasmodesmata to aid transmission. The plasmodesmata is a channel in the 
cell wall that allows neighbouring cells to communicate with each other and exchange 
materials, but is too small to permit the entry of exogenous particles or genomic materials 
[Wolf et al., 1989; Martens et al., 2006]. To overcome this barrier, plant viruses have 
evolved specialized proteins to modify the plasmodesmata. An example is the TMV, 
which expresses a 30 kDa-protein from a sub-genomic mRNA, which can dilate the host 
plasmodesmata, the increased permibility permitting the virus to move between plant 
cells [Beachy and Heinlein, 2000; Citovsky, 1999]. Similarly, the CPMV expresses a 
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special protein that forms tubular structures in the plasmodesmata to allow for its transfer 
from cell to cell [Wellink et al., 1993]. 
 
1.4.4.2 Potential as drug delivery platforms 
The protein cages of plant viruses can undergo conformational changes, including 
swelling, disassembly and reassembly, under different conditions [Bancroft et al., 1968; 
Bancroft and Hiebert, 1967; Hiebert and Bancroft, 1969; Hiebert et al., 1968]. Plant viral 
capsids can be disassembled to allow for the removal of native viral RNA, then 
reassembled to produce empty viral protein cages for drug loading. Several methods have 
been explored for this purpose, including dialysis against a medium of high pH (> 7.5) or 
exposure to heat (55 oC) [Mutombo et al., 1993], high pressure (2400 × 105 Pa, 50 min, 
25 oC) [LeimkuÈhler, 1994; Michels et al., 1999] or alkaline pH (>pH 11, 30 min, 30 oC) 
[Kaper, 1964], or subjection to freezing and thawing cycles [Michels et al., 1999]. 
Among these methods, the dialysis of a viral solution against a buffer of high pH is most 
often employed. For some plant viruses, capsid disassembly will occur when dialyzed 
against a buffer of pH 7.5 or higher [Fox et al., 1998]. Following the disassembly of the 
capsid, the viral RNA will be released. It can then be separated from the protein coats by 
centrifugation before the coat proteins are reassembled into empty capsids at lower pH 
[Douglas and Young, 1998].  
The capability to disassemble, then resemble the plant viruses in vitro offers 
opportunities for the development of drug delivery platforms. In fact, under appropriate 
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in vitro conditions, the purified coat proteins and viral RNA can be reassembled into a 
virion, which is not only similar to the native virus when viewed under an electron 
microscope, and has been shown to retain infectivity [Zhao et al., 1995]. Removal of the 
viral genomic materials prior to reassembly will cause the formation of empty protein 
cages [Bancroft et al., 1968], which often have identical structures to the native viruses 
[Fox et al., 1998]. These protein cages offer nanoscaled cavities, which may be used to 
encapsulate drug molecules for delivery.  
In addition, the viral protein cage can be made to undergo reversible conformational 
changes under specific conditions that cause the opening or closure of pores on the cage 
surface. One of the most widely studied plant viruses in this regard is the CCMV, a 28 
nm icosahedral plant virus with T = 3 and 180 coat proteins. CCMV particles were stable 
at pH 5.0, but their diameter could increase by approximately 10% when the pH was 
increased to 7.0 at low ionic strength (I = 0.1) [Zhao et al., 1995]. This swelling was 
caused by a radial expansion at the 3-fold axes of symmetry, and was accompanied by the 
appearance of 2-nm apertures at each of the axes [fox et al., 1998; Speir et al., 1995]. 
Calcium ions were important for the stability of the capsids. Swelling occurs only in the 
absence of Ca2+, the swelling phenomenon being readily reversible by lowering the pH 
and resupplying the viral particles with Ca2+. The chemical switches offered by these 
pores provide unique molecular gating mechanisms to control the containment and 
release of entrapped materials [Fox et al., 1998; Zhao et al., 1995], and create 
opportunities for the development of controlled release drug delivery platforms.  
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A review of the literature indicates that some materials could be loaded into empty 
protein cages derived from plant viruses. Again, the most widely studied example is the 
protein cage obtained from the CCMV, which has been used to load materials ranging 
from ions to polymers and metal nanoparticles. Charged species, e.g. ions, were loaded 
into CCMV protein cages by utilizing the pH-dependent gating mechanism. For example, 
the aqueous soluble tungstate ions (WO2-4 ) were loaded into the protein cages by co-
incubation at pH 6.5. Swelling of the CCMV protein cage at this pH caused the opening 
of apertures on its surface, which enabled the tungstate ions to diffuse into its interior. 
When pH of the medium was subsequently lowered to 5.0, the precursor tungstate ions 
(WO2-4) were converted to the paratungstate polyanions (H2W12O10-42), which being less 
water-soluble, would precipitate out as nanosized crystals. At the same time, the lowering 
of pH reversed the conformational change in the virus protein cage, and the closure of 
apertures on the surface of the cages ensured the successful encapsulation of nanosized 
tungstate crystals within the protein cage. Likewise, anionic polymers e.g. poly-
anetholesulfonic acid, could be encapsulated into the CCMV protein cages by a similar 
mechanism. The resultant polymer-loaded viral protein cages could be isolated from the 
empty ones by gradient centrifugation. When imaged under the TEM, the polymer-loaded 
viral protein cages appeared as uniformly sized particles whose shape was no different 
from that of the native virus [Douglas and Young, 1998]. More recently, gold 
nanoparticles (16 nm diameter) have also been successfully loaded into the CCMV 
protein cages [Chen et al., 2006].  
Electrostatic interaction appears to be critical for the loading of materials into the 
CCMV. The native CCMV coat proteins have highly basic N-termini, made up of 
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positively charged Arg and Lys that project into the interior of the viral capsid. The 
positive charges facilitate the encapsulation of anionic RNA viral genome, and the 
interaction between coat proteins and RNA is believed to be important for the initiation 
of resembly into viral capsids [Douglas and Young, 2002]. These positively charged N-
termini could be exploited for the loading of negatively charged exogenous material, such 
as the WO2-4 ions, but they would hinder the loading of positively charged materials. 
Genetic manipulation to change the amino acid sequence of the N-terminus of CCMV to 
provide an anionic interior surface has been attempted [Douglas and Young, 2002], the 
mutated coat proteins being reassembled into protein cages with no significant change in 
architecture compared to the native virus. The mutated protein cages of CCMV have been 
used successfully to encapsulate nanosized ferric ions [Douglas and Young, 2002]. The 
encapsulation of uncharged gold nanoparticles required a different approach. The gold 
nanoparticles were conjugated with carboxylated terminated thiolalkylated tetraethylene 
glycol functionality, which allowed them to mimick the electrostatic behaviour of the 
native nucleic acid to bring about initiation of the PC reassembly [Chen et al., 2006]. The 
resultant system was a nanostructure that was virus-like with a gold core.  
Researchers have also used plant viral protein cages as a template for compound 
conjugation. The protein cages provide several reactive groups e.g. Lys and Cys amino 
acids, on their surface, and they exhibit considerable stability, being able to retain their 
chemical and conformational structures under a variety of conditions. For example, the 
plant virus CPMV could retain its integrity at temperatures of up to 60 oC, or in the 
presence of small amounts of organic solvents, such as DMSO, as well as in a wide pH 
range of 3.5 to 9 [Raja et al., 2003]. Plant virus protein cages can be reacted with both 
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hydrophobic and hydrophilic molecules, including metal, polymer as well as 
protein/peptide, to produce novel nanosized compounds [Wang et al., 2002].  
The protein cage of the CPMV has been the most widely applied amongst plant 
viruses as a potential nanoscaled scaffold for compound conjugation. CPMV has served 
as a nanoscaled template for conjugation with gold nanoparticles [Soto et al., 2005; Wang 
et al. 2002]. Site-specific mutations were performed to insert the amino acid, Cys, 
between positions 98 and 99 in the coat protein of CPMV for the conjugation. Colloidal 
gold nanoparticles with diameter of 2 to 5 nm were attached to the surface of the protein 
cage by reaction with the sulfhydryl groups of the Cys. The result was a three-
dimensioned pattern with specific inter-gold particle distances [Blum et al., 2005].  
Besides inorganic gold nanoparticles, organic polymers could also be conjugated onto 
the coat protein of plant viruses. For example, the surface of the CPMV protein cage has 
been modified with poly(ethylene glycol) (mw 2000 and 5000) by N-hydroxysuccinimide 
ester-mediated reaction [Raja et al., 2003]. The CPMV retained its stability during the 
reaction process, which required exposure to a high pH (pH 8.4) for a prolonged period of 
4 h. The hydrophilic PEG-linked CPMV protein cage had the same size and morphology 
as the native virus particles but provoked a poorer immune response in the female 
mice.than the native virus. Entire proteins, e.g. Intron 8 protein, T4 lysozyme and LRR-
internalin B, were also been reported to be chemically linked to the protein cage of the 
CPMV [Chatterji et al., 2004], the protein molecules preserving their biological activity 
after conjugation. The capacity to chemically modify the surface of plant virus protein 
cage to provide specific functionalities would significantly widen the potential of these 
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cages as drug delivery platforms, including the possibility of developing the protein cages 
as targeting drug delivery systems.  
Several research groups have further explored the feasibility of using plant virus 
protein cages for foreign peptide expression. The icosahedral structure of the cages 
appears to be sufficiently robust not to be disrupted by the insertion of bioactive peptides 
[Lico et al., 2006; Shadwick and Doran, 2006]. Novel vaccines have been generated by 
introducing antigens onto the coat proteins of the CPMV [Langeveld et al., 2001] and 
TMV [McCormick et al., 2006] through genetic engineering. Chimaeric virus particles of 
CPMV expressing the peptide of the canine parvovirus were shown capable of eliciting 
high titres of the peptide-specific antibody when injected into dogs, the levels being 
sufficient to protect the dogs from a canine parvovirus challenge [Langeveld et al., 2001]. 
In another study, a peptide from the outer-membrane protein of Pseudomonas aeruginosa 
was expressed on the coat protein of TMV. Upon administration to mice, the engineered 
plant virus protein cage was able to generate high titres of antibody to protect the mice 
from the bacterial infection [Staczek et al., 2000]. A distinct advantage of these chimaeric 
plant virus platforms compared with animal virus platforms is their safety profile, as plant 
viruses have no infectivity towards the animal recipients [Nicholas et al., 2002]. 
Other bioactive functional peptides have been expressed on the surface of plant virus 
protein cages to impart novel functions. CPMV was used as a platform to display a 
heterogeneous functional peptide, a sequence derived from the binding site of CD46 to 
the measles virus. The peptide was expressed on all 180 copies of the coat protein in each 
CPMV protein cage, which provides a clustering of the peptide on the surface at high 
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concentration. As a result, the expressed peptide was able to inhibit the measles virus 
(MV) infection in mice and showed a-100 fold higher efficacy at inhibiting MV infection 
in vitro compared to the original CD46 peptide [Khor et al., 2002]. 
To summarize, plant virus protein cages present with specific properties that made 
them attractive carriers for drug delivery. They are uniformly sized, robust nanostructures 
that are precise in chemical and conformational structures. Yet they lend themselves to 
physical and chemical manipulation that not only allowed exogenous material to be 
encapsulated within the cages, but also to be conjugated onto the protein cage surface. 
Specific functions, e.g. targeting capability, may also be imparted by the conjugation of 
appropriate chemical species to the protein cage surface. In this project, the feasibility of 
producing a nanoscale targeted drug delivery platform using the Hibiscus chlorotic 
ringspot virus (HCRSV) was explored. Although the structure of the HCRSV has been 
widely studied, this virus has not been evaluated in depth for pharmaceutical applications.    
 
1.5 Hibiscus chlorotic ringspot virus 
1.5.1 Taxonomy 
The Hibiscus chlorotic ringspot virus (HCRSV) [Huang et al., 2000] is a monopartite 
virus that was first described in a hibiscus cultivar imported to the United States from El 
Salvador. The virus infects the kenaf (Hibiscus cannabinus), a woody plant of interest to 
the woodpulp industry in the United States [Johnson, 2001], and is found worldwide 
where the hibiscus is cultivated [Waterworth et al., 1976], including Singapore [Wong 
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and Chng, 1992]. It induces chlorotic ringspots on naturally infected hibiscus leaves and 
causes local lesions on infected kenaf.  
The HCRSV is a single-stranded RNA virus belonging to the Tombusviridae family 
of plant viruses [Liang et al., 2002]. Based on virion morphology, genome organization, 
physicochemical properties and amino acid sequence, the virus is classified in the genus 
Carmovirus, which also includes the Carnation mottle virus (CarMV) [Guilley et al., 
1985], Turnip crinkle virus (TCV) [Carrington et al., 1989], Melon necrotic spot virus 
[Riviere and Rochon, 1990], Cardamine chlorotic fleck virus [Skotnichi et al., 1993], 
Saguaro cactus virus [Weng and Xiong, 1997], Galinsoga mosaic virus [Ciuffreda and 
Rubino, 1998], Japanese iris necrotic ring virus [Takemoto and Kanehira, 2000] and 
Pelargonium flower break virus [Berthome and Kusiak, 1998]. 
 
1.5.2 Structure of HCRSV 
The genomic RNA (gRNA) of HCRSV is 3911 nucleotides long (Figure 1-6) and has 
the potential to encode seven major open reading frames (ORF) [Huang et al., 2000; Koh 
et al., 2002] or two subgenomic RNAs (sgRNAs) of 1.7 and 1.5 kb [Huang et al., 2000; 
Liang et al., 2002]. The gRNA could potentially encode seven viral proteins. Two 5’-
proximal ORF may encode proteins with molecular weight (mw) of 28 and 81 kDa, 
which are believed to form the putative viral RNA-dependent RNA polymerase [Liang et 
al., 2002]. Two centrally located small ORFs encode two proteins required for viral 
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movement [Hacker et al., 1992; Li, et al., 1998]. The coat protein (CP) is encoded by p38 
from the 3’-proximal open reading frames. 
 
Figure 1-6. The genomic RNA and corresponding open reading frames of HCRSV 

















Table 1-1. Amino acid sequence of the HCRSV coat protein, which is composed of three 
domains: RNA binding domain, shell-forming domain and protruding domain. 
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The 38-kDa CP of HCRSV is composed of 345 amino acids (Table 1-1), consisting of 
3 domains. The internal RNA binding domain (R) may bind with the encapsulated viral 
RNA. The shell-forming domain (S) is the construct of the PC. As is common of viruses 
in the Tombusviridae family, the CP of HCRSV has a protruding domain (P) that is 
accessible for ligand conjugation (Figure 1-7). Both the shell-forming domain and the 
protruding domain contain an 8-stranded β–sandwich fold [Doan et al., 2003]. 
 
 
Figure 1-7. Conformational structure of the HCRSV coat protein, which contains two β-
sheets: the one in the P domain is shown in red-yellow color, and the other in the S 
domain is shown in blue-green color. The structure was modeled by SWISS-MODEL 
[http://www.expasy.ch/swissmod/] 
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The HCRSV virus particle contains 180 copies of the CP, forming a 30-nm diameter 
icosahedral protein cage (PC) with T = 3 symmetry. The HCRSV particle has been 
crystallized and its structure determined at the atomic resolution of 4.5 A° [Doan et al., 
2003]. Observed by cryo-electron microscopy, the HCRSV PC has 90 dimers of 
protruding domains (Figure 1-8), again a characteristic arrangement of the Tombusviridae 
family of viruses. The S domains form fivefold and sixfold rings around the fivefold and 
threefold axes, respectively, with a depression or hole in the centre [Doan et al., 2003, 
Lee et al., 2003]. 
 
 
                                         (a)                                                  (b) 
Figure 1-8. Structure of the HCRSV virus protein cage. The coat protein is arranged in T 
= 3 icosahedral model. (a) view down from a 2-fold axis of symmetry, (b) closeup view 
down from a 3- fold axis of  symmetry [Doan et al., 2003] 
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1.6 Statement of purpose 
Chemotherapeutic agents remain a mainstay of treatment for cancer, a leading cause 
of death for human beings. Treatment outcomes for patients who are being treated with 
these potent, highly toxic drugs would be significantly improved if the drug delivery 
could be targeted specifically to the tumor cells. Targeted delivery would not only 
increase efficacy as a result of drug concentration in the target cells, but would reduce 
undesirable side effects by sparing normal cells from the cytotoxic effects of the drugs.  
Plant virus-based systems, in particular, the icosahedral plant virus protein cages 
constructed from T × 60 coat proteins, could be an attractive novel platform to develop a 
targeted delivery system for anticancer drugs. These virus protein cages are nanoscale in 
dimension, highly uniform in size and composition, and adequately robust under 
relatively harsh processing conditions of pH and ionic strength. More importantly, the 
virus protein cages readily lend themselves to physical and chemical manipulations 
without sacrificing structural integrity. The native virus capsid can be disassembled in 
vitro to remove the native RNA genomic materials, then reassembled into empty protein 
cages that are similar in morphology to the native viruses. Under appropriate conditions, 
guest molecules, e.g. drugs, could be successfully loaded and retained within the protein 
cage. Alternatively, these molecules could be chemically conjugated onto the surface of 
the protein cage, or the coat proteins could be genetically engineered to express 
exogenous peptides. These manipulations would allow the development of drug delivery 
systems with specific functionalities e.g. a capability to target cancer cells. Another 
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reason for developing plant virus-derived delivery systems was their potentially lower 
pathogenicity and immunogenicity compared with animal virus-based systems.  
To date however, there is a scarcity of research on plant virus-derived systems for the 
delivery of anticancer drugs, although a variety of other types of compounds, ranging 
from inorganic metals to organic polymers and peptides have been successfully 
conjugated on or encapsulated into plant virus protein cages. Moreover, the research has 
tended to focus on a couple of plant viruses, namely the CCMV and CPMV. Although the 
HCRSV is a common icosahedral plant virus in Singapore, its structure having been well 
established by local researchers [Doan et al., 2003], this virus had not been investigated 
for its potential as a drug delivery platform. This project was therefore initiated to 
evaluate the feasibility of using the HCRSV PC as a template for targeted drug delivery. 
The hypothesis for the project was that the purified coat proteins of HCRSV could be 
reassembled into protein cages in vitro to load an anticancer agent, and its surface could 
be modified to impart cancer-targeting functionality. Doxorubicin was used as the model 
anticancer agent and folic acid the targeting ligand.  
Various studies were conducted in this project to test the hypothesis. The objectives 
of these studies were as follows: 
(1) Preparation of purified empty protein cages of HCRSV for the loading of guest 
molecules. The study included the development of methodologies to disassemble the 
capsid of HCRSV to remove the native RNA, followed by reassembly of the purified coat 
proteins into empty protein cages. Methods were developed to characterize the HCRSV 
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coat protein and protein cages at different stages of processing, in order to provide a 
fundamental understanding of the HCRSV protein cage.  
(2) Evaluation of the mechanisms for loading guest molecules into the reassembled 
protein cages derived from the HCRSV. 
(3) Development and characterization of doxorubicin-loaded HCRSV protein cages 
whose surface had been conjugated with folic acid molecules. 
(4) In vitro evaluation of the efficacy of the doxorubicin-loaded folic acid-conjugated 
HCRSV based drug delivery systems using human ovarian carcinoma and human 
nasopharyngeal carcinoma cell models. 
 







Preparation and characterization of empty 




 Chapter 2. Preparation and characterization of empty PC derived from HCRSV  
 39
2.1 Introduction 
The primary purpose of this project was to develop a nano-sized drug delivery system 
based on the protein cage (PC) of a plant virus, the HCRSV, which belongs to the family 
of Tombusviridae, genus Carmovirus [Doan et al., 2003; Huang et al., 2000]. The 
HCRSV PC is an icosahedral structure comprising of 180 identical coat proteins (CP). 
The 38-kDa CP of HCRSV would be the most important “raw material” for this project 
as it constituted the building block for the construction of the drug delivery platform. 
However, neither HCRSV nor its CP was commercially available. Thus, for this project 
to be viable, a stable HCRSV virus resource from which a purified form of the virus 
could be harvested had to be established. In addition, methods had to be developed to 
remove the 3.9 kb RNA from the viral capsid, and to reassemble the purified CP into 
empty cages that were comparable in structure to the HCRSV capsids.  This section 
describes the development of methods to prepare and evaluate the empty HCRSV PC. 
The kenaf, a plant crop of major interest to the wood pulp industry [Johnson, 2001], 
was chosen as the host of HCRSV because it thrived in the warm and humid environment 
of Singapore. Nevertheless, care had to be exercised in the cultivation of HCRSV in the 
kenaf. Conditions that adversely affected the growth of the host, such as extreme 
temperature and humidity, inadequate sunlight, strong winds, and insects that fed on the 
kenaf leaves, would lower HCRSV yield. Insects could also contaminate the HCRSV 
source by transmitting other viruses to the kenaf, as could infection of the plant by 
viruses in the soil. Contamination of the HCRSV source was of particular concern as 
failure to detect and isolate the contaminant would result in erroneous data [Doan et al., 
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2003]. For these reasons, it was critical at the outset to establish standard operation 
protocols for the culture of the host plant culture and for virus transfection in order to 
ensure a stable and reliable HCRSV source. 
Having established the HCRSV source, methods were developed to isolate the virus 
from its host, and subsequently to produce empty PC from the purified viruses. Isolation 
and purification of the HCRSV were achieved by a series of centrifugation processes, 
including centrifugation on sucrose gradient, as these had previously been established to 
be effective for the purification of a large quantity of HCRSV [Lee et al., 2003]. Novel 
methods, however, had to be developed to produce the empty PC from the HCRSV. This 
was because preliminary experiments have shown that the published methods, including 
dialysis against a medium of high pH (7.5) [Fox et al., 1998; Zhao et al., 1995], exposure 
to heat (55 oC) [Mutombo et al., 1993], incubation at alkaline pH (> pH 11, 30 min, 30 oC) 
[Kaper, 1964], and freezing and thawing cycles [Michels et al., 1999], could not 
effectively remove the RNA from the HCRSV without destroying its CP. In this project, 
methods involving the use of urea and dialysis were optimized to produce empty PC from 
the HCRSV.  
In vitro cytotoxicity studies were included as safety was a major concern for any 
novel drug delivery system. The MTT assay, which is a quantitative colorimetric method 
developed for measuring the mitochondrial dehydrogenase activity in viable cells, was 
employed for the in vitro cytotoxicity studies against the CCL-186, OVCAR-3 and CNE-
1 cell lines. The CCL-186 cells [Nichols et al., 1977] were derived from human normal 
lung fibroblasts, and were used in this project to represent normal human cells. The 
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OVCAR-3 [Hamilton et al., 1983] and CNE-1 [Zhang et al., 2005] cell lines, respectively 
developed from human ovarian carcinoma and human nasopharyngeal carcinoma, were 
used as representative models of human cancer cells. 
 
2.2 Materials 
CH3COONa, NaCl, NaOH, CaCl2, phenyl methanesulfonyl fluoride (PMSF), 
methanol, sodium lauryl sulfate (SDS), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltertrazolium bromide (MTT) and carborundum powder were from BDH Ltd 
(Poole, England); penicillin G, streptomycin, NaHCO3, sucrose, Triton X-100, 
(NH4)2SO4 and dialysis tube (mw cutoff 12 400) were from the Sigma Chemical Co. 
(Steinheim, Germany); fetal bovine serum (FBS), trypsin-EDTA and phosphate buffered 
saline (PBS, 14.4 g/L Na2HPO4, 2.4 g/L KH2PO4, pH 7.4) were from Gibco BRL Life 
Technologies (Grand Island, NY, USA); Tris (base) was from J.T. Baker (NJ, USA); 
ethylenediaminetetraacetic acid (EDTA), dithiothreitol (DTT) and urea were from Bio-
Rad (CA, USA); β-mercaptoethanol was from Merck (Darmstadt, Germany) and agarose 
was from Biowhittaker Molecular Applications (ME, USA).  
Hibiscus chlorotic ringspot virus (HCRSV) was obtained from the infected leaves of 
kenaf grown in the laboratory of Dr. SM Wong, National University of Singapore [Huang 
et al., 2000]. The human normal lung fibroblast cell line, CCL-186 (passage 15 to 25) and 
human ovarian carcinoma cell line, OVCAR-3 (passage 22 to 32), were obtained from 
the American Type Culture Collection (ATCC, Manassas, VA, USA), while the human 
nasopharyngeal carcinoma cell line, CNE-1 (passage p + 10 to p + 20), was obtained 
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from the National Cancer Centre of Singapore. The culture medium for OVCAR-3 and 
CNE-1 cell lines was folic acid-deficient RPMI 1640 medium, and that for the CCL-186 
cells was normal RPMI 1640 medium. All culture media were supplemented with 10% of 
FBS, 0.1 g/L of streptomycin and 0.1 g/L of penicillin. 
The following buffers were used: extraction buffer (0.2 M NaOAc, 50 mM NaCl, 5 
mM EDTA, 20 mM CaCl2, pH 5.4), re-suspension buffer (50 mM NaOAc, 50 mM NaCl, 
5 mM EDTA, 20 mM CaCl2, pH 5.4), storage buffer (10 mM NaOAc, 50 mM NaCl, 5 
mM CaCl2, pH 5.4) and buffer A (50 mM NaOAc, 50 mM NaCl, 2 mM EDTA, 20 mM 
CaCl2, pH 5.0). 
 
2.3 Methods 
2.3.1 Cultivation of HCRSV 
J. Arthur Bower’s Seed and Potting Compost (William Sinclair Horticulture Ltd., 
Lincoln, UK) was used for the plant culture. The seeds of kenaf (Hibiscus cannabinus) 
[Johnson, 2001] were cultured in the wetted earth in a culture room maintained at 20 to 
25 ºC with 18 h of light per day. After germination, the kenaf plants were transferred to 
pots at a density of 2 to 3 plants per pot. When the plants had developed 4 to 5 leaves, 
usually after 2 to 3 weeks, they were placed in a dark environment for one day before 
infection with the HCRSV virus. 
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HCRSV was obtained from an infected H. rosa-sinensis plant exhibiting chlorotic leaf 
spots tested positive for HCRSV by an enzyme-linked immunosorbent assay (ELISA) 
[Lee et al., 2003]. About 2 g of the infected leaves were ground with 10 ml of ice-cold 
phosphate buffered saline (PBS, 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, pH 7.4) 
in a mortar to produce a homogeneous slurry to which carborundum powder was added. 
The carborundum powder served to facilitate virus infection by inducing mechanical 
lesions when the slurry was rubbed onto the leaves of the kenaf plant using cotton sticks. 
Two leaves per plant were inoculated, care being taken to limit the mechanical damage to 
the leaves. After 5 min incubation, the leaves were rinsed with distilled water to remove 
traces of salts and the kenaf plants were kept in the dark overnight. The plants were 
subsequently cultured in a controlled environment of 25 ºC with 18 h of light per day for 
one month. During culture, the plants were protected with gauze to prevent potential 
contamination transmitted via insects. Kenaf leaves with chlorotic spots were then 
collected and stored at -80 ºC (Forma -86C ULT Freezer, Thermo Electron Corporation, 
MA, USA) until use. 
 
2.3.1.2 Purification of HCRSV 
HCRSV was purified by sequential steps of extraction, sedimentation and 
resuspension [Lee et al., 2003]. All procedures were carried out at 4 ºC unless otherwise 
stated. Kenaf leaves exhibiting chlorotic spots were homogenized in a Waring Blender 
(Waring Products, Inc., CT, USA) with 2 to 3 volumes (w/v) of extraction buffer 
containing 0.1% of β-mercaptoethanol. The slurry was centrifuged at 12 000 g for 15 min 
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using a JA14 rotor (Beckman Coulter Inc., Fullerton,CA, USA) and the supernatant was 
collected on ice. The pellet containing the plant debris was re-extracted with one volume 
of extraction buffer containing 0.1% β-mercaptoethanol and centrifuged at 12 000 g for 
15 min to maximize the virus yield. The pooled supernatants were incubated for 2h on ice 
with one volume of saturated (NH4)2SO4 solution to sediment the virus, which was 
subsequently pelleted by centrifugation at 12 000 g for 20 min. 
The HCRSV pellet was re-suspended overnight at 4 ºC in the re-suspension buffer 
supplemented with 0.1% of β-mercaptoethanol and 1% of Triton-X100. After 
centrifugation at 12 000 g for 15 min, the supernatant was collected and put on a layer of 
10% sucrose cushion. The viruses were collected as a pellet following ultracentrifugation 
at 100 000 g for 3 h using a SW41 rotor (Beckman Coulter Inc., Fullerton,CA, USA). 
The pellet was re-suspended in a small volume (0.5 to 1 ml) of re-suspension buffer 
overnight at 4 ºC to obtain the crude virus suspension. Sucrose dissolved in the re-
suspension buffer to concentrations of 10%, 20%, 30% and 40% were layered in 
centrifuge tubes using a syringe device (Figure 2-1) to prepare the sucrose gradients. 
These were stored at 4 ºC overnight before use. The crude virus suspension was 
centrifuged at 12 000 g for 3 min to remove insoluble debris, and the supernatant was 
ultracentrifuged on the sucrose gradient at 100 000 g at 4 ºC for 3 h using the SW41 rotor. 
The virus band in the sucrose gradient was visible under a beam of light in a dark room. 
The virus band was aspirated with a pipette, diluted with 3 to 4-fold its volume of re-
suspension buffer and centrifuged at 100 000 g, 4 ºC for 3 h to sediment the virus. The 
supernatant was discarded and the virus pellet was re-suspended in 0.5 ml of the storage 
buffer. The virus dispersion was stored at 4 ºC until use. 
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Figure 2-1. Preparation of a 10%-40% sucrose gradient for HCRSV virus purification. 
Layering of the sucrose solutions was achieved by using a syringe and needle, positioned 
near the bottom of a centrifugation tube, to introduce each sucrose solution in consecutive 
order of increasing concentration into a centrifuge tube (Left). After overnight 
stabilization of the sucrose gradient, the crude virus suspension was loaded on the top 
layer of the gradient (Right). The sample was then purified by ultracentrifugation.  
 
2.3.4 MTT assay 
The determination of cell viability following exposure is a common assay to evaluate 
the in vitro cytotoxicity of biomedical materials. The MTT assay is one of several 
methods established for measuring cell viability. It is a sensitive, quantitative and reliable 
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colorimetric assay that is used not only for measuring cell viability, but also cell 
proliferation and activation [Smith et al., 2005; Mosmann, 1983]. The MTT assay is 
based on the ability of mitochondrial dehydrogenase enzymes in living cells to convert 
the water-soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
into a dark blue, water-insoluble formazan product. The intracellular formazan may be 
extracted and solubilized with an appropriate solvent, and the optical density of the 
resultant solution is directly proportional to cell viability for a wide variety of cell lines 
[Mosmann, 1983; Gerlier and Thomasset, 1986; Grailer et al., 1988].  
In this study, test samples for the MTT assay were prepared in the following manner. 
HCRSV dispersion was sterilized by filtration through a 0.22 µm membrane (Millipore 
Corporation, MA, USA), then diluted with the cell culture medium to concentrations 
ranging from 1 mg/ml to 10 ng/ml. SDS and dextran were similarly dissolved in cell 
culture medium to 0.1% w/v and used as positive and negative controls, respectively. The 
CCL-186, OVCAR-3 and CNE-1 cells were separately seeded onto 96-well plates at the 
respective densities of 5 000, 20 000 and 5 000 cells/well. After 24h incubation at 37 ºC 
under 5% CO2/95% air atmosphere in a water-jacketed autoflow CO2 incubator (NuAire, 
MN, USA), the culture medium was replaced with 200 µl of test or control sample. 
Controls also included untreated cells, which were incubated with 200 µl of the culture 
medium. After incubation for the designated period of 4 h or 3 days, the samples were 
replaced with 100 µl of MTT solution (1 mg/ml in PBS, pH 7.4) and the cells were 
incubated in the CO2 incubator for another 4 h. The MTT solution was removed and 100 
µl of DMSO was added to each well to solubilize the formazan product, which was 
quantified by measuring the optical density of the resultant solution in a microplate 
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reader (TECAN fluorimeter, MA, USA) at λ590nm. Cell viability was expressed as the 
percentage of absorbance in sample wells relative to that in control culture medium wells. 
Experiments were performed in eight replicate wells for each test and control sample. 
 
2.3.2 Viral RNA removal and PC reassembly 
2.3.2.1 Protein denaturation using urea 
Urea has a strong capacity to denature protein [da Poian et al., 1995]. At sufficiently 
high concentrations, which might range from 1 M [da Poian et al., 1995] to 8 M [Michels 
et al., 1999], urea could induce the unfolding of viral CP to disrupt the integrity of the 
capsid, thus allowing for the separation of native RNA from the viral CP [Shirley et al., 
1995; Michels et al., 1999]. The purified CP could refold and assemble into viral-like 
capsids by dialysis against an appropriate medium following the removal of urea 
[Michels et al., 1999].  
To remove the viral RNA from the HCRSV, about 0.1 ml of HCRSV dispersion (10 
mg/ml in re-suspension buffer) was incubated with 1 ml of urea solution (8 M urea, 1 M 
NaCl and 0.01 M Na2HPO4, pH 7.2) at room temperature for 10 min [Michels et al., 
1999]. The solution was centrifuged at 25 000 g for 30 min at 4 °C to separate the viral 
RNA (pellet) from the unfolded CP (supernatant). To reassemble the CP into viral-like 
PC, the supernatant was dialyzed against buffer A for 12 h at 4 °C. The precipitate was 
isolated by centrifugation at 12 000 g for 15 min at 4 °C. 
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2.3.2.2 Dialysis  
Dialysis against a buffer of high pH is another method reported to aid in the removal 
of RNA from the capsid of viruses. The RNA of CCMV was isolated from its CP 
following the disassembly of the viral capsids upon dialysis against a Tris buffer (50 mM, 
1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 0.5 M CaCl2, pH 7.5) [Zhao et al., 1995; Fox 
et al., 1998]. For this reason, the method of dialysis was also explored for the removal of 
RNA from the HCRSV capsids.  
In our experiments, 0.1 ml of HCRSV dispersion (10 mg/ml in re-suspension buffer) 
was dialyzed for 12 h against one of 6 buffers (Table 2-1) to determine the effects of Ca2+ 
and pH on the efficiency of viral RNA removal. Samples dialyzed against buffers 
containing CaCl2 (Buffers 1 - 3) were subsequently centrifuged at 25 000 g at 4 °C for 30 
min, and the supernatants were collected for optical density measurement at 260 nm 
(OD260nm) and 280 nm (OD280nm) (Beckman Du 640B spectrometer, CA, USA). Samples 
that had been dialyzed against buffers without CaCl2 (Buffers 4 - 6) were subsequently 
mixed with a 5.5 M CaCl2 solution at a volume ratio of 10:1 to achieve final CaCl2 
concentration of 0.5 M. The mixtures were incubated at 4 °C for 30 min before they were 
processed by centrifugation and subjected to optical density measurement as described 
for samples dialyzed against Buffers 1 – 3. The supernatants, which represented purified 
CP solutions, were dialyzed against buffer A for 12 h at 4 °C to initiate the reassembly of 
the CP into empty PC. 
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 pH 7.0 pH 7.5 pH 8.0 
0.5 M CaCl2 Buffer 1 Buffer 2 Buffer 3 
No CaCl2 Buffer 4 Buffer 5 Buffer 6 
Table 2-1. Buffers used for the removal of HCRSV viral RNA via the dialysis method. 
All buffers contained 50 mM Tris, 5 mM EDTA, 2 mM DTT and 0.2 mM PMSF, but 
were adjusted to different pH using 1 M NaOH or HCl solutions. In addition, Buffers 1 – 
3 contained 0.5 M CaCl2 while Buffers 4 – 6 were prepared in the absence of CaCl2.  
 
2.3.3 Characterization of HCRSV and CP 
2.3.3.1 Ultraviolet (UV) spectroscopy 
The concentration of HCRSV was evaluated by optical density measurement at 260 
nm (OD 260nm) using an extinction co-efficient of e 260nm = 5.0 [Morris and Carrington, 
1988; Lee et al., 2003]. The following equations were used to calculate the concentration 
and yield of HCRSV. The purity of HCRSV was monitored by the ratio of 
OD260nm/OD280nm. 
 
      OD 260nm x dilution factor 
        5.0 (extinction coefficient) 
          Viral Concentration (mg/ml) x volume (ml) x 100 
      Weight of leaves (g) 
 
Viral Concentration (mg/ml) =  
 Yield (mg/100g) = 
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UV spectroscopy also provided a reliable, convenient and sensitive method to 
confirm efficient viral RNA removal from the capsids [Michels et al., 1999; Douglas and 
Young, 1998]. Viral RNA and proteins have different UV spectra as the former has 
strong optical absorption at 260 nm [De Mey et al., 2006], while the CP has maximum 
absorption at 280 nm due to the presence of the amino acids, tryptophan (Trp) and 
tyrosine (Tyr), in its sequence [Mach et al., 1992]. The OD260 nm/OD280 nm ratio is a useful 
index to measure virus purity because a virus in whose structure the relative amounts of 
RNA and CP have been determined will have a defined OD260 nm/OD280 nm ratio. Changes 
to this ratio would indicate contamination and impurity [Michels et al., 1999]. In addition, 
the extinction co-efficient of the viral RNA at 260 nm is much higher than that of the CP 
at 280 nm [De Mey et al., 2006] and the virion would have a UV spectrum showing 
maximum absorption at 260 nm due to the predominance of the RNA optical absorption 
[Lee et al., 2003]. Only when the viral RNA has been removed by more than 95% would 
the CP and viral RNA have comparable optical absorption at the respective wavelengths, 
and the OD260 nm/OD280nm will decrease to below 1. Samples with OD 260 nm/OD 280 nm 
ratios lower than 0.9 may therefore be regarded as containing very little, if any, residual 
RNA or intact virions [Michels et al., 1999].  
In our study, the efficiency of RNA removal from the HCRSV was determined by 
evaluating the UV spectra and OD260 nm/OD280nm ratios of the respective supernatants. 
Since there were 6 Trp and 7 Tyr units in the sequence of the HCRSV CP, the extinction 
coefficient (e) of the CP at 280 nm was taken to be 36 200 ml/mmol [Mach et al., 1992]. 
This value was used to determine the concentration of the purified CP in the supernatants.  
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2.3.3.2 Native gel electrophoresis 
Native agarose gel electrophoresis [Newman et al., 2003] was used to analyze the 
electrostatic property of the HCRSV virions and CP. The CP and in vitro reassembled 
empty PC produced by the dialysis method, as well as the native HCRSV, were mixed 
with a loading buffer (60% sucrose solution) to give concentrations of about 1 mg/ml. 
About 10 μl of samples were loaded onto 1% agarose gel and subjected to electrophoresis 
at 5 V/cm for 1 h (Bio-Rad Sub-Cell electrophoresis system, CA, USA). The protein was 
stained with coomassie blue (0.0025%) followed by destaining overnight with a 
destaining buffer (5% acetic acid, 5% methanol). 
 
2.3.3.3 Circular Dichroism (CD) spectroscopy 
CD experiments were performed to study the conformational structure of the HCRSV 
CP. Samples including the native HCRSV, purified CP and in vitro reassembled PC were 
diluted in the re-suspension buffer to a final concentration of 0.1 mg/ml at ambient 
temperature. Analysis was performed in a CD spectrometer (Jasco J-815 
spectropolarimeter, Tokyo, Japan) using a quartz cell with a 1 mm path length. Spectra 
were recorded with a 1.0 nm bandwidth and resolution of 0.1 nm over the wavelength 
range of 190 to 260 nm. The final spectra was averaged from 3 scans and subtracted from 
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2.3.3.4 Transmission Electron Microscopy (TEM) 
The size and morphology of native HCRSV and reassembled PC were observed under 
a transmission electron microscope (TEM). Samples were diluted to 0.1 mg/ml with re-
suspension buffer, and about 10 µl of dispersion was placed on a copper grid [Lee et al., 
2003]. The samples were stained with 10 µl of 1% PTA solution, with excess PTA 
removed after 30 s by blotting. The grid was allowed to dry at ambient temperature 
before observation under a TEM (CM10; Philips Electronic Instruments, NJ, USA). 
 
2.3.3.5 Zeta size and zeta potential analysis 
Photon correlation spectroscopy (PCS), also referred to as dynamic light scattering 
and quasi-elastic light scattering [Goll and Stock, 1977; Huang et al., 2004], has been 
widely applied to measure the size of nanosized structures. It is applicable to particles of 
1 to 5 000 nm which exhibit Brownian movement in a liquid. The pace of movement can 
be detected by analyzing the time dependency of the fluctuations in light intensity 
scattered from the particles when they are illuminated with a laser beam. The speed of 
movement is inversely proportional to particle size; the smaller the particles, the faster in 
movement or diffusion. Particle size of native HCRSV and PC was determined using a 
particle size analyzer based on the PCS principle (Zetasizer 3000HSA, Malvern 
Instruments Ltd., Worcestershire, England). Samples were diluted to about 0.1 mg/ml 
with distilled water and measured at room temperature. 
Zeta potential can be determined by the electrophoretic mobility of charged particles. 
The surface charge may provide information on the stability of the particles since a 
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higher zeta potential [Yang et al., 2007] suggests stronger electrostatic repulsive forces 
between particles, and a lower risk of the particles aggregating. In this experiment, the 
zeta potentials of native HCRSV and the empty PC were determined by laser doppler 
velocimetry using the same particle size analyzer (Zetasizer 3000HSA) equipped with an 
electrophoresis cell. Samples were diluted to about 0.1 mg/ml with distilled water and 
measured at room temperature. 
 
2.4 Results and discussion 
2.4.1 Culture of plant and virus 
The kenaf grew well under the specified controlled environment, taking about 2 to 3 
weeks to grow to the stage of 4 to 5 leaves per plant. During plant growth, the 
temperature and lighting of the environment were tightly regulated, and all plants were 
protected from insects, unclean earth and strong winds. Kenaf with 4-5 leaves were 
inoculated with HCRSV by rubbing the leaves of the plant with a dispersion containing 
the virus and carborundum powder. Successful transfection was marked by the 
appearance of chlorotic ringspots, a classic symptom of plants infected with the HCRSV 
[Liang et al., 2002], on both the inoculated as well as new leaves about 10 days later 
(Figure 2-1). A previous study based on the ELISA assay has shown the HCRSV virus 
titre in the infected kenaf to fluctuate cyclically, reaching peak titres every 15 days [Lee 
et al., 2003]. Since 15 days were too short a period for the kenaf to grow an adequate 
number of leaves, HCRSV extraction was carried out on Day 30. Harvested leaves were 
either used at once or stored in a -80 °C freezer until use. 
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Figure 2-2 Kenaf leaves infected with the hibiscus chlorotic ringspot virus showing the 
characteristic chlorotic ringspots.  
 
2.4.2 Purification and yield of HCRSV 
HCRSV was successfully extracted and purified by a series of centrifugation and 
washing processes. The extraction buffer (pH 5.4) contained 20 mM of Ca2+ to stabilize 
the extracted virus particles [Lee et al., 2003]. Proteins, including the HCRSV, was 
isolated by precipitation with (NH4)2SO4, followed by centrifugation. The pellet, 
resuspended in a sodium acetate buffer containing 1% of Triton, was ultracentrifuged on 
a 10% sucrose cushion to selectively sediment materials of high density. Impurities of 
lower density that could not penetrate the 10% sucrose cushion were discarded. The 
sample was further fractionated by subsequent ultracentrifugation on a 10 to 40% sucrose 
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gradient. HCRSV, as a RNA-containing capsid, was concentrated in the central portion of 
the sucrose gradient, and was clearly visible as a milky band when observed under a 
strong beam of light in a dark room. 
The sucrose gradient was divided into 31 fractions for collection, and the HCRSV 
content in each fraction was determined by measuring the optical density of the CP at 260 
nm (OD 260nm). As shown in Figure 2-2, the OD 260nm increased gradually from fraction 9 
to reach a peak value in fraction 13 before declining to baseline level at fraction 22. This 
suggests that the HCRSV was concentrated in fractions 9 to 23 of the sucrose gradient. 
For subsequent batches of HCRSV, the virus band after collection was diluted with 3 to 
4-fold its volume of resuspension buffer to bring the sucrose content to below 10% before 
it was ultracentrifuged to pellet the purified virus particles. 
HCRSV yield was 4.6 ± 2.1 mg/100g leaves (n = 4), significantly lower than the 
reported yield of 50 – 70 mg/100 g leaves [Lee et al., 2003]. Even for subsequent batches 
of culture, in which there were overt symptoms of viral infection, the HCRSV yield from 
the kenaf leaves was no higher than 10 mg/ml. While the viral yield could be affected by 
a host of environmental factors, contamination by a virus that could not be separated 
from HCRSV by sucrose gradient ultracentrifugatin appeared to be the main contributing 
factor for the high yield of HCRSV reported in earlier studies [Doan et al., 2003; Lee et 
al., 2003].  
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Figure 2-3. Isolation of HCRSV by sucrose gradient ultracentrifugation. The sucrose 
gradient after ultracentrifugation was divided into 31 fractions for analysis, the top 
fraction denoted as Fraction 1. HCRSV content was determined from OD260nm 
measurement. Peak HCRSV concentration was found in Fraction 13. 
 
Purity of virus yield was borne out by the OD260 nm/OD280 nm ratio, a useful index for 
detecting contamination in a batch of virus. Each virus species has a OD260 nm/OD280 nm 
ratio specific to the relative amounts of RNA and CP in its structure, and the ratio is 
altered in the presence of another virus with a different RNA : protein content. In our 
experiments, the purified HCRSV had consistent OD260 nm/OD280 nm ratios of 1.55 ± 0.01 
(n = 4). While the OD260 nm/OD280 nm ratio for purified HCRSV was not known with 
certainty, this value was considerably lower than the OD260 nm/OD280 nm ratio of 1.74 
previously reported for the HCRSV suspected to be contaminated with another virus [Lee 
et al., 2003; Doan et al., 2003].  
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2.4.3 Cytotoxicity of HCRSV 
In vitro cytotoxicity of HCRSV in the concentration range of 1 ng/ml to 1 mg/ml was 
evaluated by the MTT assay. Three human cell lines were employed, the CNE-1 and 
OVCAR-3 representing cancer cells, and the CCL-186, normal cells. Dextran and SDS at 
0.1% w/v served as negative and positive controls, respectively. Cell viability was not 
significantly reduced for all 3 cell lines following incubation for up to 3 days with the 
HCRSV at all the concentrations evaluated, suggesting that the plant virus was not 
cytotoxic against any of the human cell lines studied (Figure 2-4). These results are in 
agreement with the general consensus that plant virus generally lacks the ability to enter, 
multiply and transfect animal cells. The HCRSV-derived PC may therefore be regarded 
as a potentially safe platform for drug delivery in animals and humans.  
 
2.4.4 RNA removal and reassembly of PC 
Urea, a strong reagent which can unfold and destroy the conformational structures of 
most proteins, has been used to promote the disassembly of virus particles [Michels et al., 
1999]. Protein denaturation was applied in this study by incubating the HCRSV with 8 M 
of urea. The native RNA was discarded via centrifugation, and the purified CP was 
reassembled into viral-like particles by dialysis against a sodium acetate buffer. 
Successful RNA removal was reflected in a much lower mean OD260 nm/OD280 nm ratio of 
0.7 ± 0.1 (n = 3) obtained for the resultant dispersion. The OD260 nm/OD280 nm values 
correlated with those obtained in another study that employed urea to separate the RNA 
from the CP of the Turnip yellow mosaic virus [Michels et al., 1999]. 









































































































































Figure 2-4 Cell viability of (a) CCL-186, (b) OVCAR-3 and (c) CNE-1 cells as measured 
by the MTT assay following incubation for 4h and 3 days with HCRSV of different 
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Urea was, however, a strong reagent that could destroy the conformation of the 
HCRSV CP. By comparison, dialysis offered milder processing conditions. Dialysis of 
HCRSV was initially conducted against a Tris buffer of pH 7.5 (50 mM, 1 mM EDTA, 1 
mM DTT, 0.5 mM PMSF, 0.5 M CaCl2), as this buffer has been reported to be effective 
for the removal of the CCMV RNA from its capsids [Zhao et al., 1995; Fox et al., 1998]. 
However, the dialysis did not produce a change in the OD260nm/OD280nm ratio for the 
HCRSV dispersion, which retained a value of 1.5 after treatment, indicating that the RNA 
was not efficiently removed. A survey of the literature suggested that pH and Ca2+ were 
important factors. Plant viruses could be made to swell at pH higher than 6.5 [Douglas 
and Young, 1998] but capsid disassembly might require higher pH [Fox et al., 1998]. 
Ca2+ was necessary for the reassembly of CP into capsids, but the swelling and 
disassembly of virus particles may require an absence of Ca2+ [Fox et al., 1998; 
Morgunova et al., 1993]. On this basis, Tris buffers having pH of 7 – 8, with and without 
0.5 M CaCl2, were prepared for the dialysis of the HCRSV (Table 2-1). The effectiveness 
of each buffer was determined by measuring the OD260nm/OD280nm ratio of the dispersion 
obtained after the CP had been isolated from the RNA, and reassembled by dialysis 
against a sodium acetate buffer (Table 2-3). Of the 6 buffers employed, the most effective 
was buffer 6 (pH 8.0, without CaCl2), which resulted in the lowest OD260nm/OD280nm 
value of 0.6. Further evidence was obtained by adding CaCl2 to the dialyzate as Ca2+ 
could neutralize and precipitate the freed viral RNA. Precipitation was observed upon the 
addition of 0.5 M of CaCl2 to samples dialyzed against buffer 6, but not in those dialyzed 
against the other 5 buffers. The collective results suggested that HCRSV capsid 
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disassembly occurred in the absence of Ca2+ at a pH higher than that reported for the 
disassembly of CCMV.  
 
 pH 7.0 pH 7.5 pH 8.0 
With 0.5 M CaCl2 1.5 1.5 1.6 
No CaCl2 1.5 1.6 0.6 
Table 2-3. OD260nm/OD280nm values of HCRSV dispersions obtained by dialysis against 
different Tris buffers, followed by RNA removal by centrifugation and coat protein 
reassembly by dialysis against a sodium acetate buffer. Tris buffers having pH in the 
range of 7.0 to 8.0 were prepared in the presence or absence of 0.5 M CaCl2.  
 
2.4.5 UV spectroscopy 
The UV spectra of purified CP obtained by urea incubation and dialysis are shown in 
Figure 2-4 b and c. Compared with the UV spectrum of native HCRSV (Figure 2-5 a), the 
spectra for the CP showed a shift in the absorption peak from 260 to 280 nm, which 
reflected a change from RNA- to protein-dominated UV absorption in the sample. This 
shift, together with the low OD260nm/OD280nm values (0.6 - 0.7), was taken as evidence 
that the viral RNA was successfully removed from the HCRSV following urea incubation 
or dialysis against a Tris buffer (pH 8, no Ca2+).  
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Figure 2-5 UV spectra of (a) HCRSV, (b) coat protein purified by urea incubation 
method and (c) coat protein purified by dialysis against a pH 8.0 Tris buffer devoid of 
CaCl2. 
 
2.4.6 Native gel electrophoresis 
Native agarose gel electrophoresis has been used to analyze the conformational 
structure of proteins and viruses [Kim et al., 2000; Newman et al., 2003] because it does 
not employ protein denaturation reagents, and can thus reflect the size as well as 
electrostatic properties of these samples. Figure 2-5 shows the results of native gel 
electrophoresis of HCRSV, the purified CP and reassembled empty PC obtained from 
HCRSV by the dialysis method.  
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                                                        1          2         3  
 
Figure 2-6. Native agarose gel electrophoresis of HCRSV (line 1), CP produced by 
dialysis method (line 2) and in vitro reassembled empty PC produced by the dialysis 
method (line 3). 
 
Following gel electrophoresis, the HCRSV migrated in the direction of the anode, 
suggesting a net negative charge, while the reassembled empty PC remained at the site of 
application, which was indicative of neutrality under the electrophoresis pH of 7.5. 
Analyses by other techniques (sections 2.4.7 to 2.4.9) had suggested that the PC 
resembled the HCRSV in size, morphology and protein conformation. Thus, the 
differences in net charge between the two species could be attributed to the lack of a viral 
RNA in the PC sample, as the phosphate acid groups of the viral RNA would contribute 
negative charges to the capsid [Schaldach et al., 2005]. On this basis, it was not 
surprising that the purified CP also remained at the site of application following gel 
electrophoresis. There was, however, evidence of some migration, which might be 
attributed to the smaller size of the CP. By comparison, the reassembled PC would be a 
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large moiety comprising of 180 copies of the CP if it truly resembled the native HCRSV 
capsid. These data indirectly confirmed the successful removal of viral RNA from the 
HCRSV by the dialysis method. 
 
2.4.7 Circular dichroism (CD) spectrum 
Circular dichroism (CD) is observed when an optically active compound absorbs left- 
and right-handed circularly polarized light at different extents. It is a rapid and 
convenient method for characterizing the secondary structures of peptides and proteins. 
CD signals in the far UV region (180 ~ 260 nm) reflect peptide bond absorption, which is 
useful for predicting the secondary structures of proteins and peptides [Greenfield, 1996; 
Maruyama et al., 1986]. A typical CD spectrum for a protein bearing the β-sheet 
conformation is a characteristic valley at 215 nm. 
Each HCRSV CP contains two β-sheets. One is in the shell-forming domain and the 
other is in the protruding domain [Doan et al., 2003]. The native conformational structure 
of the CP is, however, susceptible to harsh processing conditions, and the loss of 
conformational structure can result in a failure of the CP to reassemble into virions. For 
this reason, CD experiments were carried out to determine whether the native 
conformational structure of the HCRSV CP was maintained after the processes of 
purification, extraction, disassembly and reassembly.  
As shown in Figure 2-6, the HCRSV showed a typical minimum at 215 nm, 
suggesting the existence of β-sheet structure. The purified CP, whether obtained by urea 
incubation or dialysis, also showed a minimum, though of lesser intensity, around the 
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same wavelength. Similarly, a valley at 215 nm was observed in the CD spectrum of the 
empty PC reassembled from CP obtained by dialysis. Collectively, the data indicated that 
the processes of extraction, purification and reassembly did not destroy the protein 
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Figure 2-7. CD spectra of HCRSV virions, coat proteins obtained by dialysis and urea 
incubation, as well as empty PC reassembled from coat protein obtained by the dialysis 
method. 
 
2.4.8 Morphology of HCRSV and reassembled PC  
Viewed under the TEM, the purified HCRSV appeared as uniformly sized spherical 
particles with diameter of about 30 nm (Figure 2-7a), which corresponded well with the 
description of HCRSV reported in another study [Doan et al., 2003]. Figures 2-7 b and c 
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show the TEM micrographs of PC reassembled from purified HCRSV CP obtained by 
urea incubation and dialysis, respectively. Both PC appeared as spherical particles with 
comparable diameter and morphology as the native HCRSV, suggesting that the CP 
could reassemble in vitro into empty PC that resembled the native HCRSV. This capacity 
for in vitro reassembly was similar to that observed for the CCMV CP [Douglas and 
Young, 1998]. A comparison of Figures 2-7 b and c indicated that the CP produced by 
the dialysis method yielded better quality PC, in terms of size uniformity and well-
defined morphology, than the CP produced by urea incubation. For this reason, the 
dialysis method was used to prepare subsequent batches of HCRSV-derived PC for 
further experimentation.  
2.4.9 Zeta size and zeta potential 
The HCRSV virion and empty PC had similar mean sizes of about 50 nm when 
measured by the zeta sizer. These values, which reflected the hydrodynamic volumes of 
the particles, were larger than those observed under the TEM. While size analysis by the 
TEM was dependent on the electron cloud density of the samples, the hydrodynamic 
volume included the adsorbed layer of counterions and water molecules, and would tend 
to yield larger values. The zeta potential of HCRSV was around -2.5 mV, the negative 
charge corresponding with the gel electrophoresis results. In contrast, the reassembled 
empty PC derived from HCRSV had zeta potential of +1.4 ± 0.1 mV, the positive charge 
reflecting the absence of RNA in the particles. Thus, the zeta potential values provided 
yet additional evidence that the viral RNA was successfully removed from the capsids. 
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The zeta size, on the other hand, indicated that the CP had reassembled into empty PC 
that were of comparable size to the native HCRSV. 
 
     
(a)                                                                                (b) 
 
(c) 
Figure 2-8. TEM photos of (a) native HCRSV, (b) empty PC reassembled from coat 
protein produced by urea incubation method and (c) empty PC reassembled from coat 
protein produced by dialysis method.  
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 HCRSV Empty PC 
Diameter (nm) 44 ± 2 46 ± 8 
Zeta Potential (mV) -2.4 ± 0.2 1.4 ± 0.1 
Table 2-4. Mean size and zeta potential of native HCRSV and empty PC prepared by the 
dialysis method (Mean ± SD, n = 3). 
 
2.5 Conclusion 
HCRSV was successfully cultured in kenaf leaves and efficiently purified by serial 
centrifugations on sucrose gradients to give a reproducible yield of 4 to 5 mg of purified 
HCRSV per 100 g of leaves It was therefore possible to obtain a stable source of HCRSV 
for subsequent experimentation using the kenaf culture. MTT assay suggested that the 
HCRSV was not cytotoxic against the human derived CCL-186, OVCAR-3 and CNE-1 
cells following incubation for up to 3 days at concentrations as high as 1 mg/ml.  
HCRSV RNA was successfully isolated from the CP either by incubation with 8 M of 
urea or dialysis against a Tris buffer of pH 8 in the absence of Ca2+. The purified CP 
could reassemble into empty PC by dialysis against a sodium acetate buffer of pH 5 in the 
presence of Ca2+. The empty PC were comparable to the native HCRSV in size, 
morphology, and protein conformation. However, PC assembled from CP obtained by the 
milder dialysis method were more uniform in size and better defined in morphology than 
those derived from CP obtained by urea incubation. Thus, the dialysis method was 
deemed to be an appropriate method for producing subsequent batches of HCRSV-
derived CP and PC. 
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3.1 Introduction  
Plant viruses may be induced to undergo conformational changes, such as swelling or 
disassembly, under a specific environment. For instance, viruses that are stable at low pH, 
such as the tomato bushy stunt virus [Perez et al., 2000], CCMV [Tama and Brooks, 2002] 
and TCV [Sorger et al., 1986], have been shown to undergo radial expansion at high pH. 
The swelling creates pores or openings on the surface of the viruses and, in some cases, 
may result in the disassembly of the virus particles [Fox et al., 1998]. The CP that are 
isolated from the disassembled virus particles can subsequently be made to reassemble in 
vitro to form empty PC [Bancroft et al., 1968] that are identical in structure to the capsids 
of the native viruses [Fox et al., 1998]. The empty PC of CCMV so assembled have been 
shown to be capable of encapsulating a host of guest ions and molecules, such as the 
paratungstate ion (H2W12O10-42), decavanadate ion (V10O6-28), polyanetholesulfonic acid 
[Douglas and Young, 1999] and gold [Chen et al., 2006]. The guest compounds did not 
appear to significantly alter the morphology and size of the PC, which retained similar 
dimensions to the native virus. Empty plant virus-derived PC may therefore have the 
potential to provide constrained environments for drug delivery. The monodispersity of 
these particles, along with their nanosized dimensions, adds to their advantages for drug 
delivery applications. 
The model virus in this project, the HCRSV, is a member of the genus Carmovirus in 
the Tombusviridae family of plant viruses [Huang et al., 2000; Liang et al., 2002]. The 
native virus is 30 nm in diameter [Lee et al., 2003], has a 4 kb genomic RNA and a 
capsid comprising of 180 CP subunits, each of which has mw approximately 37 kDa [Ke 
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et al., 2004; Lee , et al., 2003]. Preliminary experiments (Chapter 2) had shown it was 
possible to separate the RNA from the CP, and to subsequently reassemble the CP in 
vitro into empty HCRSV-like PC. This chapter explores the feasibility of encapsulating 
guest compounds into the nanosized inner cavity of the HCRSV-derived PC. Different 
types of guest compounds were used to evaluate the effect of charge, mw and chemical 
group on the loading capability of the PC. FITC-dextrans (FD, mw of 4, 10, 75 and 150 
kDa) were used as neutral guest molecules (Figure 3-1, a) while polystyrenesulfonic acid 
(PSA), a strong acid with multiple sulfonic acid groups (mw range of 1.4 to 990 kDa, 
Figure 3-1, b), served as negatively charged molecules. Polyacrylic acid (PAA), a weak 
acid with multiple carboxylic acid groups (Figure 3-1, c), was also used in order to 
evaluate the effect of different acid groups on the loading capacity of the HCRSV-
derived PC.  
As the ultimate objective of this project was to formulate a targeting system for 
anticancer drug delivery, this chapter also explored the feasibility of conjugating the folic 
acid molecule as a targeting ligand for the HCRSV-derived PC. Folic acid was 
conjugated onto the CP of native HCRSV particles by a 2-step carbodiimide crosslinking 
reaction before RNA removal. The experiments in this chapter evaluated the effects of 









(b)                                        (c) 
Figure 3-1. Structures of guest molecules used for the evaluation of the loading capacity 
of HCRSV-derived protein cages. (a) FITC-dextran (FD), (b) polystyrenesulfonic acid 
(PSA) and (c) polyacrylic acid (PAA).  
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3.2 Materials 
Methanol was from BDH Ltd (Poole, England). Polystyrenesulfonic acid (PSA) (mw 
of 1.4, 4.3, 13, 75, 200 and 990 kDa), polyacrylic acid (PAA) (mw of 450 kDa), FITC-
dextran (FD) (mw of 4, 10, 75 and 150 kDa), 1-Ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDAC) and N-hydroxysuccinimide (NHS) were from 
Sigma Chemical Co. Buffer solutions included buffer A (50 mM NaOAc, 50 mM NaCl, 2 
mM EDTA, 20 mM CaCl2, pH 5.0), buffer B (Tris buffer made up with 50 mM of Tris, 2 
mM of DTT, 0.2 mM of PMSF, and 5 mM of EDTA, pH 8.0) and buffer C (Tris buffer 
made up with 50 mM of Tris, 2 mM of DTT, 0.2 mM of PMSF, 5 mM of EDTA, and 1 
M of NaCl, pH 8.0). All other materials and buffer solutions were the same as those listed 
in section 2.2. 
3.3 Methods 
For simplicity of description, HCRSV-derived PC loaded with FD, PSA and PAA are 
denoted as PC-FD, PC-PSA and PC-PAA, respectively. The mw of the cargoes in kDa 
are placed before their names, e.g. PC loaded with PSA of 13 kDa is denoted as PC-
13PSA. Folic acid-conjugated PC is denoted as fPC, and the related products are known 
as fPC-PSA and fPC-PAA.  
3.3.1 Preparation of PC loaded with guest molecules 
The HCRSV CP was purified by the dialysis method as described in section 2.3.2.2. 
In brief, the HCRSV solution was dialyzed against the Ca2+-free buffer B overnight, and 
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incubated with 0.5 M of CaCl2 for 30 min at 4 °C. The viral RNA was removed by 
centrifugation at 25 000 g, 4 °C for 30 min and the CP in the supernatant was used for 
loading guest molecules. Loading was effected by dialyzing the CP solution (0.5 ml) 
against buffer C for 4 h, followed by incubation of the CP (1 mg/ml) with FD (2:1 w/w), 
PSA (3:1 w/w) or PAA (3:1 w/w) in buffer C for 8 h at 4 oC. The resultant samples were 
dialyzed against 500 ml of buffer A for 15 h at 4°C to reassemble the CP into PC.  
 
3.3.2 Preparation of fPC loaded with guest molecules  
The carbodiimide coupling method involving EDAC and NHS was used to conjugate 
the folic acid onto the HCRSV capsids [Reddy et al., 2001; Drabick et al., 1998; Stella et 
al., 2000; Zhang et al., 2004; Bharali et al., 2005]. EDAC is a zero-length crosslinking 
agent widely employed for the coupling of carboxyl groups to primary amines (Figure 3-
2). EDAC has been used in diverse applications, such as peptide synthesis and the 
attachment of haptens to carrier proteins to form immunogens [Drabick et al., 1998]. In 
these reactions, the amine-reactive O-acylisourea intermediate is highly susceptible to 
hydrolysis. To extend the half-life of the intermediate in aqueous solutions, NHS is often 
added to convert the intermediate to an amine-reactive sulfo-NHS ester. The latter 
possesses sufficient stability to permit the crosslinking reaction to proceed, the two-step 
procedure significantly increasing the efficiency of EDAC-mediated coupling reactions 
[Zhang et al., 2004; Grabarek and Gergely, 1990; Staros et al., 1986].  
For this project, 5 mg of folic acid, 50 mg of EDAC and 50 mg of NHS were 
dissolved in 50 ml of bicarbonate buffer (50 mM NaHCO3, pH 6) at ambient temperature. 
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The reaction mixture was incubated with 5 mg of HCRSV at 4 oC for 8 h, then 
concentrated to about 0.5 ml by ultrafiltration (Amicon Ultra-15 filter device, mw cut-off 
10 000, Millipore, MA, USA) and washed thrice with 10 ml of resuspension buffer 
(section 2.2) to remove the unreacted materials. Dialysis against a Tris buffer (pH 8, 
without Ca2+), as described in section 2.3.2.2, was employed to remove the viral RNA 
and purify the CP. The conjugated folic acid in a sample was quantified based on OD360 
nm measurements using an extinction coefficient of 5312 mol-1cm-1 (Beckman Du 640B 
spectrometer, CA, USA) [Stella et al., 2000; Zhang et al., 2004; Shinoda et al., 1998; 
Dube et al., 2002]. The conjugation efficiency was defined as the weight ratio of folic 
acid to CP, the protein content of a sample being determined by the biscinchoninic acid 
assay (BCA) according to the manufacturer’s directions (Section 3.3.3.2 B) [Smith et al., 
1985]. Reassembly of the purified folic-acid conjugated CP into PC, with simultaneous 
loading of FD, PSA and PAA, were also conducted using methods similar to those 
described in section 3.3.1 for the unconjugated CP. 
 
 
Figure 3-2. Reaction scheme for folic acid conjugation to HCRSV particles by the two-
step carbodiimide method. 
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3.3.3 Characterization  
3.3.3.1 Sucrose gradient centrifugation 
Sucrose gradient centrifugation was used as the technique for determining whether the 
guest molecules had been successfully loaded into the PC and fPC. The samples were put 
on 10-40% sucrose gradients (9 cm in height) and centrifuged for 3 h at 27 000 rpm, 4 °C 
using the SW41 rotor. Control samples, which consisted of 1 mg/ml of FD, PSA, 
HCRSV, CP, empty PC or mixtures of empty PC and polyacid in buffer A, were similarly 
subjected to the sucrose gradient separation. Fractions of the sucrose gradient were 
collected and analyzed. FD samples were assayed by measuring the fluorescence of each 
fraction at λ ex 485 nm and λ em 535 nm (TECAN SpectraFluor). The optical density of 
HCRSV and PSA samples was determined at 260 nm and 262 nm, respectively, while 
those of CP, empty PC and PAA were determined at 280 nm (Beckman Du 640B 
spectrophotometer). Fractions that tested positive for the respective cargo were collected 
and diluted with up to 4 times their volume with buffer A. The solutions were 
concentrated to 0.5 ml by ultrafiltration before being used for further analysis.  
 
3.3.3.2 Loading efficiency 
The dual wavelength method and BCA-UV method were used to quantify the amount 
of PSA loaded in the PC. The loading efficiency was calculated on the basis of loaded 
PSA weight to CP weight in the system. These methods were, however, not applied to the 
calculation of the loading efficiency of fPC-PSA because of interferences among the UV 
spectra of folic acid, PSA and CP. 
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(A) Dual wavelength method 
PSA loaded in the PC was quantified by dual-wavelength UV spectroscopy [Szabo 
and Maguire, 1993] on the basis that PSA showed maximum absorption at 262 nm while 
the PC had maximum absorption at 280 nm. PC-PSA samples were purified by sucrose 
gradient centrifugation, and the optical density of pooled sucrose gradient fractions 
containing the PC-PSA was measured at these two wavelengths. The respective optical 
density was expressed in the form of equations (3-1) and (3-2). 
OD 262 nm = OD 262 nm, PSA + OD 262nm, PC     (3-1) 
OD 280 nm  = OD 280 nm, PSA + OD 280 nm, PC     (3-2) 
From the spectra of pure PSA and purified PC, equations (3-3) and (3-4) were 
obtained. 
OD 262 nm, PSA = 5.0 × OD 280 nm, PSA     (3-3) 
OD 262 nm, PC = 0.66 × OD 280 nm, PC     (3-4) 
The 4 equations were rearranged to give equations (3-5) and (3-6), from which the 
absorption of PSA at 262nm and that of PC at 280nm were calculated.  
OD 262 nm, PSA = 5.0 × (OD 262 nm – 0.66 × OD 280 nm) / 4.34  (3-5) 
OD 280 nm, PC = OD 280 nm – (OD 262 nm – 0.66 × OD 280 nm) / 4.34  (3-6) 
Calibration plots of PSA (concentration vs OD 262 nm, PSA) were obtained over the 
concentration range of 0.02 mg/ml to 0.2 mg/ml. Standard solutions were prepared by 
dissolving PSA in buffer A that contained PC at 5 times the weight of PSA. The 
concentration of PC in test samples was calculated by using equation (3-7) 
C PC (mg/ml) = OD 280 nm, PC × 36971 / e     (3-7) 
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where the extinction coefficiency (e) was calculated as 41760 ml/mmol based on its 
amino acid sequence [Mach et al., 1992]. PSA loading efficiency was calculated as the 
percent weight of loaded PSA relative to the weight of PC, and this was transformed into 
the number of PSA molecules loaded in each PC (n) by using the equations (3-8) and (3-
9).  
Loading efficiency (%) = C PSA / C PC × 100%    (3-8) 
n = Loading efficiency × 36 971 × 180 / mw PSA    (3-9) 
 
(B) BCA-UV method 
In the BCA-UV method, the concentration of PC was quantified using the BCA 
protein assay kit according to the manufacturer’s instructions [Smith et al., 1985]. The 
principle underlying the assay is illustrated as follows: 
1. Protein (peptide bonds) + Cu2+ ―—→ tetradentate-Cu1+ complex 
2. Cu1+ complex + BCA ―—→ BCA-Cu1+ complex 
A working solution was prepared by mixing 25 parts of solution A (sodium carbonate, 
sodium bicarbonate and sodium tartrate in 0.2 N NaOH), 24 parts of solution B (4% BCA 
in water) and 1 part of solution C (4% cupric sulfate pentahydrate in water). The 
calibration curve was obtained by incubating 1 ml of working solution with 1 ml of CP 
solution (concentration ranging from 2 to 40 μg/ml) at 37 °C for 2 h, followed by cooling 
to room temperature over 20 min, and measuring the absorbance of the samples at 595 
nm. The equipment (TECAN fluorimeter) was calibrated with CP standard solutions 
(Appendix I). The concentration of PSA was measured by UV absorption at 262 nm after 
 Chapter 3. Preparation and characterization of HCRSV-derived PC for drug delivery  
 78
compensating for the contribution of the PC using equation (3-4) and (3-1). Loading 
efficiency and the number of PSA molecules loaded in each PC were calculated using 
equations (3-8) and (3-9), respectively.  
 
3.3.3.3 Other characterization techniques 
PSA- and PAA-loaded PC were purified by sucrose gradient centrifugation. 
Fractions containing the PC were pooled together, washed by ultrafiltration with 3 to 4 
fold their volumes of buffer A and concentrated to less than 1 ml. Morphology of the 
particles were observed under the TEM using the method described in section 2.3.3.4. 
Conformational structures were analyzed by circular dichroism (CD) spectroscopy using 
the same protocols described in section 2.3.3.3. For the determination of size and zeta 
potential, the samples were diluted to ~0.1 mg / ml with distilled water and analyzed in a 
particle sizer as described in chapter 2.3.3.5. For the native agarose gel electrophoresis 
experiments, the samples were diluted with loading buffer (60% sucrose solution) to 
about 1 mg/ml and analyzed using the conditions described in section 2.3.3.2. 
 
3.4 Results and discussion 
3.4.1 PC loaded with guest molecules 
PC loaded with PSA were screened at 262 nm, which corresponded to the λ max of 
PSA. When subjected to sucrose-gradient centrifugation, free PSA molecules at all mw 
used were concentrated in fractions collected from the top of the gradient. For the PC 
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loaded with PSA of 1.4 kDa (PC-1.4PSA), the OD 262 nm values for fractions collected 
from the top of the sucrose gradient were above baseline levels (Figure 3-3 a), suggesting 
that the PSA in the sample was predominantly in the free form. For the PC-4.3PSA, the 
OD 262 nm value was found to decline gradually from the top fraction. The trailing OD 262 
nm suggests a poor retention of the loaded PSA, which was probably released and 
deposited into the various fractions during the centrifugation process. In contrast, the OD 
262 nm profiles of PC-PSA loaded with PSA ≥ 13 kDa typically showed a maximum value 
for fractions near the middle of the gradient, usually centred on fraction 12, which 
corresponded to fractions that would contain the PC (Figure 3-3 b). Low OD 262 nm values 
were observed for fractions located at the top of the sucrose gradient. In addition, 
fractions with high OD 262 nm values also had OD 262 nm/OD 280 nm ratio greater than 1.0, 
indicating a high PSA to CP content. Based on these results, it is evident that the larger 
PSA molecules were more successfully loaded in the HCRSV-derived PC than the 
smaller PSA molecules, a phenomenon that might be attributed to the poor retention of 
the smaller PSA molecules within the PC. On the basis of their morphology and size, the 
PC were expected to be similar structurally to the native HCRSV in having nanoscale 
cavities in the viral shell [Doan et al., 2003; Douglas & Young, 1998]. A cargo of small 
molecules, like the 1.4 kDa PSA, might be efficiently loaded into the PC, but these would 
diffuse readily across the cavities and be poorly retained within the PC upon dilution. 
Conversely, PSA molecules of 13 kDa or greater that were too large to pass through the 
cavities were effectively retained within the PC even after sucrose density gradient 
centrifugation. The partial retention of the 4.3 kDa PSA in the PC following sucrose-
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density gradient centrifugation suggests that the mw of these PSA molecules was close to 
the passage limit of the cavities. 
One PAA sample of mw 450 kDa was loaded into the PC. Compared with PSA, 
which contained strong sulfonic acid groups (pKa < 1), PAA contained weaker 
carboxylic acid groups (pKa ~ 4.5) that would become partially ionized at pH 5. The PC-
PAA had a sucrose gradient separation profile similar to those observed for the PC-PSA 
samples, in that the OD 280 nm value measured for fractions located at the top of the 
sucrose gradient was minimal, but it increased to a maximum value in the fraction near 
the middle of the gradient, centering on fraction 11 (Figure 3-3, c). This suggests that 
different types of polyacids could be loaded into the PC. In addition, for both the PC-PSA 
(≥ 13 kDa) and PC-PAA samples, the fraction with maximum absorbance corresponded 
to the fraction with maximum native HCRSV (Figure 2-3), suggesting that these cargo-
loaded PC were comparable in size and density to the native virus. 
In contrast, all samples in which the neutral FD (4–150 kDa) was mixed with the CP 
for reassembly into PC-FD showed strong fluorescence only in those fractions located at 
the top of the sucrose gradient, at positions corresponding to the respective controls of 
free FD (Figure 3-3, d). Negligible fluorescence was detected in the middle fractions 
collected from the sucrose gradient, suggesting that the FD was not loaded into the PC. 
This failure to load might be attributed to the FD not being encapsulated when the CP 
reassembled into PC, or to the entrapped FD being poorly retained within the PC after 
being subjected to sucrose gradient centrifugation. The former hypothesis appears more 
likely because two of the FD samples (75 and 150 kDa) were of higher mw than the 
successfully loaded 13-kDa PSA molecules. If they were successfully encapsulated 
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within the PC, they would have been effectively retained upon dilution because their 
large size would limit loss through the cavities in the PC. Since FD did not contain 
ionizable groups and was neutral at the loading pH, the failure to encapsulate FD 
suggests that electrostatic interaction may be necessary for cargo encapsulation during 
CP reassembly. This is in agreement with previous findings that the amino acid groups in 
the interior of a plant virus capsid play an important role in material loading [Douglas 
and Young, 1998; Douglas and Young, 1999]. In the case of HCRSV, the positively 
charged Arg and Lys moieties located at the N terminus of the CP would render the inner 
cavity of the PC attractive for the binding of negatively charged compounds. This has 
been aptly demonstrated by the successful loading of polyacids during CP reassembly. 
Two lines of evidence affirmed that the polyacids were encapsulated within the cavity 
of the PC rather than adsorbed or conjugated onto the PC surface. The first evidence was 
the negligible encapsulation of polyacids with low mw. Had the polyacids been bound 
onto the surface of the PC, the reaction would proceed even with smaller sized polyacids. 
The other evidence was the failure to load the guest molecules in control experiments in 
which the reassembled PC were incubated with either PSA (13 to 990 kDa) or PAA (450 
kDa) (data presented in Appendix II). If the polyacid molecules were bound to the 
surface of the PC, loading should be facilitated with preformed PC. However, for the 
polyacids to be encapsulated within the cavity of the preformed PC, the molecules must 
enter the PC through the surface cavities and be effectively retained upon dilution. This 
would be difficult to achieve, for small molecules that could permeate the cavities during 
loading would not be efficiently retained upon dilution, while larger polyacids that might 
be efficiently retained would not be able to enter the cavities for successful loading in the 
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first place. On the basis of these evidences, it may be concluded that both PSA and PAA 






























































                                      (c)                                                                    (d) 
Figure 3-3. Analysis by sucrose gradient centrifugation of the efficiency of loading guest 
compounds into the HCRSV-derived PC. (a) PC loaded with PSA of mw 1.4 and 4.3 kDa 
(b) PC loaded with PSA of mw 13, 75, 200 and 990 kDa, (c) PC loaded with PAA of mw 
450 kDa, (d) PC loaded with FD of mw 4, 10, 75 and 150 kDa.  
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3.4.2 fPC loaded with guest molecules 
Folic acid was conjugated onto the CP of native HCRSV by the 2-step carbodiimide 
method. Successful conjugation was confirmed by UV absorption profile. Unlike the CP 
isolated from the native HCRSV, the CP purified from folic acid-conjugated HCRSV 
exhibited significant absorbance at wavelengths longer than 300 nm (Figure 3-4). A 
comparison with the UV spectrum of folic acid suggests that this difference in UV 
absorbance profile could be attributed to the conjugated folic acid. Folic acid conjugation 
efficiency (Weight folic acid / Weight CP) was 1.9 ± 0.1% (n = 3), which translated to about 
2 folic acid molecules conjugated to each CP. Since the icosahedral HCRSV capsid is 
made up of 180 CP units [Doan et al., 2003], the implication is that each fPC particle 
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Figure 3-4. UV spectra of folic acid, CP and folic acid-conjugated CP.  
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The 2-step carbodiimide method selectively coupled carboxyl groups to primary 
amines. For this reason, the Lys amino acids located on the surface of the PC were 
hypothesized to be the target sites for folic acid conjugation. The amino acid sequence of 
HCRSV CP is well established [Doan et al., 2003], and a conformational modeling of the 
HCRSV CP was performed using the software, SwissModel [Schwede et al., 2003]. The 
SwissModel contained amino acid sequences of known structure in its template library 
and, based on the structures of sequences with >25% identity with the HCRSV, an 
optimized structure for the HCRSV CP was generated (Figure 3-5). This structure was 
similar to that generated from another study [Doan et al., 2003] in showing the P domain 
connecting to the S domain through a thin hinge. Based on the generated conformation, 
three Lys groups in the P domain, indicated by yellow boxes in Figure 3-5, were 
identified as the possible sites for folic acid conjugation due to their accessibility. Lys 
groups were also present in the S and N domains of the HCRSV CP, but these would be 
more difficult to access when the conjugation reaction was performed on intact HCRSV 
capsids. The number of protruding Lys groups in the conformation also agreed well with 
the conjugation efficiency of 2 folic acid molecules per CP. Assuming the purified 
HCRSV-derived CP retained the same conformation upon reassembly in vitro, the Lys 
conjugation sites on the P domain could be advantageous as the protruded folic acid were 
more likely to retain their receptor recognition capability. This was confirmed by the data 
generated in chapter 5.  
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Figure 3-5. A conformation model of the HCRSV CP as generated by the SwissModel. 
The three Lys amino acid groups (marked by yellow boxes) in the protruding (P) domain 
are postulated to be the sites for folic acid conjugation. 
 
The capacity of the resultant fPC to load guest molecules was studied using PSA (mw 
≥ 13 kDa) and PAA as model compounds. As was observed of the corresponding 
unconjugated PC samples, the fPC-PSA and fPC-PAA samples showed maximum UV 
absorption at 260 nm in fraction 12 after sucrose gradient centrifugation (Figure 3-6). The 
conjugated folic acid therefore did not adversely affect the reassembly of the CP into PC, 
nor did it hinder the encapsulation of guest compounds into the PC. Thus the fPC could 
also be considered to be a potential carrier for drug delivery. 
































                                       (a)                                                                  (b) 
Figure 3-6. Analysis by sucrose gradient centrifugation of the efficiency of loading guest 
compounds into the folic acid-conjugated HCRSV-derived PC (fPC) (a) fPC loaded with 
PSA of mw 13, 75, 200 and 990 kDa (b) fPC loaded with PAA of mw 450 kDa. 
 
3.4.3 Characterization of polyacid-loaded PC and fPC 
Further characterization was performed on PC and fPC successfully loaded with 
PSA (mw ≥ 13 kDa) and PAA. Folic acid conjugation was observed not to change the 
CD spectrum of the HCRSV-derived PC. Neither did the loading of PSA and PAA. The 
CD spectra for all the polyacid-loaded PC and fPC samples showed a minimum 
wavelength around 215 nm, indicating that the encapsulated PSA and PAA did not affect 
the β-sheet in the CP structure (Figure 3-7). 
























































                                                                  (b) 
Figure 3-7. CD spectra of (a) PC-PSA and PC-PAA, and (b) fPC-PSA and fPC-PAA 
samples. All samples showed a characteristic β-sheet structure with a valley between 210 
to 220 nm. 
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Observed under the TEM, the polyacid-loaded PC and fPC samples appeared as 
monodispersed, discrete spherical particles with diameter of approximately 30 nm 
(Figure 3-8). This morphology was observed regardless of the mw and nature of polyacid 
loaded, and it was comparable to the morphologies of native HCRSV and empty PC 
shown in Figure 2-7. 
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(c)                                                                        (d) 
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(e)                                                                        (f) 
  
(g)                                                                        (h) 
  
                        (i)                                                                        (j) 
Figure 3-8. TEM of HCRSV-derived PC loaded with guest molecules. (a) PC-13PSA, (b) 
PC-75PSA, (c) PC-200PSA, (d) PC-990PSA, (e) PC-PAA, (f) fPC-13PSA, (g) fPC-
75PSA, (h) fPC-200PSA, (i) fPC-990PSA, (j) fPC-PAA. 
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Mean size of the polyacid-loaded PC and fPC, as measured by the particle size 
analyzer, was within the narrow range of 46 (fPC-75 kDa PSA) to 55 nm (PC-13 kDa 
PSA) (Table 3-1). As with the native HCRSV, these values were larger than the particle 
diameter observed under the TEM as they represented the hydrodynamic volume of the 
particles. However, the mean sizes of the cargo-loaded PC and fPC were comparable to 
that of the native HCRSV (44 nm). The polyacid-loaded PC and fPC samples had zeta 
potential of between -2.3 to -2.9 mV (Table 3-1). These values were again comparable 
with the zeta potential of native HCRSV (-2.4 mV), suggesting that the polyacid-loaded 
PC had similar negative surface charges as the native virus. Given the differences in mw 
and acid type among PSA, PAA and the native viral RNA, it would appear that the total 
charge conferred was independent of the type and mw of the polyacids contained within 
the viral structure. It was also not influenced by differences in the degree of ionization of 
the three polyacids at pH 5. This phenomenon may be attributed to the existence of a 
buffering system in the PC, possibly the basic amino acids in the CP could neutralize the 
anionic charges on the polyacid cargo.  
Native gel electrophoresis was performed to provide further information on the size 
and surface charge of the polyacid-loaded PC and fPC samples. As shown in Figure 3-9 
(a), the native HCRSV moved towards the anode due to the presence of the negatively 
charged viral RNA. The absence of RNA in the CP and PC resulted in these samples 
remaining at the loading sites. Once the PC was loaded with a polyacid, however, the 
sample once again migrated towards the anode. Despite the differences in mw and acid 
type of the cargo, all the PC-PSA and PC-PAA samples were observed to migrate to 
comparable distances upon electrophoresis, and this position was comparable to that of 
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the native HCRSV. These data are in agreement with the particle size, zeta potential and 
TEM data in suggesting that the polyacid-loaded PC had comparable size and charge to 
the native HCRSV. Folic acid conjugation did not affect this phenomenon, the polyacid-
loaded fPC showing similar electrophoresis rates as the native HCRSV and polyacid-
loaded PC samples, while the empty fPC had comparable electrophoresis rate as the 
empty PC (Figure 3-9, b and c).  
 
Sample Zeta size (nm) Zeta potential (mV) 
HCRSV 44 ± 2 -2.4 ± 0.2 
PC-13PSA 55 ± 2 -2.4 ± 0 
PC-75PSA 52 ± 1 -2.4 ± 0.2 
PC-200PSA 53 ± 3 -2.9 ± 0.5 
PC-990PSA 50 ± 1 -2.4 ± 0.1 
PC-450PAA 50 ± 3 -2.3 ± 0.2 
fPC-13PSA 49 ± 4 -2.5 ± 0.3 
fPC-75PSA 46 ± 7 -2.3 ± 0.3 
fPC-200PSA 47 ± 3 -2.4 ± 0.4 
fPC-990PSA 52 ± 2 -2.4 ± 0.5 
fPC-450PAA 48 ± 2 -2.3 ± 0.1 
Table 3-1. Zeta potential and zeta size of native HCRSV, and polyacid-loaded PC and 
fPC. Data represent mean ± SD, n = 3. 
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                                          (b)                                                               (c) 
Figure 3-9.Native gel electrophoresis of native HCRSV and poly-acid loaded PC and fPC 
samples. (a) Lines 1 to 8 are HCRSV, purified CP, empty PC, PC-13PSA, PC-75PSA, 
PC-200PSA, PC-990PSA, PC-PAA, (b) Lines 1 to 6 are HCRSV, fPC-13PSA, fPC-
75PSA, fPC-200PSA, fPC-990PSA, fPC-PAA, (c) Lines 1 to 3 are folic acid-conjugated 
CP, empty fPC and native HCRSV. 
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3.4.4 Loading efficiency of PC-PSA samples 
The dual wavelength and BCA-UV methods were used to quantify the amount of 
PSA loaded in the PC. The loading efficiency was calculated on the basis of the weight of 
loaded PSA to weight of CP in the system. As seen in Table 3-2, the data obtained from 
both assay methods correlated well with each other.  
Despite a 75-fold difference in mw, PSA of 13 to 990 kDa were encapsulated with 
comparable efficiency into the PC. The PSA loading efficiency of 15 to 20% also 
correlated closely with the value of 19% calculated for the genomic RNA (3911 bytes, 
1,260 kDa) in the native HCRSV. This suggests that the PC of HCRSV was capable of 
encapsulating exogenous materials to an amount equivalent to the mass of its native 
genomic material. 
The number of PSA molecules encapsulated per PC was approximated based on the 
PSA loading data and the corresponding PSA mw (Table 2). For the largest PSA 
molecule, whose mw (990 kDa) approached that of the genomic RNA, only 1 molecule 
was accommodated in each PC. This restriction in cargo loading size is not surprising, 
and is in fact an acknowledged limitation in viral-based gene delivery systems [Dong et 
al., 1996]. A linear relationship (n = 1/mw × 106, R2 = 0.9969) was observed to describe 
the relationship between the number of PSA molecules loaded into each PC (n) and the 
mw of the PSA. The protein cage of the PC therefore showed considerable ability for 
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Mw of cargoes 13 kDa 75 kDa 200 kDa 990 kDa 
Loading 
efficiency (%) 
19.6 ± 1.7 17.1 ± 1.7 20.0 ± 1.0 15.8 ± 2.1 
BCA-UV 
method Number of PSA 
per PC (n) 
101 15 7 1 
Loading 
efficiency (%) 
20.9 ± 2.6 16.7 ± 4.8 20.3 ± 1 14.9 ± 2.6Dual 
wavelength 
method 
Number of PSA 
per PC (n) 
107 14 6 1 
Table 3-2. Efficiency of loading PSA of different mw into the HCRSV-derived PC.  
 
3.5 Conclusion 
Our study indicated that empty PC derived from the HCRSV had the capacity to 
accommodate exogenous materials in its cavity. The loading of guest molecules was 
influenced by the electrostatic interactions between the cargo and the amino acids 
presenting in the cavity of the PC. The positively charged Arg and Lys moieties located 
at the N-terminal of the CP appeared to make the inner cavity of the PC attractive for the 
binding of negatively charged compounds, as demonstrated by the successful loading of 
PSA and PAA. In contrast, as neutral molecules without ionizable groups, all of the FDs 
were not encapsulated within the PC, suggesting that electrostatic interaction was the 
mechanism for cargo encapsulation in the HCRSV-derived PC. Aside from the negative 
charge, the size of the cargo molecule was another prerequisite for successful 
encapsulation, as only polyacids with mw no less than 13 kDa were encapsulated into the 
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PC. In addition, the loading of guest molecules into the HCRSV-derived PC had to be 
carried out simultaneously with the reassembly of CP into PC, and not with preformed 
PC.  
Folic acid could be conjugated to the CP prior to its reassembly into PC without 
affecting the conformational structure of the PC. About 360 folic acid molecules could be 
successfully conjugated onto each PC, and the presence of the folic acid did not appear to 
affect the capability of the PC to encapsulate guest molecules.  
The PSA (≥13 kDa)- and PAA-loaded PC and fPC, despite differences in the mw and 
acid type of their cargoes, were comparable in size, morphology and protein 
conformation to each other and to the native HCRSV with its RNA load. The loading 
efficiency of PSA was also independent of its mw, but the number of PSA molecules that 
could be accommodated per PC particle was inversely proportional to the mw of the PSA. 
This suggests that the number of guest molecules that could be accommodated was 
limited by the volume of the PC cavity. Reassembly of the CP into PC was not affected 
by the size of the guest molecules, but continued to occur by a precise mechanism that 
yielded particles of uniform size and morphology. This is an advantage over the drug-
loaded liposome and polymer nanoparticle systems, which tended to present in a range of 
sizes even within a batch. The collective data therefore suggest that the HCRSV-derived 
PC had attractive features as a platform for drug delivery applications. 
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4.1 Introduction 
Literature reports on plant viruses to be employed as potential carriers have shown 
cargo loading to be achieved through covalent reaction between the guest molecules and 
specific amino acids presenting on the interior surface of the viral protein coat [Hooker et 
al., 2004; Schlick et al., 2005]. Experiments conducted with the HCRSV-derived PC had 
indicated, however, that it was possible to encapsulate guest molecules during the 
reassembly of CP into PC without involving a chemical reaction (Chapter 2). Two 
prerequisites have been identified for the successful loading and retention of guest 
molecules in the HCRSV-derived PC. Firstly, the guest molecule should possess a net 
negative charge as the entrapment was achieved via non-covalent electrostatic attractions 
between the guest molecule and the amino acids of the PC. This reversible binding also 
appeared to initiate the reassembly of the icosahedral PC structure. Secondly, the guest 
molecule should have an adequately high mw to avoid excessive leaching of encapsulated 
material via the surface cavities of the PC upon dilution. Successful loading of polyacids 
with mw above 13 kDa had been demonstrated with the HCRSV-derived PC. However, 
there is to date no report on the loading of small chemotherapeutic drugs into plant viral 
PC by non-covalent encapsulation, although this method has proven effective for the 
loading of crystals [Douglas and Young, 1998; Douglas et al., 2002], polymers [Douglas 
and Young, 1998] and gold nanoparticles [Chen et al., 2006; Loo et al., 2006]. For the 
HCRSV-derived PC to be applied as a targeting anticancer drug delivery platform, it 
must possess the capacity to hold the anticancer drug securely until the drug is due for 
release at the target tissue. The objective of the experiments in this chapter was to 
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evaluate the feasibility of loading a model anticancer drug, doxorubicin, into the 
HCRSV-derived PC. 
Doxorubicin is widely used in cancer chemotherapy. It is indicated for the treatment 
of ovarian cancer [Rose, 2005], breast cancer [Kaklamani and Gradishar, 2005], lung 
cancer [Koukourakis et al., 2002], non-Hodgkin’s lymphoma [Schriber, 2002], and 
Hodgkin’s sarcoma [Connors, 2005]. Doxorubicin has manifold mechanisms of action. It 
can bind to cellular DNA by intercalating between the base pairs of the DNA helix 
[Capranico et al., 1986], cause DNA fragmentation by inhibiting topoisomerase II 
[Jarvinen et al., 2000], or form complexes with iron to produce free radicals that cleave 
DNA and cell membranes [Xu et al., 2005]. Unfortunately, doxorubicin therapy, although 
highly effective, is also associated with many side effects, including nausea, vomiting, 
low blood cell counts, mouth ulcers and hair loss. These side effects have been attributed 
to the non-selectivity of action and low therapeutic index of doxorubicin. Consequently, 
it is believed that doxorubicin therapy can be optimized by confining drug release only to 
the tumor tissues [Rivera, 2003]. A successful example of such a delivery system is 
Doxil®, a liposomal doxorubicin formulation where the drug is encapsulated within the 
aqueous core of the liposomes via a salt gradient [Lasic et al., 1992]. Following 
intravenous administration, doxorubicin is accumulated in the cancer tissues via the 
enhanced permeability and retention phenomenon [Greish et al., 2004]. The liposomes 
are PEGylated (Figure 4-1) to reduce uptake by the RES, thus further improving the 
clinical outcome of doxorubicin therapy [Gabizon et al., 1993].  
 Chapter 4. Preparation and characterization of doxorubicin-loaded PC  
 99
 
Figure 4-1. Schematic diagram showing the principles underlying the formulation of 
Doxil® - doxorubicin is encapsulated within a liposome whose surface is covered by a 
layer of methoxypolyethylene glycol [http://www.doxil.com]. 
 
Liposomes, as well as many polymeric nanoparticles, are products of the top-down 
approach in nanotechnology. Liposomes are prepared by the spontaneous assembly of 
lipid and/or PEGylated lipid molecules, while polymer nanoparticles are prepared by the 
condensation of soluble polymer macromolecules through solvent evaporation or the 
addition of a poor solvent or counterion. These methods of synthesis often result in 
particles that vary considerably in size and shape, even within a batch [Mozafari, 2005]. 
For example, liposomes classified as multilamellar vesicles (MLV) or large unilamellar 
vesicles (LUV) are inherently polydisperse, exhibiting sizes that may vary within 
hundreds of nanometers or even several microns [Szoka and Papahadjopoulos, 1978; 
Mozafari, 2005]. Small unilamellar vesicles (SUV) can be more homogeneously sized, 
but they have a tendency to undergo rapid aggregation and fusion, which in turn increases 
the effective particle size and size range [Wilschut et al., 1985]. Such within-batch 
variability is undesirable because size and shape are important parameters that can 
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influence the biodistribution profile of nanoparticles. Larger particles are less efficiently 
taken up by cells, and are more readily detected and removed by the RES [Panyam and 
Labhasetwar, 2003]. Tomii [Tomii 2002] has estimated that particles had to be 50 nm or 
smaller to evade the RES.  Such particles could also more readily localize at tumor and 
inflammatory sites that present with high vascular permeability [Tomii, 2002; Seki et al., 
1994]. Particle shape also influences nanoparticle-cell interactions, for the uptake of 
spherical gold nanoparticles by Hela cells was reported to be at least 3-fold higher than 
that of similarly sized rod-shape gold particles [Chithrani et al 2006]. 
These reasons provide the impetus to produce a nanoscale drug delivery system of 
doxorubicin with uniform size and morphology. Nanoscale platforms with precise 
structure and function, such as ferritin, carbon nanotube and viral capsid, have shown 
promise as drug carriers. Of these, the icosahedral plant viruses are the most extensively 
researched. Proof of concept was first demonstrated with the PC of CCMV, which could 
host foreign ions as well as polyacids [Douglas and Young, 1998]. Through gene 
mutation, the inner surface of the CCMV PC could be modulated to host positive or 
negative ions [Douglas et al., 2002]. More recently, gold nanoparticles of 16 nm were 
also encapsulated within the brome mosaic virus- (BMV) derived PC [Chen et al., 2006].  
However, doxorubicin, like many other anticancer drugs, is a small molecule (mw = 
545 Da), and it is positively charged (pKa = 8.4) in physiological fluids as well as under 
the conditions employed for the reassembly of the HCRSV-derived PC [Gallois et al., 
1998]. These properties made it difficult to load and retain doxorubicin within the PC by 
simple encapsulation during the reassembly process. To impart the requisite size and 
charge to the anticancer agent, we employed the aid of a polyacid. This method, which 
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we termed “polyacid association”, involved the simultaneous loading of doxorubicin with 
polystyrenesulfonic acid (PSA) of mw 200 kDa into the PC of the HCRSV. The 3:1 
(PSA:drug) w/w ratio of mixing ensured the attraction of doxorubicin molecules to the 
polyacid by electrostatic forces, and a net negative charge for the resultant complex. The 
complex thus provided the nucleus for binding with, and initiation of the final reassembly 
of CP into the PC (Figure 4-2). This chapter discusses the preparation and 
characterization of the doxorubicin-loaded HCRSV-derived PC. It also examines the 
effect of folic acid conjugation on the efficiency of loading doxorubicin into the PC. 
 
4.2 Materials 
Doxorubicin hydrochloride injection (50 mg in 25 ml, USP) was purchased from 
Pharmacia (Bentley, WA, Australia). Tripolyphosphate acid (TPP) was from Sigma 
Chemical Co. and the the BCA Protein Assay Reagent Kit was from Pierce Chemical 
Company. The following buffers were used: buffer A (50 mM NaOAc, 50 mM NaCl, 2 
mM EDTA, 20 mM CaCl2, pH 5.0), buffer B (Tris buffer made up with 50 mM of Tris, 2 
mM of DTT, 0.2 mM of PMSF, and 5 mM of EDTA, pH 8.0) and buffer D (50 mM 
Tris/base, 5 mM EDTA, 2 mM DTT, 0.2 mM PMSF, 1 M NaCl, pH 7.0). All other 
materials and buffers were the same as those listed in sections 2.2 and 3.2. 
 
4.3 Methods 
4.3.1 Preparation of PC-Dox and fPC-Dox 
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The following operations were performed at 4 ºC unless otherwise stated. HCRSV-
derived CP were purified by the dialysis method as described in section 3.3.1. In brief, 
0.1 ml of HCRSV (10 mg/ml) in re-suspension buffer was dialyzed overnight against 
1000 ml of buffer B. It was then incubated with CaCl2 (0.5 M) for 30 min and centrifuged 
at 25 000 g for 30 min to pellet the viral RNA. The supernatant was further dialyzed 
against 1000 ml of buffer D for 4 h to obtain the purified CP.  
Several methods were explored for the preparation of doxorubicin-loaded PC (PC-
Dox). In method A, 1 ml of purified CP (1 mg/ml) in buffer D was incubated with 
doxorubicin (10% w/w based on the weight of CP used) for 8 h. The solution was 
adjusted to pH 5 with a concentrated NaOAc buffer (1 M NaOAC, pH 5.0), and CaCl2 
was added to a final concentration of 5 mM to reassemble the PC. The solution was 
incubated for 15 h at ambient temperature to reassemble the PC. Similar processing steps 
were used for methods B and C. However, in method B, 30% (w/w) of TPP was added to 
the mixture of CP and doxorubicin to evaluate whether the negatively charged TPP could 
aid in initiating CP reassembly and in binding the doxorubicin to the PC cavity. Method 
C employed polystyrenesulfonic acid (PSA) (Figure 4-2) in place of TPP. In this case, the 
CP (1 ml, 1 mg/ml) was incubated with 0.5 ml of solution containing 0.2 mg/ml of 
doxorubicin and 0.6 mg/ml of PSA (mw 200 kDa) in buffer D. 
Control experiments were designed to evaluate whether it was possible to load 
doxorubicin through the induced opening of cavities on the surface of preformed PC  To 
do this, PC loaded with PSA of mw 200 kDa (PC-200PSA) was prepared as described in 
section 3.3.1. The preformed PC-200PSA in buffer A (1 mg/ml, 0.1 ml) was dialyzed 
against 500 ml of buffer A (pH 5.0), NaOAc buffer (50 mM NaAc, 50 mM NaCl, 2 mM 
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EDTA, 5 mM CaCl2, pH 6.0) or Tris buffer (50 mM Tris, 50 mM NaCl, 2 mM EDTA, 2 
mM of DTT, 0.2 mM PMSF, 5 mM CaCl2, pH 7.0) for 4 h to induce the opening of 
surface cavities, then incubated overnight with 0.1 mg/ml of doxorubicin. The resultant 
solutions were adjusted to pH 5 with NaOAc buffer (1 M NaOAc, pH 5.0) to complete 
the drug loading process. 
All samples following drug loading were subjected to 10-40% sucrose gradient 
centrifugation at 100 000 g for 3 h (as described in section 4.3.2.1) to identify the 
existence of doxorubicin-loaded PC. Samples which showed successful drug loading 
were centrifuged at 100 000 g for 1 h at 4 ºC on a 15% sucrose gradient cushion. The 
supernatant and sucrose solution were discarded and the pellet containing PC-Dox was 
resuspended in a small volume (~ 0.1 ml) of buffer A. Samples were stored at 4 °C until 
use. 
To prepare folic acid-conjugated CP, the native HCRSV was conjugated with folic 
acid by the 2-step carbodiimide method as outlined in section 3.3.2. These folic acid-
conjugated HCRSV was processed as described for the native HCRSV to obtain the folic 
acid-conjugated CP. Reassembly of the purified folic-acid conjugated CP into fPC, with 
simultaneous loading of doxorubicin and PSA, was conducted using method C. 
Doxorubicin was also incubated with preformed fPC at pH 7. The resultant samples were 
analyzed, and drug-loaded samples (fPC-Dox) were purified by sucrose gradient 
centrifugation as described for PC-Dox.  
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Figure 4-2. Schematic illustration of the preparation of doxorubicin-loaded PC (PC-Dox) 
and folic acid-conjugated doxorubicin-loaded PC (fPC-Dox). Steps A1 and B2 are 
indicative of the removal of viral RNA from the plant virus and purification of CP, 
respectively. Steps A2 and B3 involve the encapsulation of polyacid and doxorubicin 
during the reassembly of PC. Step B1 refers to the conjugation of folic acid onto the 
protein coat of the native HCRSV. 
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4.3.2 Characterization  
Sucrose gradient centrifugation was performed to confirm the existence of PC-Dox 
and fPC-Dox. About 0.5 ml of control or sample solutions were ultracentrifuged on 10-
40% sucrose gradient at 100 000 x g for 3 h. Controls included solutions of free 
doxorubicin, doxorubicin and PSA complex (Dox-PSA), empty PC and native HCRSV. 
Samples analyzed were those of doxorubicin incubated with CP under the reassembly 
condition (Method A), doxorubicin incubated with TPP and CP under the reassembly 
condition (Method B), doxorubicin incubated with PSA and CP (or fCP) under the 
reassembly condition (Method C), and doxorubicin incubated with preformed PC-
200PSA (or fPC-200PSA) at pH 5, 6, and 7. Samples containing HCRSV and empty PC 
were analyzed at 260 nm and 280 nm, respectively, while samples containing 
doxorubicin were measured at 485 nm.  
Native gel electrophoresis was performed on free doxorubicin, Dox-PSA, HCRSV, 
PC-Dox, fPC-Dox, doxorubicin incubated with preformed PC-200PSA at pH 7, and 
doxorubicin incubated with preformed fPC-200PSA at pH 7, using the method described 
in section 3.3.3.3. Bands of CP were visualized by Coomassie blue staining, while the 
doxorubicin bands were visualized under ultraviolet light (Bio-Rad Molecular Imager 
ChemiDoc XRS System, CA, USA). Morphology of PC-Dox and fPC-Dox were 
observed under the TEM using the method described in section 2.3.3.4. Zeta size and zeta 
potential of PC-Dox and fPC-Dox were analyzed by the zeta sizer using the protocols 
described in section 2.3.3.5.  
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4.3.3 Loading efficiency (LE), encapsulation efficiency (EE) and reassembly 
efficiency (RE) 
The loading efficiency (LE), encapsulation efficiency (EE), and reassembly 
efficiency (RE) were calculated using equations 4-1 to 4-3, respectively. In addition, the 
number of doxorubicin molecules encapsulated within each PC (N) and the doxorubicin 
concentration within each PC (C loaded Dox) were calculated using equations 4-4 and 4-5, 
respectively. Doxorubicin was assayed by fluorimetric spectroscopy. The amount of 
doxorubicin in the samples was calculated by comparing its OD485 nm with those of 
standard solutions, both of which were diluted with buffer A (pH 5) prior to measurement. 
The amount of CP in each sample was quantified by the BCA assay for protein after the 
encapsulated doxorubicin was removed via 6-day dialysis against PBS (pH 7.4).  
 
LE (%) = Weight loaded doxorubicin  / Weight PC × 100%    (4-1) 
EE = Weight loaded doxorubicin  / Weight total doxorubicin used × 100%   (4-2) 
RE = Weight PC / Weight total CP used × 100%      (4-3) 
N = LE / mw doxorubicin × (mw CP × 180)      (4-4) 
C loaded doxorubicin (mM) = mw CP × 180 × LE / (mw doxorubicin ×V × 6.02 × 1023)  (4-5) 
 
mw doxorubicin and mw CP values were 545 and 37 000, respectively. V refers to the 
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4.3.4 Drug Release Profile 
Drug release experiments were performed by the dialysis method [Liu et al., 2005]. 
Fifty μl of free doxorubicin solution, PC-Dox and fPC-Dox dispersions, each equivalent 
to doxorubicin concentration of 1000 μg/ml, were placed in separate dialysis tubes (mw 
cut-off 12 400, Sigma-Aldrich) and dialyzed against 25 ml of PBS (pH 7.4) at 37 °C. At 
specified time points, 0.2 ml of the dialysis buffer was sampled for fluorescence 
measurements (Ex 480 nm, Em 535 nm) (TECAN SpectraFluor, MA, USA) to quantify the 
released doxorubicin. Doxorubicin diluted with PBS to 0.2 to 4 μg/ml was used as 
standard solutions for calibrating the spectrophotometer. 
 
4.4 Results and discussion 
4.4.1 Preparation of PC-Dox and fPC-Dox 
Three different methods were used to load doxorubicin, a small molecule (mw = 545 
Da) with a positive charge (pKa = 8.4), into the HCRSV-derived PC during the 
reassembly process. Method A, where doxorubicin alone was incubated with the CP 
under the reassembly conditions, had been successfully applied to the loading of 
negatively charged macromolecules, PSA and PAA (Chapter 3). This method was, 
however, ineffective at loading the doxorubicin molecules. Analysis of the sample by 
sucrose gradient centrifugation (Figure 4-4b) showed fraction 2 to have the highest 
doxorubicin concentration, and fractions 9 to 15 to have negligible doxorubicin content.  
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Method B was an adaptation of the “pH gradient method”, which was reported to be 
highly efficient for the loading of doxorubicin into liposomes [Fritze et al., 2006]. In this 
method, the liposomes were first loaded with a high concentration of acid, such as citric 
acid, before incubation with doxorubicin. As the weakly basic drug became attracted to 
the encapsulated acid, an influx of doxorubicin ensued, resulting in high drug loading. 
Applying the same principle, TPP, a polyvalent acid, was incubated with doxorubicin and 
the CP under the reassembly conditions. TPP was chosen because it had similar chemical 
structure to the phosphate groups present in viral RNA, and was therefore unlikely to 
destabilize the HCRSV CP. The addition of TPP, however, failed to facilitate the loading 
of doxorubicin into the HCRSV-derived PC. Sucrose gradient centrifugation again 
showed the drug to be concentrated in the initial fractions, not in the middle fractions 
which contained the reassembled PC (Figure 4-4 b). This failure to load was probably 
due to the mw of the cargos. As both TPP and doxorubicin were small molecules, the 
TPP-doxorubicin complex might not meet the threshold size essential for effective 
retention within the PC cavity. Even if the TPP or TPP-doxorubicin complex had a high 
affinity for the inner space of the PC, they would still leach out through the surface 
cavities of the PC upon dilution. For the same reasons, no attempt was made at 
preloading the HCRSV-derived PC with TPP before the addition of doxorubicin. 
Method C was inspired by the viral RNA structure, which had the organic bases of 
purine and pyrimidine covalently attached to the phosphoric acid-sugar chain (Figure 4-3, 
a), thus providing a mechanism for retaining the bases within the PC. We hypothesized 
that basic drugs of low mw, like doxorubicin, could also be retained within the viral PC 
by binding with a negatively charged macromolecule that was encapsulated within the PC. 
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This principle was utilized in method C, where the CP was incubated with doxorubicin 
and PSA of 200 kDa at the weight ratio of 1:3. The employment of a higher PSA content 
was to ensure adequate binding sites for the doxorubicin molecules, and to allow the 
resultant doxorubicin-PSA complex to possess the net negative charge essential for 
interaction with the viral CP. Unlike the covalent bonds that exist between the organic 
bases and the phosphoric acid-sugar chain in the viral RNA, reversible electrostatic 
attraction was employed to attach the doxorubicin molecules to the PSA backbone. The 
reversibility of interaction was important, for it allowed for subsequent drug release from 
the viral PC upon appropriate stimulation. This novel method of loading doxorubicin 
with the aid of a high-mw polyacid was termed “polyacid association”.  
 
(a)                                                        (b) 
Figure 4-3 Illustration of the structure of (a) viral RNA, in which bases are covalently 
conjugated with phosphoric acid-sugar chain, and (b) doxorubicin-PSA complex, in 
which the weakly basic drug was attached to the polyvalent acid by reversible 
electrostatic interactions.  
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Samples prepared by the polyacid association method were subjected to sucrose 
gradient centrifugation, and the red color typical of doxorubicin was reflected in fraction 
12 (Figure 4-4 c). As this fraction was coincident with that containing the reassembled 
PC-200PSA, it implicated a successful doxorubicin loading into the PC. The product is 
denoted as PC-Dox. Parallel experiments performed with the folic acid-conjugated CP 
(fCP) produced comparable results (Figure 4-4, c), indicating that folic acid conjugation 
did not hinder doxorubicin loading into the PC by the polyacid association method. Both 
PC-Dox and fPC-Dox after centrifugation were at similar positions on the sucrose 
gradient as the native HCRSV particles, suggesting that all three particles had 
comparable densities.  
 
Douglas and Young (1998) had reported yet another method for loading guest 
molecules into plant virus-derived PC. In their method, the empty virus PC was caused to 
swell so that cavities on the surface of the PC were sufficiently widened to allow the 
transfer of guest molecules into the interior of the PC. We adapted this method by loading 
doxorubicin into preformed PC-200PSA. Again, PC loaded with PSA was used rather 
than the blank PC to take advantage of the binding sites offered by PSA for retaining the 
doxorubicin molecules within the PC. Preformed PC-200PSA was incubated in buffers of 
pH 5, 6 or 7 to induce the opening of surface cavities through protein conformational 
change. The swollen PC-200PSA was then incubated with doxorubicin before the 
samples were analyzed by sucrose gradient centrifugation. As seen in Figure 4-4 b, all 3 
samples showed high doxorubicin concentration in fractions 1-3, and negligible 
doxorubicin content in fraction 12, suggesting that doxorubicin was not successfully 
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loaded into the preformed PC-200PSA. By extension, it may be concluded that 
doxorubicin loading occurred simultaneously with PC reassembly in method C, and that 
the loaded doxorubicin was contained predominantly within the PC cavity, not on the PC 
surface. The data also support the proposition that doxorubicin loading was dependent 
upon its interaction with the polyacid, PSA. In the preformed PC-200PSA, drug loading 
could not take place because the PSA was less accessible for interaction following its 
encapsulation within the PC.  
 
4.4.2 Characteristics of PC-Dox and fPC-Dox 
Native agarose gel electrophoresis was applied to analyze the size and charge 
properties of the samples. Bands containing doxorubicin were observed with the naked 
eye (red spot) or under UV illumination (strong fluorescence), while bands containing 
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Figure 4-4 Sucrose gradient centrifugation analysis of samples following different 
methods of doxorubicin loading. Samples without doxorubicin were analyzed at 260 nm 
and 280 nm, to detect HCRSV and reassembled PC, respectively, while samples 
containing doxorubicin were measured at 485 nm. (a) Control samples of HCRSV, empty 
PC, free doxorubicin and doxorubicin-200PSA complex; (b) Samples obtained by 
incubating doxorubicin with CP, with and without the addition of TPP; and samples 
obtained by incubating doxorubicin with preformed PC-200PSA at pH 5, 6 and 7. (c) 
Samples obtained by incubating doxorubicin with CP (or fCP) in the presence of PSA 
(200 kDa). These samples are denoted as PC-Dox and fPC-Dox, respectively.  






Figure 4-5 Native agarose gel electrophoresis of (a) HCRSV, fPC-Dox, PC-Dox, 
doxorubicin, and doxorubicin-PSA complex (Lanes 1 to 5, respectively); (b) samples 
obtained by incubating doxorubicin with native HCRSV, pre-formed PC-200PSA and 
fPC-200PSA (Lane 1 to 3, respectively). The three columns represent images obtained 
using a digital camera (left), under ultraviolet light illumination (middle) and after 
staining with coomassie blue (right).  
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As shown in Figure 4-5 a, gel electrophoresis caused the free doxorubicin to migrate 
to the cathode, while PC-Dox, fPC-Dox, and the doxorubicin-PSA complex moved in the 
opposite direction towards the anode. The relative positions of the bands indicated the 
opposing polarity of the samples, and confirmed that the PSA-doxorubicin complex 
possessed a net negative charge. A comparison of the gels following coomassie blue 
staining showed that the doxorubicin band co-localized with the protein bands in the PC-
Dox and fPC-Dox samples, once more underscoring the successful encapsulation of the 
drug in the viral PC. Compared with the native HCRSV, the PC-Dox and fPC-Dox 
possessed a slightly lower charge density. In previous experiments, HCRSV-derived PC 
loaded with PSA alone was determined to have the same negative charge density as the 
native HCRSV (section 3.4.3). Therefore the lower charge density of PC-Dox and fPC-
Dox might be attributed to the loaded doxorubicin. The result obtained for fPC-Dox was 
comparable to that for PC-Dox, again indicating that the conjugation of folic acid did not 
affect the size or charge of the CP and PC. 
Samples in which doxorubicin was incubated with the pre-formed PC-200PSA 
showed an absence of drug-loaded PC (Figure 4-5, b). This negative control, together 
with the results obtained from the sucrose gradient analysis, further confirmed the 
necessity of encapsulating doxorubicin during the process of PC reassembly. 
A trail of doxorubicin was observed in the gel samples for PC-Dox and fPC-Dox 
(Figure 4-5, a and b), suggesting that the drug was released during the electrophoresis 
process. A similar phenomenon was observed for the doxorubicin-PSA complex. These 
 Chapter 4. Preparation and characterization of doxorubicin-loaded PC  
 115
results affirmed the reversible interaction between doxorubicin and PSA, and suggested 
that drug release from the PC readily occurred upon dilution. 
     
                              (a)                                                                   (b) 
Figure 4-6 TEM micrographs of (a) PC-Dox, and (b) fPC-Dox. The doxorubicin-loaded 
viral like particles were comparable in size and morphology to the native HCRSV (Figure 
2-7). 
Under the TEM, PC-Dox and fPC-Dox appeared as spherical particles with diameter 
of about 30 nm, which was comparable with the native HCRSV (Figure 4-6). The 
morphology of the HCRSV-derived PC was therefore unaffected by the simultaneous 
loading of polyacid and doxorubicin, together with surface folic acid conjugation. It may 
thus be considered to be a robust nanosize drug delivery platform.   
Like the polyacid-loaded PC (section 3.4.3) and native HCRSV (section 2.4.9), the 
PC-Dox and fPC-Dox appeared larger when measured by the zeta sizer (Table 4-1) than 
when observed under the TEM. The mean diameters were, however, no different from 
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corresponding sizes for the HCRSV and PC-200PSA. Zeta potentials for PC-Dox and 
fPC-Dox were -1.6 mV and -1.4 mV, respectively (Table 4-1), lower than the value of -
2.4 mV measured for the native HCRSV. This difference in surface charge, which was in 
agreement with the agarose gel electrophoresis results, could only be attributed to the 
positively charged doxorubicin. It has previously been shown in section 3.4.3 that the 
zeta potential of PSA-loaded PC and fPC (Table 3-1) were comparable with that of native 
HCRSV, and were independent of the mw and nature of polyacids encapsulated within 
the PC. The lower zeta potentials of PC-Dox and fPC-Dox might be due to the presence 
of adsorbed doxorubicin molecules. These molecules were, however, unlikely to be 
present in significant amounts as the PC-Dox and fPC-Dox retained a net negative charge. 
Moreover, negligible doxorubicin content was registered when the drug was incubated 
with preformed PC-200PSA and fPC-200PSA (Figure 4-4), although surface adsorption 
of doxorubicin, if it occurred, would be favored under such circumstances.  
 PC-Dox fPC-Dox PC-200PSA HCRSV 
Zeta size (nm) 48 ± 4 49 ± 2 53 ± 3 44 ± 2 
Zeta potential -1.6 ± 0.1 -1.4 ± 0.1 -2.9 ± 0.5 -2.4 ± 0.2 
Table 4-1. Zeta size and potential of PC-Dox and fPC-Dox (mean ± SD, n = 3). 
 
4.4.3. Loading efficiency (LE), encapsulation efficiency (EE) and reassembly 
efficiency (RE) 
Various parameters were determined to evaluate the efficiency of method C in 
loading doxorubicin into the HCRSV-derived PC and fPC. The EE of doxorubicin was 
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expressed as the percent weight of doxorubicin loaded in a sample relative to the total 
weight of doxorubicin used for the preparation. EE for PC-Dox and fPC-Dox amounted 
to 59% and 49%, respectively (Table 4-2). Considering the small size and positive charge 
of doxorubicin, these EE values were deemed to be satisfactory, and were possibly 
achieved through the formation of a stable doxorubicin-PSA complex during 
encapsulation. 
RE, which was the ratio of reassembled PC to the total CP used in the sample 
preparation, was another parameter measured. A high RE was important as the drug 
could only be encapsulated within the reassembled PC. RE for PC-Dox and fPC-Dox 
were relatively low, at 75% and 64%, respectively (Table 4-2). Loss of CP and 
reassembled PC during processing and transfers would account for the low values 
obtained.   
LE was calculated as the weight of loaded doxorubicin relative to the weight of PC in 
a sample. The number of doxorubicin molecules encapsulated within each PC (N Dox) was 
then determined based on the LE value, the mw of doxorubicin (mw = 544) and the mw 
of CP (mw = 37000). In addition, the concentration of loaded doxorubicin (C loaded Dox) 
was estimated (equation 4-5) based on the LE value and the inner volume of the PC. LE 
values of 7.8% and 7.5% were obtained for PC-Dox and fPC-Dox, respectively (Table 4-
2), comparable with other nano-sized systems, such as chitosan micelles and alginate 
nanoparticles [Xiangyang et al., 2007; Chavanpatil et al., 2007]. These values would 
translate to about 900 doxorubicin molecules encapsulated in each PC for both samples. 
The encapsulated doxorubicin concentration was about 300 mM, based on an inner 
diameter of 110 Å for the HCRSV-derived PC [Doan et al., 2003]. 










PC-Dox 7.8 ± 0.5 59.3 ± 13.7 74.7 ± 12.1 953 
fPC-Dox 7.5 ± 0.3 48.7 ± 4.7 63.8 ± 5.1 916 
 
Table 4-2. Loading efficiency, encapsulation efficiency, reassembly efficiency and NDox 
calculated for PC-Dox and fPC-Dox (mean ± SD, n = 3).  
 
4.4.4 Drug release profile 
The release of doxorubicin from PC-Dox and fPC-Dox following dilution was 
evident during sucrose gradient centrifugation and agarose gel electrophoresis. 
Spectrophotometric measurements following sucrose gradient centrifugation showed 
increasing doxorubicin concentration from fractions 0 to 10. Since the PC was retained in 
fraction 12, this suggested that doxorubicin was released from the PC as they sediment 
along the centrifugation path. The agarose gel also showed a strong trail of doxorubicin 
associated with the bands for PC-Dox and fPC-Dox (Figure 4-5, a). As the protein bands 
of PC-Dox and fPC-Dox (Figure 4-5, a) did not exhibit degradation trails, the PC were 
probably stable under the experimental conditions. The orange color trails and 
fluorescence trails might therefore be attributed to the doxorubicin which had been 
leached from the PC. 





















Figure 4-7. In vitro doxorubicin release profiles of PC-Dox and fPC-Dox under simulated 
physiological conditions (n = 3). Free doxorubicin served as control.  
 
To obtain the drug release profile, in vitro drug release experiments were conducted 
under simulated physiological conditions (pH 7.4, 37 °C) [Liu et al., 2005]. Sustained 
release was evident when the drug release profiles of PC-Dox and fPC-Dox were 
compared with that of free doxorubicin (Figure 4-7). More than 80% of the drug load was 
released from the free doxorubicin into the receptor chamber after 5 h, whereas the drug-
loaded PC yielded the same amount of doxorubicin only after 24 h. Drug release from the 
PC-Dox and fPC-Dox did not, however, occur at a constant rate. There was a fairly rapid 
release of doxorubicin in the initial phase, where 40% of the drug load was released in 4 
h, followed by a slower pace of release of the remaining drug load from the PC. The 
mechanisms that effect drug release upon dilution were probably similar to those that 
allowed doxorubicin to be loaded into the viral PC in the first place, i.e. reversible 
electrostatic attraction with the polyacid and physical entrapment by the viral PC. The 
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sustained-release profile, coupled with the almost complete release of the entire drug load, 
rendered the HCRSV PC as an attractive platform for controlled release drug delivery. 
However, to reduce drug release during storage, the samples should be stored in small 
volumes of resuspension buffer at low temperature (4°C). 
 
4.5 Conclusion 
Doxorubicin, being a positively charged small molecule, could not be loaded into the 
HCRSV-derived PC without the addition of a negatively-charged adjuvant. The size of 
the adjuvant was important, as a small molecule like TPP was inefficient at retaining the 
doxorubicin within the PC cavity. A novel method, named “polyacid association”, which 
involved the simultaneous encapsulation of doxorubicin with a polyacid, was 
successfully employed to load doxorubicin into the HCRSV-derived PC. This method 
was equally efficient at loading doxorubicin into the folic acid-conjugated PC. The 
resultant samples, denoted as PC-Dox and fPC-Dox, were homogenously sized and 
shaped, and they retained similar morphology and size to the native HCRSV. Drug 
encapsulation efficiency for both samples was within the acceptable range of 49 – 59%, 
with each PC particle containing about 900 entrapped doxorubicin molecules. The 
encapsulated drug was readily released from the PC-Dox and fPC-Dox upon dilution, 
with both samples exhibiting a sustained drug release profile at simulated physiological 
conditions. On the basis of these results, it may be concluded that the PC-Dox and fPC-
Dox could be efficiently produced and they have potential as a drug delivery platform for 
anticancer agents.  
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5.1 Introduction 
In chapter 4, the anticancer agent, doxorubicin, was shown to be successfully loaded 
into the cavity of the HCRSV-derived PC by a “polyacid association” method to give 
PC-Dox and fPC-Dox. To investigate the potential of applying PC-Dox and fPC-Dox as 
cancer chemotherapeutic agents, in vitro studies were performed to determine their 
uptake and cytotoxicity in cancer and normal cells. 
The in vitro experiments were conducted on cell cultures. Cell culture is a convenient, 
cheap and standardized technique for the evaluation of biomedical materials. Unlike in 
vivo animal models, cell cultures can provide ideal models with a high degree of 
consistency and reproducibility. Cell cultures have been applied to determine the effects 
of compounds on the physiology and biochemistry of specific cell types [Mosmann, 1983; 
Lim and Lim, 2006] and to provide mechanistic data under standardized conditions 
[Reddy et al., 2001]. In addition, techniques such as fluorimetry [Ren and Wei, 2004] 
and laser confocal microscopy [Xiong, et al., 2005] have been developed to monitor the 
effects of exogenous materials on intracellular biological processes in cell cultures. Other 
techniques, such as the MTT assay [Mosmann, 1983; Grailer et al., 1988], have been 
established to quantify cell viability as well as the in vitro efficacy of anticancer agents. 
Three cell lines were used in our study. The CCL-186 cells [Nichols et al., 1977] 
were derived from human lung fibroblasts and were chosen to represent normal cells. 
The OVCAR-3 cell line was derived from a human ovarian adenocarcinoma [Hamilton et 
al., 1983], and it was chosen because ovarian cancer is responsive to doxorubicin 
[Markman, 2006] and the FR has been reported to be over-expressed in ovarian cancer 
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cells [Ross et al., 1994], including the OVCAR-3 [van Steenis et al., 2003]. A human 
nasopharyngeal carcinoma cell line, CNE-1, was also used as a cancer cell model 
because nasopharyngeal cancer is prevalent in South-East Asia [Li et al., 2004; Wu et al., 
2006].  
Four doxorubicin formulations, denoted as I, II, III and IV (Table 5-1), were 
evaluated. Free doxorubicin (I) served as a control. Formulations II and III consisted of 
PC-Dox and fPC-Dox, respectively, and were used to compare the effectiveness of the 
HCRSV-derived PC as a delivery platform and the conjugated folic acid as a cancer 
targeting ligand. The vehicle for these formulations was folic acid-deficient RPMI-1640 
medium. Formulation IV comprised of fPC-Dox dispersed in the RPMI-1640 medium 
supplemented with 1 mM folic acid, and this formulation was applied to determine the 
role of the FR in the cellular uptake of fPC-Dox.  
 
Formulation Description 
I Free doxorubicin 
II PC-Dox  
III fPC-Dox 
IV fPC-Dox with 1 mM folic acid 
Table 5-1. Doxorubicin formulations used in the in vitro evaluation of the efficacy of PC-
Dox and fPC-Dox. I, II and III were dispersed or dissolved in folic acid-deficient RPMI-
1640 medium while IV was dispersed in the same medium supplemented with 1 mM of 
folic acid 
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Several techniques were applied to evaluate the biological activity of the 
formulations. Cell-associated doxorubicin following uptake experiments was quantified 
by fluorescence spectroscopy, while the viewing of the cells under a confocal scanning 
laser microscope aided in the localization of intracellular doxorubicin. Flow cytometry 
was also applied to measure the intracellular doxorubicin at single-cell level, while the 
efficacy of the formulations was evaluated via the MTT assay. Results from these 
experiments were consolidated to provide a profile of the targeting capability, uptake 
efficiency and cytotoxicity of PC-Dox and fPC-Dox in cancer cells. 
 
5.2 Materials 
Except for acetonitrile (CH3CN), which was from the Sigma Chemical Co., all 
materials and cell lines were the same as those listed in sections 2.2, 3.2 and 4.2. The 
cells were cultured using the same conditions as those described in section 2.2. 
 
5.3 Methods 
5.3.1 Folic acid uptake 
Folic acid uptake experiments were performed to confirm the over-expression of the 
folic acid receptor in the OVCAR-3 and CNE-1 cells cultured in folic acid-deficient 
RPMI-1640 medium. CCL-186, OVCAR-3 and CNE-1 cells cultured in 75 cm2 flasks to 
80% confluence were trypsinized after washing thrice with 10 ml of PBS. During culture, 
the OVCAR-3 and CNE-1 cells were incubated in folic acid-deficient RPMI-1640 
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medium while the CCL-186 cells were cultured in normal RPMI-1640 medium. To 
prepare for the folic acid uptake experiments, all 3 cell lines after detachment were pre-
incubated with 10 ml of folic acid-deficient RPMI-1640 medium for 4 h at 37 ºC in the 
CO2 incubator. The medium was discarded, and the cells were subjected to 3 cycles of 
washing with 10 ml of PBS followed by centrifugation at 2 000 rpm for 2 min. The cells 
were then incubated at 37 ºC at a density of 1000 000 cells/ml with fresh RPMI 1640 
medium supplemented with 1 mg/L of folic acid. At specified periods of 30, 60 and 120 
min, 1 ml-aliquots were sampled, and the uptake process was immediately quenched on 
ice. The cell aliquots were washed thrice, each time with 1 ml of ice-cold PBS, and 
vortexed with 0.5 ml of lysis buffer (50 mM Tris, 0.8% Triton X-100, 0.2% SDS, pH 
7.4). One volume of CH3CN was added with vigorous mixing to precipitate the proteins. 
After centrifugation at 25 000 g for 15 min, the supernatants were collected for folic acid 
assay by HPLC.  
HPLC analysis was conducted at ambient temperature in a reverse phase C18 column 
(4.6 × 250 mm, Waters Corporation, Milford, MA, USA) using a mobile phase of 
NaOAc buffer (50 mM NaOAc, pH 5.5) and CH3CN in a volume ratio of 93:7. Flow rate 
was set at 1.0 ml/min and the eluent was detected at 290 nm. Folic acid dissolved at 30 to 
200 ng/ml in the cell lysate solutions of the corresponding unexposed cell cultures were 
used to calibrate the HPLC. Cellular protein in each sample was quantified by the BCA 
method as described in section 3.3.3.2, and the cell-associated folic acid was expressed 
as ng folic acid/mg protein. 
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5.3.2 Doxorubicin uptake 
The strong fluorescence emitted by doxorubicin (Ex 480nm and Em 540nm) made it 
possible to quantify cellular doxorubicin uptake by fluorescence spectroscopy and cell 
cytometry. It also rendered it possible to use the confocal scanning laser microscope to 
visualize the intracellular location of the doxorubicin following its cellular uptake.  
 
5.3.2.1 Fluorescence spectroscopy 
Fluorescence spectroscopy provides a simple and accurate method for quantifying the 
cellular uptake of the formulations under investigation. The cells could be washed with 
an appropriate buffer after an uptake experiment to remove unassociated doxorubicin, 
and the residual cell-associated doxorubicin was quantified by measuring the 
fluorescence of the cell lysate [Xiong, et al., 2005].  
 
To perform the cellular uptake experiments, formulations I, II, III and IV were 
prepared at 5 µg/ml equivalent doxorubicin concentration. The 3 cell types were 
separately seeded onto 6-well plates (Nunc™, Nalge Nunc International, Denmark) at a 
density of 100 000 cells/well and incubated for 24 h at 37 ºC in the CO2 incubator. After 
the cells were rinsed thrice with PBS, they were incubated for 2 h with 1 ml of specified 
formulation. The cells were subsequently washed thrice with ice-cold PBS and lyzed 
with 0.5 ml of lysis buffer [Veldman et al., 2005]. Cell-associated doxorubicin was 
determined by measuring the fluorescence of the lysate using a microplate reader 
(TECAN fluorometer) while the protein content in the cell lysate was measured using the 
BCA protein assay kit (section 3.3.3.2). The microplate reader was calibrated with 
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solutions of doxorubicin dissolved at 1 to 10 μg/ml in the corresponding cell lysate 
solutions. Drug uptake was expressed as the weight of cell-associated doxorubicin (ng) 
per unit weight (μg) of cellular protein. 
 
5.3.2.2 Confocal scanning laser microscopy 
Confocal scanning laser microscopy (CSLM), otherwise known as laser scanning 
confocal microscopy (LSCM), is a well established method to obtain high-resolution 
images or 3-D reconstructions of biological specimens [Hale and Matsumoto, 1993]. 
Compared with the conventional fluorescence microscope, the confocal microscope has 
several advantages. CLSM can be used to detect more than one fluorescent material in 
cellular milieu simply by varying the excitation and emission wavelengths used for 
viewing a sample [Mo and Lim, 2005]. Unlike the photomicrographs of conventional 
fluorescence microscopy, which tended to be blurred and to give poor contrast due to the 
fluorescent light scattered around the image, especially fluorescence originating from 
planes other than the plane of focus, the confocal microscope can exclude most of this 
unfocused light to provide sharp images. The confocal microscope also enables the 
observation of selected thin layers from a thick specimen, further improving resolution 
and contrast [Cullander, 1998; Robinson, 2001].  
To prepare cells for CSLM, formulations I, II, III and IV were prepared at 5 µg/ml 
equivalent doxorubicin concentration. Cells grown in 75 cm2 flasks were trypsinized 
after reaching 80% confluence and resuspended in 10 ml of cell culture medium. About 
0.4 ml of cell suspension was placed in the well of a Lab-Tek chambered cover glass 
system (Nalge Nunc International, Naperville, IL, USA) and incubated at 37 ºC in 95% 
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air/5% CO2 environment for 24 h. The cells were rinsed thrice with PBS, and incubated 
with 0.4 ml of a specified formulation for 1 h at 37 ºC in 95% air/5% CO2 environment. 
Uptake was terminated by aspirating the formulation and washing the cells thrice with 
PBS. Residual doxorubicin in the cell samples was visualized under a confocal 
microscope at Ex480nm and Em540nm (CSLM, Zeiss Axiovert 200M, Oberkochen, 
Germany) [Xiong et al., 2005]. 
 
5.3.2.3 Flow cytometry 
Flow cytometry provides a means to measure certain physical and chemical 
characteristics of cells as they travel in suspension through a sensing point one by one 
[Xiong et al., 2005]. Both living and fixed cells can be analyzed as long as they present 
as single cells. At the sensing point, cells are detected based on fluorescence 
measurements. Although the flow cytometer makes measurement on one cell at a time, it 
can process thousands of cells in a few seconds, and is therefore a powerful tool for 
counting cells with different optical characteristics and structural features [Jorgensen, 
2005]. In this project, successful doxorubicin uptake by a cell was reflected by higher 
fluorescence measurement in flow cytometry, and the fluorescence distribution profiles 
of cell populations were used to compare the uptake efficiency of the 4 formulations. 
Cells cultured in 75 cm2 flasks were trypsinized after washing thrice with 5 ml of 
PBS. Formulations I, II, III and IV were prepared at 20 µg/ml equivalent doxorubicin 
concentration. The trypsinized cells (100 000 cells) were incubated with 1 ml of specified 
formulation for 1 h at 37 ºC in 95% air/5% CO2 environment. Doxorubicin uptake was 
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then quenched on ice and the cell suspensions were washed thrice with ice cold PBS. The 
cells were pelleted by centrifugation at 2 000 rpm for 2 min and resuspended in PBS at a 
density of 1000 000 cells/ml. The cell suspensions were subjected to flow cytometry 
analysis at Ex 480nm and Em 540nm (Altra TM, Beck-Coulter Inc., Germany). Data for each 
sample was based on the analysis of 20 000 cells. 
 
5.3.3 Cytotoxicity assay 
The in vitro efficacy of formulations I to IV was evaluated using the MTT assay. The 
experimental protocols were adapted from methods reported for folic acid-targeting 
systems [Lee and Low, 1995; Saul et al., 2003; Pan et al., 2002; Yang et al., 2004]. The 
CCL-186 and CNE-1 cells were cultured in 96 well-plates at a seeding density of 5 000 
cells/well while the OVCAR-3 cells were similarly cultured at a seeding density of 20 
000 cells/well. OVCAR-3 and CNE-1 cells were cultured in folic acid-deficient RPMI 
1640 medium, and CCL-186 cells were cultured in normal RPMI 1640 medium. After 24 
h incubation at 37ºC in a 5% CO2/95% air atmosphere, the culture medium was aspirated, 
and the cells were washed thrice with PBS. The four formulations (Table 5-1) were 
prepared to give equivalent doxorubicin concentrations in the range of 0.005 to 30 μg/ml. 
After 2 h incubation with 0.1 ml of a specified formulation, the cells were washed thrice 
in PBS followed by incubation with 0.2 ml of fresh cell culture medium for 3 days. Cell 
viability was then determined by the MTT assay as described in section 2.3.4, and the 
IC50 values were calculated by the nonlinear regression sigmoidal dose-response equation 
(GraphPad Prism Version 3.00, CA, USA) . 
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5.4 Results and discussion 
5.4.1 Folic acid uptake  
The two cancer cell models were cultured in folic acid-deficient media to induce the 
expression of the FR [Reddy et al., 2001]. Cellular folic acid uptake experiments were 
subsequently performed to determine the level of expression of the receptor in each cell 
line. The cell-associated folic acid was determined by HPLC assay. This method was 
convenient for the quantification of cellular folic acid uptake, provided the intracellular 
enzymes did not degrade the internalized folic acid too rapidly. 
Under the experimental conditions employed, folic acid was observed to elute from 
the HPLC chromatogram as a well-resolved peak at 9 min. Figure 5-1 shows typical 
HPLC chromatographs of the cell lysate solutions obtained from CCL-186, OVCAR-3 
and CNE-1 cells following the folic acid uptake experiments. A similar folic acid peak 
was clearly discernible in the chromatographs of the OVCAR-3 and CNE-1 samples, 
indicating that the folic acid uptake rates in these cells were sufficiently large to 
overwhelm any intracellular metabolic pathways. Conversely, the absence of an apparent 
folic acid peak in the chromatographs of the CCL-186 cells was suggestive of a poor 
folic acid uptake rate by these cells.  
Figure 5-2 shows the cell-associated folic acid content as a function of exposure time 
for the 3 cell models. Folic acid uptake by the OVCAR-3 cells was rapid, with saturation 
evident at 30 min of incubation. CNE-1 cells showed time-dependent folic acid uptake, 
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the cell-associated folic acid content following 30 min incubation being about 65% of 
that obtained after 1 h. However, folic acid uptake by the CNE-1 cells appeared to also 
peak after 1 h, the cells exhibiting a comparable cell-associated folic acid content as the 
OVCAR-3 cells. By comparison, the CCL-186 cells registered negligible folic acid 
uptake even after 2 h of incubation. Taken together, the results suggested that the 
OVCAR-3 and CNE-1 cells over-expressed the FR to comparable extents, while the 
CCL-186 cells appeared to lack the FR. Therefore, the OVCAR-3 and CNE-1 cells were 
appropriately applied as cancer cell models for the FR-targeting fPC-Dox formulation, 
while the CCL-186 cells were a suitable model of FR-deficient normal cells.  
(a)                                                                   (b) 
(c)                                                                      (d) 
Figure 5-1. HPLC chromatographs of (a) folic acid (Retention time, Rt =  9 min); and (b) 
CCL-186 cells, (c) OVCAR-3 cells and (d) CNE-1 cells after 2 h of incubation with 1 
mg/L of folic acid at 37°C.  

























Figure 5-2 Effects of incubation time on folic acid uptake (ng/mg cellular protein) in the 
OVCAR-3, CNE-1 and CCL-186 cell models (Mean ± SD, n = 3). At 0 min, all 3 cell 
lines did not contain detectable levels of cell-associated folic acid.  
  
5.4.2 Doxorubicin uptake  
Cellular doxorubicin uptake was visualized by confocal microscopy and quantified 
by fluorimetry. Quantitative data showed a 2-fold higher cellular uptake of doxorubicin 
from fPC-Dox than from PC-Dox by the OVCAR-3 cells (Figure 5-3). A similar 
phenomenon was observed for the CNE-1 cells, which showed a 3-fold higher uptake of 
doxorubicin when incubated with fPC-Dox than with PC-Dox. Uptake of doxorubicin 
from PC-Dox was, however, no different from that from free doxorubicin for both cell 
lines, suggesting that doxorubicin encapsulation within the HCRSV-derived PC could 
not by itself aid in the intracellular accumulation of the drug in the OVCAR-3 and CNE-
 Chapter 5. In vitro evaluation of the efficacy of doxorubicin-loaded PC  
 133
1 cells. The fPC-Dox formulation did not result in an enhanced uptake of doxorubicin for 
the CCL-186 cells, which showed comparable drug uptake (2 ng/μg protein after 2 h 
incubation) from the free doxorubicin, PC-Dox and fPC-Dox samples (Figure 5-3). 
The higher uptake rate of fPC-Dox in the cancer cells relative to normal cells might 
be explained by the up-regulation of FR in the former. To confirm a folic acid-mediated 
mechanism, the uptake experiments for fPC-Dox were conducted in the presence of 
excess free folic acid (formulation IV). The folic acid served as a competitive inhibitor, 
and if it were added at sufficiently high concentration, would block cellular fPC-Dox 
internalization via the FR-mediated endocytosis pathway. This was indeed observed, as 
the co-incubation of fPC-Dox with folic acid was found to negate the higher cellular 
doxorubicin uptake associated with the fPC-Dox sample for both the OVCAR-3 and 
CNE-1 cells. That a FR-mediated uptake mechanism was operative in the cellular uptake 
of fPC-Dox would affirm the participation of the conjugated folic acid in ligand-receptor 
binding at the cell surface. Thus, it may be concluded that the conjugation of folic acid to 














































































































Figure 5-3. Cellular uptake of doxorubicin by (a) CCL-186, (b) OVCAR-3 and (c) CNE-
1 cells incubated with free doxorubicin (I), PC-Dox (II) and fPC-Dox (III). Uptake of 
fPC-Dox was also undertaken in the presence of folic acid (IV). Data represent mean ± 
SD (n = 3). 
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Confocal micrographs provided supporting evidence for the folic acid-mediated 
preferential uptake of fPC-Dox by the OVCAR-3 and CNE-1 cells (Figure 5-4). 
OVCAR-3 and CNE-1 cells incubated with fPC-Dox showed more intense fluorescence 
compared to corresponding cells incubated with free doxorubicin or PC-Dox. Upon the 
addition of folic acid to the fPC-Dox sample, however, the fluorescence exhibited by the 
cells was reduced to a level similar to those observed in cells incubated with PC-Dox or 
free doxorubicin. For the CCL-186 cells, slightly stronger fluorescence was observed in 
cells incubated with free doxorubicin than in cells incubated with PC-Dox or fPC-Dox. 
The implication is that the loading of doxorubicin into the HCRSV-derived PC might 
actually decrease its uptake by the FR-deficient cells. These observations are therefore in 
good agreement with the quantitative uptake data. 
The confocal micrographs provided another interesting observation. Doxorubicin 
typically accumulates in the nuclei of cells [Goren et al., 2000], and this was observed 
when formulation I (free doxorubicin) was administered to the 3 cell lines (Figure 5-4). 
However, the bright fluorescence spots attributed to the fPC-Dox were observed to be 
scattered in the cell cytoplasm rather than concentrated in the nuclei of the cells. This 
phenomenon was particularly evident in the case of the OVCAR-3 cells (Figure 5-4, b). 
The distribution of fPC-Dox in the cell cytoplasm would be consistent with a FR-
mediated uptake mechanism, as the drug-loaded PC following endocytosis would be 
directed to the endosomes [Chatterjee et al., 2001].  
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(a) 
   
(b) 
   
(c) 
Figure 5-4. Confocal micrographs of (a) CCL-186 cells, (b) OVCAR-3 cells, and (c) CNE-1 cells following incubation for 1 h 
with formulations I, II, III and IV (from left to right). Green fluorescence is indicative of the presence of doxorubicin. 
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Flow cytometry provided yet further supporting evidence for the differential uptake 
of doxorubicin formulations by the cancer and normal cells. Analysis of the CCL-186 
cells following uptake experiments showed a shift in the fluorescence peak, with cells 
incubated with doxorubicin formulations exhibiting stronger fluorescence, consistent 
with doxorubicin internalization, than untreated blank cells. There were, however, no 
significant shifts in the flow cytometry data for the CCL-186 cells exposed to the 
different doxorubicin formulations, indicating that doxorubicin uptake in these cells was 
not enhanced by the HCRSV-derived PC delivery platform (Figure 5-5, a). In contrast, 
the flow cytometry profiles of the cancer cell lines, OVCAR-3 and CNE-1, showed a 
significant shift to higher fluorescence when these cells were incubated with fPC-Dox 
than with free doxorubicin or PC-Dox. When uptake of fPC-Dox was conducted in the 
presence of excess folic acid, the resultant flow cytometry profile was similar to that of 
PC-Dox, again confirming a FR-mediated uptake mechanism.  
A comparison of the flow cytometry profiles across different cell lines indicated a 
more homogeneous distribution of fluorescence in the OVCAR-3 cells than in the CNE-1 
cells, which in turn exhibited a more homogenous fluorescence profile than the CCL-186 
cells. These differences might be attributed to variation in the cell morphology. While the 
CNE-1 and OVCAR-3 cells were spherical in shape, the CCL-186 cells were elongated, 
and this elongation might have contributed to the less than homogeneous fluorescence 









                             (a)                                                                   (b) 
 
(c) 
Figure 5-5. Distribution of cellular fluorescence as evaluated by flow cytometry of (a) 
CCL-186 cells; (b) OVCAR-3 cells; and (c) CNE-1 cells following the incubation of the 
cells for 1 h at 37°C with free doxorubicin (I), PC-Dox (II), fPC-Dox (III) and fPC-Dox 
with 1 mM folic acid (IV). Untreated cells served as blank. Flow cytometry profile was 
generated from the analysis of 20 000 cells. 
 
 
 Chapter 5. In vitro evaluation of the efficacy of doxorubicin-loaded PC  
 139
5.4.5 Cytotoxicity assay 
Cytotoxicity of the various doxorubicin formulations against the OVCAR-3, CNE-1 
and CCL-186 cells was assessed via the MTT assay after 2 h of exposure (Table 2). The 
IC50 doxorubicin values, which represented the concentration of doxorubicin required for 
reducing the cell viability to 50%, was determined from the sigmoidal dose-response 
equation (Equation 5-1).  
Y = min + (max – min) / (1 + 10 × logIC50-X)    (5-1) 
where Y was the cell viability measured by the MTT assay, X was the drug concentration 
expressed in logarithmic form (log C), and “min” and “max” were the cell viabilities 
obtained at the highest and lowest doses of 30 and 0.005 μg/ml, respectively [Curran-
Everett, 2005]. IC50 doxorubicin values were calculated from the equation using the 
GraphPad Prism 3.0 software.  
In previous experiments, the native HCRSV had not been shown to exhibit overt 
toxicity towards the CCL-186, OVCAR-3 and CNE-1 cells at concentrations of up to 1 
mg/ml (section 2.4.3). This concentration was higher than the concentrations of HCRSV-
derived PC present in the PC-Dox and fPC-Dox formulations (protein concentration < 
500 μg/ml) that were administered to the cells. In addition, a separate MTT assay for PSA 
(200 kDa), which had been incorporated into the PC-Dox and fPC-Dox formulations, had 
shown all three cell lines to have a viability of no less than 95% in the presence of 100 
µg/ml PSA (Appendix III). On the basis of these preliminary data, any cytotoxicity 
associated with PC-Dox and fPC-Dox exposure might be attributed to the doxorubicin 
present in these formulations.  
 Chapter 5. In vitro evaluation of the efficacy of doxorubicin-loaded PC  
 140
The sigmoidal-dose response curves and resultant IC50 doxorubicin values for the various 
formulations are shown in Figure 5-6 and Table 5-1, respectively.  Compared with the 
free doxorubicin and PC-Dox formulations, the fPC-Dox significantly shifted the dose-
response curve to the left for the OVCAR-3 cells (Figure 5-6, b). This resulted in a 
decrease in the IC50 doxorubicin value by 4-fold. In contrast, the PC-Dox formulation 
produced comparable IC50 doxorubicin values to the free doxorubicin formulation, further 
affirming that drug encapsulation in the HCRSV-derived PC would not by itself confer 
additional benefits to its delivery to cancer cells. The enhancement of kill associated with 
fPC-Dox was again mediated by the conjugated folic acid, for the addition of excess free 
folic acid effectively abolished the added effect.  
Similar results were observed for the CNE-1 cells, although these cells were more 
sensitive to doxorubicin than the OVCAR-3 cells, as evident from the dose-response 
curves (Figure 5-6, c) and IC50 doxorubicin values obtained (Table 5-1). Like the OVCAR-3 
cells, the CNE-1 cells were about 4-fold more sensitive to the fPC-Dox formulation than 
to the free doxorubicin formulation.  
A comparison of the IC50 doxorubicin across cell types indicated that the CCL-186 cells 
were the most resistant to doxorubicin cytotoxicity, about 4-fold more than the OVCAR-
3 cells, and 20-fold more than the CNE-1 cells. Interestingly, the encapsulation of 
doxorubicin in either the PC-Dox or fPC-Dox led to a 1.6 to 1.7-fold increase in mean 
IC50 doxorubicin value against the CCL-186 cells, alluding to a conferred protection of the 
cells against the drug. The differences in values were, however, not statistically 
significant. 
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Figure 5-6. Dose-response curves of doxorubicin formulations for (a) CCL-186, (b) 
OVCAR-3 and (c) CNE-1 cells. Cell viability was determined by the MTT assay. 
Formulations evaluated comprised of free doxorubicin (I), PC-Dox (II), fPC-Dox (III) 
and fPC-Dox with 1 mM of folic acid (IV). Data represent mean ± SD, n = 3. 
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IC50 (µg / ml, mean ± SD)  
Formulation 
CCL-186 OVCAR-3 CNE-1 
I 1.95 ± 0.15 0.48 ± 0.02 0.10 ± 0.05 
II 3.41 ± 0.15 0.64 ± 0.10 0.20 ± 0.02 
III 3.19 ± 0.39 0.11 ± 0.01* 0.027 ± 0.003* 
IV 2.27 ± 0.27 0.49 ± 0.02 0.17 ± 0.02 
Table 5-2. IC50 doxorubicin values for CCL-186, OVCAR-3 and CNE-1 cell lines exposed 
to free doxorubicin (I), PC-Dox (II), fPC-Dox (III) and fPC-Dox with 1 mM folic acid 
(IV). Analysis by one-way ANOVA indicated that the IC50 doxorubicin produced by fPC-
Dox was significantly lower than those of the other formulations for the OVCAR-3 and 
CNE-1 cells. PC-Dox and fPC-Dox did not decrease the IC50 doxorubicin compared with 
free doxorubicin in the CCL-186 cells (* P < 0.05 compared with other formulations, n = 
3). 
5.5 Conclusion 
Folic acid uptake experiments confirmed that the cancer cell models comprising of 
OVCAR-3 and CNE-1 cell lines could over-express the FR when cultured in folic acid-
deficient RPMI 1640 medium. The CCL-186 cells, which were derived from a human 
diploid fibroblast, did not over-express the FR when cultured under normal RPMI 1640 
medium. It could therefore be applied as a control cell for the evaluation of FR-targeting 
systems.   
Data obtained from fluorescence spectroscopy, confocal microscopy and flow 
cytometry indicated that the folic acid-conjugated fPC-Dox formulation could effectively 
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enhance doxorubicin uptake and cytotoxicity in the OVCAR-3 and CNE-1 cell cultures. 
On the other hand, the corresponding formulation without folic acid conjugation, the PC-
Dox, was not an efficient delivery system for cancer chemotherapy. This is reasonable 
considering the current lack of evidence to support the cytoinvasive and cytotoxicity 
properties of plant viruses, including the HCRSV, in animal cells. PC-Dox could, 
however, be useful in clinical applications where sustained drug release and/or protection 
against cytotoxic drugs are desired. 
The enhanced uptake of fPC-Dox in the cancer cells was inhibited by the co-
administration of excess folic acid, indicating with the involvement of the FR-mediated 
endocytosis pathway. This would account for the failure of fPC-Dox to enhance the 
uptake and cytotoxicity of doxorubicin in the FR-deficient CCL-186 cells. The selectivity 
of action of the fPC-Dox in cancer cells warrant further evaluation of this system as a 
targeting platform for anticancer drug delivery.  
The circulating endogenous folate concentration in human is around 10 ng/ml [Mito, 
Takimoto et. al., 2007]. This concentration was similar to that found in the folic acid-
deficient RPMI 1640 medium supplemented with 10% of FBS [Lee and Low, 1995]. As 
the cellular drug uptake and cytotoxicity experiments were performed with doxorubicin 
formulations diluted in this medium, the in vitro results may well reflect the effects of 
endogenous folic acid on the efficiency of the HCRSV-based drug delivery systems. 
Further in vivo experiments will be helpful to substantiate the findings.  
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The hypothesis for this project was that protein cages (PC) derived from the plant 
virus, Hibiscus chlorotic ringspot virus (HCRSV), could serve as a platform for the 
development of a targeting anticancer drug delivery system. Compared with other 
nanoscale drug delivery platforms, the PC reassembled from the identical coat proteins 
(CP) of plant viruses have the advantages of being uniform in size and precise in 
structure. To obtain the CP, however, the native virus must be made to undergo capsid 
disassembly so that the viral RNA could be isolated and removed. The purified CP would 
require reassembly in vitro to give PC of consistent properties, preferably one that would 
be comparable in size and shape to the stable native viral capsid. In addition, the PC must 
be capable of holding a drug cargo during storage and to release it selectively into the 
target cancer tissue. The purpose of this project was to perform experimentation to test 
the hypothesis.  
The raw material for the development of the drug delivery system was the HCRSV-
derived CP. To ensure project continuity and reproducibility of data, it was vital to secure 
a reliable source of purified CP. This started with the cultivation of the HCRSV. The 
HCRSV was successfully cultured in kenaf leaves under controlled environment and 
efficiently purified by serial centrifugation on sucrose gradients to give reproducible 
yields of 4 to 5 mg of purified HCRSV per 100 g of leaves. These yields, although low, 
were adequate to meet the needs of the project.  
The HCRSV capsids could be disassembled by incubation with 8 M of urea or by 
dialysis against a Tris buffer of pH 8 in the absence of Ca2+. Successful RNA removal 
was confirmed by the lower OD 260 nm/OD 280 nm values obtained for CP isolated from the 
disassembled mixture (∼ 0.6) than for the native HCRSV (∼1.5). The purified CP could 
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also be readily reassembled into empty PC by dialysis against a sodium acetate buffer of 
pH 5 in the presence of Ca2+. Particle size measurement, together with transmission 
electron microscopy (TEM), provided proof that the reassembled PC, in particular those 
produced by the dialysis method, were comparable in size and morphology to the native 
HCRSV.  
These methods were deemed to be effective and sufficiently mild, as circular 
dichroism analysis did not register major conformational changes in the protein structure 
following capsid disassembly and subsequent PC reassembly. They were therefore 
considered to be satisfactory in providing a stable supply of HCRSV-derived CP and PC 
for subsequent experimentation in this project. The scale of production was, however, 
small. On a commercial scale, it is probably not viable to obtain the purified PC from 
cultivated HCRSV. HCRSV cultivation in plants was influenced by environmental 
variables that might be difficult to control, and the subsequent processing that was 
necessary to produce the purified CP could be difficult to reproduce on a large scale. 
Moreover, the PC yield relative to the amount of resources invested into the process was 
low. Alternative methods could therefore be explored. One technique is to produce the 
HCRSV-CP by DNA recombinant technology, as the amino acid sequence of the CP is 
known. However, the CP produced must be able to fold and reassemble into PC that 
possesses the uniformity of size and precision of structure of the native HCRSV capsid.   
Experiments involving the loading of PSA, PAA and FD into the HCRSV-derived PC 
indicated that the PC had the capacity to load exogenous materials that were negatively 
charged and had mw above a threshold value. These two prerequisites were congruent 
with the structure of the native HCRSV, which comprised of a negatively charged viral 
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RNA (3911bytes, 1,260 kDa) encapsulated within the protein capsid. Loading of PSA (13 
to 990 kDa) and PAA (450 kDa) must be initiated concurrently with the assembly of the 
PC, for it was not possible to load any of these polyacids into preformed PC. A 
hypothesis was that surface cavities present on the preformed PC would limit cargo 
loading post-assembly. Molecules too large to traverse the cavities could not be loaded, 
while molecules capable of entering the cavities would, as readily, leached out through 
the cavities during subsequent processing. Conversely, when cargo loading was initiated 
together with PC reassembly, the cargo molecules participated in electrostatic 
interactions with the appropriate amino acids of the CP, and this could initiate PC 
reassembly [Douglas and Young, 1998]. The molecules were then enveloped within the 
PC during the reassembly process and, if they were too large to penetrate the cavities, 
would be effectively retained even upon subsequent processing. The partial retention of 
the 4.3 kDa-PSA in the PC suggested that the size of this molecule was close to the 
passage size limit of the cavities. The requirement for electrostatic interactions also 
explained why it was not possible to load the neutral FD molecules into the HCRSV-
derived PC, despite some of the FD molecules meeting with the threshold mw.  
Native gel electrophoresis data were in agreement with the particle size, zeta potential 
and TEM data in suggesting that the polyacid-loaded PC had comparable size and charge 
to the native HCRSV. Moreover, despite the 75-fold difference in mw, PSA of 13 to 990 
kDa were encapsulated with comparable efficiency into the PC. The PSA loading 
efficiency of 15 to 20% also correlated closely with the value of 19% calculated for the 
genomic RNA in the native HCRSV. This suggests that the PC of HCRSV was capable 
of encapsulating exogenous materials to an amount equivalent to the mass of its native 
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genomic material. While the loading efficiency of PSA was independent on its mw, the 
number of PSA molecules that could be accommodated per PC particle (n) was inversely 
proportional to the mw of the PSA according to the relationship, n = 1/mw × 106 (R2 = 
0.9969). For the largest PSA molecule, whose mw (990 kDa) approached that of the 
genomic RNA, only 1 molecule was accommodated in each PC. This restriction in cargo 
loading size based on the capacity of the virus cavity is not surprising, and is in fact an 
acknowledged limitation in viral-based gene delivery systems [Dong et al., 1996]. 
Collectively, these data indicated that the reassembly of HCRSV-derived CP into PC, 
even in the presence of guest molecules, had occurred by a precise mechanism to yield 
particles of uniform size and morphology. The robustness of structure is an advantage 
over polymer nanoparticles prepared by condensation for drug delivery, many of which 
had sizes that would vary with the nature and concentration of drug loaded [Mozafari, 
2005; Szoka and Papahadjopoulos, 1978]. 
To impart a capability to target cancer tissues that over-express the folic acid receptor, 
the native HCRSV was conjugated with folic acid by a 2-step carbodiimide method. The 
conjugated folic acid did not affect the disassembly of the HCRSV, nor did it hinder the 
subsequent reassembly of the CP into fPC. Folic acid conjugation efficiency was 1.9%, 
which translated to about 360 folic acid molecules per fPC. The conjugation sites had not 
been determined with certainty in this project but, based on computer simulated modeling, 
the folic acid molecules were likely to be conjugated at the two exposed Lys sites of the 
protruding domain of the CP. The folic acid was conjugated at a high number, but it did 
not affect the capacity of the fPC to encapsulate PSA and PAA at similar loading 
efficiencies as the unconjugated PC. In addition, the PSA- and PAA-loaded fPC were 
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comparable in size, morphology and conformational structure to the corresponding 
polyacid-loaded PC without folic acid conjugation. The results further underscored the 
robustness of the PC structure.  
Doxorubicin, the model anticancer drug used for the project, did not satisfy the twin 
requisites of possessing a negative charge and a mw above the specified threshold for 
loading into the PC. To overcome these barriers, a novel method named “polyacid 
association” was developed. This method involved the simultaneous encapsulation of 
doxorubicin with PSA (200 kDa), the PSA aiding in the retention of doxorubicin within 
the PC and fPC through the formation of a semi-stable complex by electrostatic 
interactions. The resultant systems, denoted as PC-Dox and fPC-Dox, were 
homogenously sized and shaped, and were similar in morphology and size to the native 
HCRSV. Drug encapsulation efficiency for both samples was within the acceptable range 
of 49 – 59%, with each PC containing about 900 entrapped doxorubicin molecules. The 
drug load in the PC-Dox and fPC-Dox was equivalent to 7 - 8% w/w, comparable with 
the load of other nano-sized systems of doxorubicin, such as chitosan micelles 
[Xiangyang et al., 2007] and alginate nanoparticles [Chavanpatil et al., 2007].  
The encapsulated drug in PC-Dox and fPC-Dox was readily released upon dilution, 
with both samples exhibiting a sustained drug release profile at simulated physiological 
conditions. About 40% of the drug load was released within the initial 4 h, followed by a 
slower release of the remaining drug load from the PC over the next 20 h. The rapid drug 
release rate would be advantageous if it could be designed to occur only at the targeted 
site, since a premature drug release would negate the benefits conferred by the PC 
formulation. To achieve such a precise and controlled drug release mechanism would 
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necessitate further optimization of the PC-Dox and fPC-Dox formulations. A suitable 
dosage form (e.g. using a capsule to hold the PC formulation) or administration method 
(e.g. direct tumor injection or inhalation of lyophilized PC) may be helpful towards 
keeping the drug within the PC until it is to be released into the targeted sites. 
Proof of concept of the delivery systems was obtained by evaluating the efficacy of 
the PC-Dox and fPC-Dox formulations in representative cell culture models. The cancer 
cell models were OVCAR-3 (human ovarian epithelial adenocarcinoma) and CNE-1 
(human nasopharyngeal carcinoma), while the CCL-186 (human diploid fibroblast) cell 
line was used as a normal cell model. To ensure the cell models were appropriate for the 
evaluation of a folic acid-conjugated delivery system, folic acid uptake experiments were 
conducted. The data confirmed the over-expression of the folic acid receptor in the 
OVCAR-3 and CNE-1 cells cultured in folic acid-deficient RPMI-1640 medium, while 
the CCL-186 cells did not over-express the folic acid receptor when cultured in normal 
RPMI-1640 medium. Data obtained from fluorescence spectroscopy, confocal 
microscopy and flow cytometry supported the enhanced efficacy of fPC-Dox relative to 
PC-Dox and doxorubicin in solution. The fPC-Dox formulation was found to enhance 
doxorubicin uptake in the OVCAR-3 and CNE-1 cells by 2 to 3-fold. Although this 
enhancement in cellular uptake might be regarded as modest compared with other folic 
acid-based targeting systems, which typically increased cellular uptake by 7 [Saul et al., 
2003] to 40 [Lee and Low, 1995] folds, it was nevertheless accompanied by significantly 
higher cytotoxicity as evaluated by the MTT assay. The cytotoxicity of fPC-Dox could 
not be attributed to the CP or PSA because the HCRSV and PSA at concentrations 
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equivalent to those applied in the PC-Dox and fPC-Dox formulations had been shown by 
the MTT assay to be non-cytotoxic towards the 3 cell lines.  
Cellular uptake and cytotoxicity of PC-Dox were comparable to doxorubicin in 
solution, suggesting that doxorubicin encapsulation within the HCRSV-derived PC could 
not by itself increase drug efficacy in the cancer cell models. This is because drug uptake 
from the PC-Dox probably occurred by a mechanism similar to that of the free drug, i.e. 
by passive diffusion [Mulder et al., 1995]. Unlike the fPC-Dox, PC-Dox did not present 
with a ligand that could stimulate cellular uptake by a receptor-mediated endocytic 
pathway, and there is currently no evidence to support the cytoinvasive and cytotoxicity 
properties of plant viruses, including the HCRSV, in animal cells. Moreover, the in vitro 
drug release data had shown a fair amount of the encapsulated drug to be released from 
the PC-Dox upon dilution, and the released drug would enter the cells in a manner similar 
to that of the free doxorubicin formulation. This in turn would drive more encapsulated 
drug to be dissociated from the PSA backbone and be released into the cellular milieu to 
be taken up by the cells by passive diffusion. However, it might also be argued that the 
PC-Dox could be internalized by the cells by a non-receptor mediated endocytic pathway, 
as the size of the PC was comparable to the optimized size of nanoparticles shown to be 
transported via this pathway [Chithrani et al., 2006]. Certainly the TEM micrographs 
supported the PC presence in the cell cytoplasm, which was consistent with the 
trafficking pathway of endocytosed particles. 
While the PC-Dox was unable to increase the efficacy of doxorubicin, this 
formulation could be adapted to applications where sustained drug release is desired. For 
this to be realized, however, the PC-Dox may have to be further optimized.  An example 
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would be to deliver the PC-Dox in a enteric-coated capsule that is able to deliver the 
formulation to the intestinal epithelium for drug release and subsequent absorption. 
Otherwise, the dilution of the formulation during its passage to the site of absorption 
could lead to premature drug release.  
Co-administration of an excessive amount of folic acid was shown to negate the 
enhanced cellular uptake of fPC-Dox by the OVCAR-3 and CNE-1 cells, thus lending 
support to the role of the folic acid receptor in mediating the cellular uptake of this 
formulation. Supporting evidence was provided by the TEM micrographs, which showed 
the intracellular doxorubicin to be distributed in the cell cytoplasm, consistent with the 
trafficking pathway of vesicles involved in folic acid-mediated endocytosis. On the basis 
of these data, it might be surmised that the conjugated folic acid on the fPC-Dox was still 
capable of binding with the membrane folic acid receptor to initiate endocytic uptake, and 
that the fPC-Dox was not too large to be endocytosed by this pathway. This mechanism 
of uptake of the fPC-Dox provided for its selectivity of action, for it failed to show an 
enhanced uptake in the folic acid receptor-deficient CCL-186 cells. Consequently, the 
fPC-Dox can be considered to have the potential to be applied as a targeting platform for 
anticancer drug delivery, and its formulation should be further optimized to realize this 
potential.  
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Results from this project have shown that the HCRSV-derived PC can serve as a 
carrier for drug delivery, and that the PC can be functionalized with folic acid for 
enhanced drug delivery into cancer cells that over-express the folic acid receptor. Much 
work remains to be done, however, before this delivery platform can be approved for 
clinical applications. The following studies will aid in moving the HCRSV-derived PC 
towards this direction.  
Production of the purified CP from plant-cultivated HCRSV has been identified as a 
possible hindrance towards achieving a scaled up production of the PC for drug delivery. 
The cultivation of HCRSV-infected kenaf was time-consuming, with each batch of 
purified HCRSV taking months to produce. Moreover, the yield of HCRSV was low, and 
its contamination by opportunistic virus remained a constant threat despite the use of an 
isolated environment for cultivation. For the HCRSV-derived PC to move into animal 
and clinical studies, a more efficient method has to be developed to produce the purified 
CP on a larger scale. Protein expression by E. coli or yeasts using DNA recombinant 
technology can be a more cost-effective method for producing a large quantity of purified 
CP within a few days. However, the recombinant CP must be capable of reassembling 
into PC that possesses the beneficial characteristics of the native HCRSV capsids. 
Biodistribution and pharmacokinetic studies should be conducted on the blank 
HCRSV-derived PC, fPC-Dox and PC-Dox. In particular, it will be interesting to 
evaluate whether the PC is capable of trafficking across absorptive epithelia. This is 
because the CPMV, a plant virus similar to the HCRSV, has been found distributed in a 
wide variety of tissues following oral administration in mice [Rae et al., 2005]. As the 
mechanism of absorption is not presently known, this could be determined using the 
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appropriate cell model, e.g. the Caco-2 cell monolayers cultured on Transwells inserts to 
represent intestinal epithelium. To apply the HCRSV-derived PC as a carrier for oral drug 
delivery, experiments must also be conducted to verify its stability in the GI milieu. 
Therefore, studies on the degradation of the PC under different physiological 
environment, and in the presence of proteases or the cytochrome P450 family of enzymes, 
should be undertaken. Studies to determine the predominant mode of clearance of the PC 
in vivo, as well as its propensity to mount an immune response in animal models, will 
generate further supporting data to assess its potential for clinical application.  
The fPC-Dox formulation has been shown to enhance doxorubicin uptake in cancer 
cell models that over-express the folic acid receptor. Additional studies will have to be 
performed to confirm its targeting capability and efficacy in vivo. In particular, it will be 
necessary to establish whether the fPC-Dox can target cancer tissues when injected 
intravenously. The formulation can also be further improved, as the increase in cellular 
doxorubicin uptake associated with fPC-Dox was modest compared to other folic acid-
based targeting systems. For example, a folic acid-targeting liposomal system of 
aclacinomycin A has been shown to enhance drug uptake by 200-fold in the a human 
nasopharyngeal cancer line (KB), and to enhance the corresponding drug cytotoxicity by 
90 fold [Shiokawa et al., 2005]. In the liposomal system, the folic acid was conjugated to 
the liposome via a long chain PEG linker (mw 5000) with a view to increase the 
accessibility of folic acid for interaction with the FR. A similar conjugation strategy can 
be considered for the HCRSV-based PC system to improve its uptake and cytotoxicity 
against cancer cells.  
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Other than doxorubicin, the HCRSV-derived PC can be considered for the delivery of 
other drugs. The present study has shown that it is possible to use the PC to load 
negatively charged macromolecules. On this basis, the PC can be evaluated as a gene 
vector, although surface functionalization is probably required to allow the PC to deliver 
therapeutic levels of DNA into animal cells. The PC can also be used to load small 
molecules based on the “polyacid association” concept. This method of loading, however, 
causes the system to release a bolus dose of the encapsulated drug upon dilution. The 
formulation will therefore have to be modified to ensure the encapsulated drug is released 
only at the target site. Studies can be conducted, for example, to test whether it is feasible 
to place the formulation into enteric-coated capsules or tablets for delivery to the 
intestinal epithelium.   
To summarize, the application of plant virus-derived PC for drug delivery is in its 
infancy, but the potential appears to be highly promising. As more is understood of how 
these platforms can be harnessed for drug delivery, it is reasonable to predict that safe 
and effective drug delivery systems based on plant virus-PC will become available in the 
not too distant future. 
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Appendix I. BCA calibration curve produced using CP. 

















Appendix II. Sucrose gradient centrifugation analysis of pre-reassembled PC incubated 
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Appendix III. Cytotoxicity of 100 µg/ml 200 kDa PSA to three cell lines (n = 8) 
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